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Abstract 
 
The work described in this thesis concerns the design, synthesis and DNA binding 
activity of functionalised iron(II) supramolecular helicates.  
 
DNA and the ways that organic and metallo-molecules recognise and bind to it are 
reviewed. The field of supramolecular chemistry and particularly supramolecular 
helicates is considered, including those developed as anticancer agents.  
 
The design of a novel functionalisation route for the development of functionalised 
helicates is presented. The synthesis and characterisation of several metallo-helicates 
functionalised with simple chemical groups, such as hydroxyl and phenyl moieties, is 
described. Studies reveal that this functionalisation does not inhibit the inherent DNA 
binding activity of these types of cylinders.  
 
The development of steroid-hormone functionalised iron(II) helicates for targeted 
delivery to cancerous tissues is also detailed, including their synthesis and 
characterisation. These steroid functionalised complexes bind to DNA, inducing 
changes in the DNA conformation. 
 
The design, synthesis and characterisation of several metallo-helicates functionalised 
with targeting sugar vectors, is also presented. These sugar-conjugates can bind to 
DNA, causing intramolecular coiling and unwinding of the DNA helix. 
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Abbreviations 
 
δ   chemical shift (NMR)  
ε   molar absorption coefficient (mol-1dm3cm-1) 
Φ    DNA unwinding angle 
λ   wavelength 
λmax   wavelength maximum 
A    adenine (DNA base) 
BF4   tetrafluoroborate 
br   broad (in NMR and IR data) 
C   circular (form of plasmid DNA) 
C   cytosine (DNA base) 
CD   circular dichroism 
CDCl3   deuterated chloroform 
CD3CN  deuterated acetonitrile 
cm   centimetre 
13
C NMR  carbon nuclear magnetic resonance (spectroscopy) 
ct-DNA  calf thymus deoxyribonucleic acid 
d   doublet (NMR) 
2D-COSY  two dimensional correlation spectroscopy (NMR) 
dd   doublet of doublets (NMR) 
DNA   deoxyribonucleic acid 
D2O   deuterated water 
EI   electron impact (mass spectrometry) 
ESI   electrospray ionisation (mass spectrometry)  
FW   formula weight 
G   guanine (DNA base) 
HIV   human immunodeficiency virus 
HMG   high mobility group (protein) 
1
H NMR  proton nuclear magnetic resonance (spectroscopy) 
HRMS   high resolution mass spectrometry 
hrs   hours 
Hz   hertz 
ICD   induced circular dichroism 
ILD   induced linear dichroism 
IR   infra-red (spectroscopy) 
J   coupling constant (NMR) 
K   Kelvin 
LD   linear dichroism 
m   medium (in IR data) 
m   multiplet (in NMR data) 
M   molar (mol dm
-3
) 
μM   micromolar  
mdeg   millidegrees 
MeCN   acetonitrile 
MeOH   methanol 
MHz   megahertz 
MLCT   metal to ligand charge transfer 
mM   millimolar 
mmol   millimole 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
m/z   mass to charge ratio 
nm   nanometre 
NMR   nuclear magnetic resonance (spectroscopy) 
32
P   phosphorus-32 (isotope) 
PAGE   polyacrylamide gel electrophoresis 
PDB   protein data bank (file) 
PF6   hexafluorophosphate 
ppm   parts per million 
RNA   ribonucleic acid 
s   strong (in IR data) 
s   singlet (in NMR data) 
SC    supercoiled (form of plasmid DNA) 
sh   shoulder (UV-Vis)   
T   thymine (DNA base) 
t   triplet (NMR) 
td   triplet of doublets (NMR) 
∆-TRISPHAT  [∆-tris(tetrachloro-1,2-benzenediolato)phosphate(V)] 
UV   ultraviolet (light/spectroscopy) 
UV-Vis  Ultraviolet-visible (spectroscopy)  
w   weak (IR)  
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Chapter 1: Introduction 
 
Deoxyribonucleic acid (DNA) is one of the most important biomolecules in living 
organisms. DNA allows the storage of genetic information, which is then translated via 
proteins into essential cellular processes that maintain cell function. It is the role of DNA 
in encoding these processes, and our increased understanding of these cellular events such 
as DNA replication and gene expression, that makes it a target for the diagnosis and 
treatment of disease. A large and varied range of natural and synthetic ligands that bind to 
DNA, and inhibit or alter the biological activity of DNA, have been discovered or 
developed as therapeutic agents. The development of drug molecules with a higher 
specificity for DNA may lead to a greater control of gene expression and therefore an 
improved therapeutic efficacy of anticancer drugs.  
 
1.1 DNA structure 
The structure of DNA was first elucidated in 1953 by Watson and Crick.
1
 It is a helical 
molecule formed of two strands, with each strand composed of a backbone of alternating 
ribose sugar and phosphate groups (Fig. 1.1).
1,2
 An aromatic nitrogenous base is attached 
to each ribose sugar, with the hydrophobic bases pointing into the helix and the hydrophilic 
sugar-phosphate units pointing outwards.
2,3
 The bases are joined together in pairs, one 
from each strand, by hydrogen bonds which consequently also hold the two DNA strands 
together.
2
 There are four DNA bases; two of which are purines, adenine (A) and guanine 
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(G), and two pyrimidines, cytosine (C) and thymine (T).
2
 Pairing only occurs between a 
purine base and a pyrimidine base, either A with T or C with G (Fig. 1.1).
2
 The attachment 
of the base pairs to the sugar-phosphate backbone is rather asymmetrical, leading to two 
grooves being formed in the double helix called the major and minor grooves.
4
  
 
 
 
Figure 1.1 Structure of deoxyribose phosphate backbone (top) and DNA bases and their base pairing 
(bottom). [Reproduced from Ref 3] 
 
There are many possible conformations of duplex DNA, of which three are more common, 
the A-form, B-form and Z-form (Fig. 1.2). The B-form of DNA is a right-handed helix, 
when viewed down the helical axis, consisting of ten base pairs per turn and has a deep and 
narrow minor groove and a wide and shallow major groove.
5
 A-DNA is also a right-
handed helix, however it consists of eleven base pairs per turn and so is shorter and fatter 
than B-DNA.
5
 The minor groove of A-DNA is shallow and wide while the major groove is 
extremely narrow.
5
 Z-DNA is a left-handed helix with a zigzag conformation due to an 
alternating purine-pyrimidine base sequence.
5
 It has 12 base pairs per helical turn, with a 
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single narrow minor groove and no major groove.
5
 The B-DNA conformation is believed 
to be the most prevalent in biological systems.
3
  
                   
 
Figure 1.2 Structure of A-DNA (PDB 5ANA)6 (left), B-DNA (PDB 3BSE)7 (middle), and Z-DNA (PDB 
1DCG)8 (right). 
 
1.2 DNA recognition 
DNA binding by natural and synthetic small molecules can be grouped into five categories; 
(1) major groove binding, (2) minor groove binding, (3) sugar-phosphate backbone 
binding, (4) intercalation and (5) coordinative binding.  
 
1.2.1 Major groove binding 
Relatively little research has been conducted into major groove recognition by synthetic 
drugs. This is likely due to the fact that major groove binding is mainly limited to 
biological macromolecules such as proteins, as the dimensions of the groove are usually 
too large for synthetic DNA-binders.
9
 These protein-DNA interactions allow essential 
biological processes such as transcription to occur.
10
 These interactions are non-covalent in 
nature and are therefore reversible. Interaction between the protein and the target DNA is 
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mainly through hydrogen bonding to the DNA base pairs, however the formation of van 
der Waals contacts plays a role.
11
 The protein can recognise the DNA base pairs on the 
floor of the major groove by their hydrogen bond donor/acceptor functionalities.
10
 Binding 
in the major groove often causes kinking or bending at the interaction site, changing the 
width and depth of the DNA groove.
11
  
 
The part of the protein that actually interacts with the DNA major groove is most 
commonly an α-helix moiety (Fig. 1.3).11 Examples of α-helix proteins that bind in the 
major groove are helix-turn-helix, zinc-binding and leucine zipper proteins.
11
 The majority 
of zinc-binding proteins are involved in gene regulation and many of these are 
transcription factor proteins.
11,12
 A crystal structure of a Zif268-zinc finger peptide 
complex containing three zinc fingers crystallised with a short DNA sequence (Fig. 1.3) 
shows that the α-helix of each finger fits directly into the major groove.12 Each finger 
interacts with three base pairs via hydrogen bonding and most of these contacts are made 
with a G rich strand of DNA.
12
 
         
 
Figure 1.3 Docking of α-helix in DNA major groove [Reproduced from Ref 11] (left); Crystal structure of 
Zif268-zinc finger binding in major groove of DNA (PDB 1ZAA)12 (right). 
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Small molecule drugs that reside in the major groove usually are anchored there by 
intercalative interactions (see Section 1.2.4). For example, ditercalinium (Fig. 1.4) is a 
synthetic major groove binder derived from the natural product ellipticine.
13
 It has 
anticancer activity and binds to DNA in the major groove.
13
 The crystal structure of the 
drug bound to double stranded DNA shows the linker bound in the major groove of the 
DNA with the two aromatic moieties bis-intercalated between the base pairs.
13
 
 
 
Figure 1.4 Structure of ditercalinium (left); Crystal structure of ditercalinium binding in DNA major groove 
(PDB 1D32)13 (right). 
 
1.2.2 Minor groove binding 
The minor groove is narrow and deep, with the floor of the groove consisting of the edges 
of the DNA bases and the walls formed from the sugar-phosphate backbone.
4
 The surfaces 
of the walls of the groove are made up of hydrogen atoms from the sugar-phosphate 
backbone and so are hydrophobic in nature.
4
 Interaction between minor groove binders and 
DNA occurs mainly through hydrogen bonding, electrostatic and van der Waals 
interactions and frequently occurs with some degree of sequence specificity.
4,9
 A/T rich 
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regions of the DNA have an overall negative charge, and are more flexible than G/C rich 
regions, and so positively charged DNA binders prefer these sequences of DNA, giving 
rise to this sequence specificity.
4,9
  
 
Distamycin (Fig. 1.5) has anti-tumour and antibiotic properties.
14
 It is a natural minor 
groove binder, binding with sequence specificity for A/T rich sequences of DNA via 
hydrogen bonds.
14
 The interaction between distamycin and DNA is further strengthened by 
hydrophobic and van der Waals interactions between the aromatic rings of the molecule 
and the walls of the minor groove. Electrostatic interactions between the positively charged 
propylamidinium group and the negatively charged DNA also contribute.
14
  
 
 
 
Figure 1.5 Structure of distamycin (left); Crystal structure of distamycin binding in DNA minor groove 
(PDB 2DND)14 (right).  
 
Berenil (Fig. 1.6), a synthetic minor groove binder, has anti-protozoal properties and is 
used to treat parasitic tyrpanosomal infections.
4
 It binds to A/T rich regions of the minor 
groove with the positively charged amidinium group hydrogen bonded to the oxygens of 
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the thymine bases.
15
 There are also hydrophobic and van der Waals interactions between 
the molecule and the minor groove walls, which are lined with hydrogen atoms from the 
sugar-phosphate backbone.
15
 
 
Figure 1.6 Structure of berenil (left); Crystal structure of berenil binding in DNA minor groove (PDB 
1D63)15 (right). 
 
Hoechst (Fig. 1.7) is a synthetic fluorescent DNA stain and also has antibiotic properties.
16
 
It has a preference for binding to A/T rich sequences of DNA, forming hydrogen bonds 
between the amine hydrogens of the benzimidazole and the nitrogens of the adenine bases 
and oxygens of the thymine bases.
16
 Binding of Hoechst to DNA causes the minor groove 
to widen and the helix to bend slightly.
16
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Figure 1.7 Structure of Hoechst (left); Crystal structure of Hoechst binding in DNA minor groove (PDB 
8BNA)16 (right). 
 
Recently, an aromatic aza-bisbenzamidine functionalised with a coumarin fluorophore was 
developed (Fig. 1.8).
17
 The compound shows sequence preference for A/T rich regions of 
DNA.
17
 It also exhibits some fluorescence emission and this was found to be greatly 
enhanced in the presence of DNA.
17
  
 
Figure 1.8 Structure of aza-bisbenzamidine functionalised with a coumarin fluorophore.17 
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1.2.3 Sugar-phosphate backbone binding 
The sugar-phosphate backbone of DNA is made up of alternating sugar and phosphate 
units and so is negatively charged and hydrophilic.
3
 Natural proteins with cationic charged 
regions can bind to the sugar-phosphate backbone and form hydrogen bonds with the 
phosphate units and the DNA bases.
3
  
 
There are few examples of synthetic sugar-phosphate backbone binding molecules, 
however a cationic trinuclear platinum(II) drug (Fig. 1.9) developed by Farrell binds 
specifically to the sugar-phosphate backbone.
18
 It is made up of three cationic square 
planar platinum(II) centres, that are unable to bind covalently to the DNA, and 
hydrophobic linking segments.
18
  
 
 
Figure 1.9 Structure of Farrell’s trinuclear platinum drug.18 
 
 
This long molecule interacts with the sugar-phosphate backbone of double stranded DNA 
in a number of ways (Fig. 1.10).
18
 It extends along the negatively charged backbone 
interacting via electrostatics, and spans the minor groove.
18
 The complex also forms 
bidentate hydrogen bonds between its amine and ammine groups and the phosphate 
oxygens, known as phosphate clamps.
18
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Figure 1.10 Crystal structure of Farrell’s trinuclear platinum drug binding to sugar-phosphate backbone of 
DNA (PDB 2DYW)18 (left); Schematic diagram of a phosphate clamp (right). 
 
1.2.4 Intercalation  
DNA binding by intercalation is the most common way that small molecules interact with 
DNA and a significant number of therapeutic drugs are intercalators.
9
 Intercalation 
involves the insertion of a planar aromatic molecule, or part of a molecule, between the 
base pairs of duplex DNA.
9
 This space between the base pairs is hydrophobic and the 
intercalator can form π-π stacking interactions with the bases closest to it.3 Intercalators are 
often positively charged and so interact with the negatively charged DNA via electrostatic 
interactions.
9
 Intercalation causes unwinding of the DNA helix and these structural 
modifications can lead to inhibition of processes such as transcription, replication and 
DNA repair.
3,19
   
 
Daunorubicin (Fig. 1.11) is a DNA intercalator from the anthracycline family. It is used as 
an antibiotic and to treat a variety of cancers.
20
 This planar aromatic molecule is found to 
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intercalate between cytosine and guanine DNA bases, with the amino sugar extending into 
the minor groove making several van der Waals contacts with the DNA bases. Hydrogen 
bonds formed between daunorubicin and the DNA bases aid in stabilising the interaction.
20
 
 
 
Figure 1.11 Structure of daunorubicin (left); Crystal structure of two daunorubicin molecules intercalating 
between DNA base pairs (PDB 1D12)20 (right). 
 
Ellipticine (Fig. 1.12) is also an intercalator and a potent anticancer drug.
21
 It intercalates 
between cytosine and guanine DNA bases, forming π-π stacking interactions.21 This 
intercalation causes unwinding and lengthening of the DNA helix.
21
 
 
 
Figure 1.12 Structure of ellipticine (left); Crystal structure of two ellipticine molecules intercalating between 
DNA base pairs (PDB 1Z3F)21 (right). 
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There are also many synthetic metallo-intercalators. The metal, usually a transition metal, 
is incorporated so as to impart positive charge, increasing the electrostatic interactions of 
the intercalator with DNA.
3
 
 
One of the first examples of a metallo-intercalator was Lippard’s platinum(II) terpyridine 
complex (Fig. 1.13). It was found to bind strongly to DNA by intercalation, with the π-π 
stacking interactions with the DNA bases enhanced by the cationic metal centre.
22,23
  
 
 
Figure 1.13 Structure of Lippard’s platinum(II) terpyridine intercalator.22 
 
 
Another example of a metallo-intercalator is an octahedral ruthenium(II) complex with 
several aromatic ligands (Fig. 1.14).
24
 The dipyridophenazine ligand (dppz) is able to 
intercalate into the DNA with sequence preference for adenine and thymine DNA bases.
24
 
Due to the ruthenium centre, the complex is luminescent and this luminescence is 
significantly enhanced when in the presence of DNA.
24
 Therefore this ‘light switch’ 
complex has many applications as a diagnostic or therapeutic drug.
24
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Figure 1.14 Structure of [Ru(phen)2(dppz)]
2+ (left); Crystal structure of dppz moiety of [Ru(phen)2(dppz)]
2+ 
intercalating between DNA base pairs (PDB 4E7Y)24 (right). 
 
1.2.5 Coordinative DNA binding: platinum based drugs 
Coordinative binding involves the formation of direct covalent bonds between the DNA 
binding molecule and the DNA bases.
9
 It is normally sequence specific with the 
preferential binding sites being the N7 position of guanine and adenine bases in the DNA 
major groove.
9,25
 Coordinative binding usually involves cross-linking between DNA 
strands, inhibiting base pairing and preventing the separation of DNA strands in DNA 
processes such as replication and transcription.
9
  Anti-cancer chemotherapy was founded 
on alkylating agents that bind coordinatively to DNA, and these compounds are still 
clinically important today.
9
 Cisplatin is one of the most well-known examples of 
coordinative binding drugs. 
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1.2.5.1 Cisplatin 
Cisplatin, cis-diamminedichloroplatinum(II) (Fig. 1.15), is a very potent anti-tumour 
drug.
26
 Its activity was first discovered accidentally by Rosenberg in 1965 when it was 
found that platinum salts inhibited cell division in the bacterium Escherichia coli.
27
 
Cisplatin has been a significant drug in the treatment of cancer since its initial use in 1978, 
and is very effective against tumour types such as testicular, ovarian, small-cell lung 
cancer and head and neck cancers.
28,29
 
 
The structure of cisplatin consists of two strongly coordinated ammonia ligands and two 
weakly coordinated chloride ligands, bound to a square-planar platinum(II) centre with cis 
conformation.
  
 
 
Figure 1.15 Structure of cisplatin. 
 
However, this is not the structure of the complex that actually binds to the DNA once it has 
crossed the cell membrane by passive diffusion or via copper transporters.
30,31 
One of the 
chloride ligands is first hydrolysed to form the cationic aquated species, cis-
[Pt(NH3)2Cl(OH2)]
+
,
32 
 and it is this potent electrophile that can react with the DNA bases 
via its platinum metal centre (Fig. 1.16).
29
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Figure 1.16 Schematic representation of cisplatin hydrolysis and subsequent DNA binding (where N7-G is 
the N7 atom of G). 
 
Two metal coordination bonds are formed with two neighbouring A and/or G purine bases 
(Fig. 1.17) on the same strand of DNA, through their N7 atoms, forming a bifunctional 
adduct.
29,33
  
 
 
Figure 1.17 Structure of platinum bound to adenine (left) and guanine (right). 
 
Several different adducts are formed between cisplatin and DNA (Fig. 1.18) with the 1,2 
intrastrand Pt-GG adduct thought to be the most significant in the anti-cancer activity of 
cisplatin.
34 
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Figure 1.18 Representation of adducts formed between cisplatin and DNA; (a) interstrand crosslink; (b) 1,2-
intrastrand crosslink; (c) 1,3-intrastrand crosslink and (d) protein-DNA crosslink. [Reproduced from Ref 26] 
 
These intrastrand crosslinks have been found to damage DNA by causing a kink in the 
double helix at around 45º, towards the site of platination.
33,35
 This kinking produces a 
specific structural motif 
36
 which is recognised by nuclear high-mobility group (HMG) 
proteins.
29
 These HMG proteins bind to the kinked parts of the DNA preventing the 
binding of normal DNA repair proteins, such as those that carry out nucleotide excision 
repair, which may hinder transcription and DNA replication activities.
25,37
  
 
Although cisplatin has worldwide clinical approval, is one of the foremost anti-cancer 
drugs,
25
 and is used to treat 50-70% of all cancer patients
38
 there are several major 
disadvantages of this drug.
39
 Many tumours develop cisplatin resistance
25,40
 and the drug 
does not work for all primary tumours, for example breast and prostate cancer, the two 
most frequent cancers.
25
 Treatment with cisplatin causes severe side effects such as 
nephrotoxicity, neurotoxicity, loss of sensation to the extremities and nausea,
25,41
 due to the 
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poor specificity of cisplatin for tumour cells. Platination occurs in all cells leading to 
normal cells and tissues being damaged.
25,42
  
 
1.2.5.2 Second generation platinum drugs 
Due to the limiting factors of cisplatin, there has been a vast amount of research in the last 
few decades to discover new anti-cancer drugs with reduced side effects and improved 
properties.  
 
Carboplatin (Fig. 1.19) has worldwide clinical approval.
43
 It forms the same adducts with 
DNA as cisplatin, and has shown cytotoxic activity against the same tumour types.
44
 The 
bidentate leaving group renders the drug less toxic than cisplatin.
43, 44
 Consequently 
carboplatin is only used in cases where the patient is otherwise compromised, for example 
the elderly or those with HIV.
25
  
 
 
 
Figure 1.19 Structure of carboplatin (left), oxaliplatin (middle) and lobaplatin (right).43,45 
 
Oxaliplatin (Fig. 1.19) has a carboxylato leaving group and a 1,2-diaminocyclohexane 
(DACH) non-leaving group.
45
 This leaving group is hydrolysed less readily and so 
oxaliplatin is less toxic than cisplatin, and the side effects of the drug are much 
reduced.
45,46
 Oxaliplatin forms [Pt(dach)] adducts with DNA and so has a different 
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spectrum of activity than that of cisplatin.
25, 45
 It is cytotoxic against tumour types that are 
not treatable with cisplatin or that are cisplatin resistant.
25, 47
   
 
Lobaplatin (Fig. 1.19) has a 1,2-dimethylaminocyclobutane non-leaving group
44,45
 
 
and 
therefore also forms DNA adducts that differ from those of cisplatin.
44,45
 It is less toxic 
than cisplatin due to its leaving group.
45 
Lobaplatin has no clinical advantages over 
cisplatin.
25
 
 
1.2.5.3 Multi-nuclear platinum drugs  
Multi-nuclear platinum drugs are structurally very different from cisplatin and therefore 
form different types of platinum-DNA adducts and so unsurprisingly have different clinical 
activity.
48
 
 
Farrell’s tri-platinum agent BBR3464 (Fig. 1.20) has undergone phase II clinical trials and 
has been found to be far more potent than cisplatin and can be used to treat cisplatin-
resistant cancers.
49
 It has DNA binding and anti-tumour activity distinct from that of 
cisplatin and other mononuclear platinum agents.
49
 The two reactive platinum centres of 
the complex are spaced far apart and so the platinum-DNA adducts that are formed are 
long-range adducts.
49
 The central platinum centre cannot covalently bind to DNA, however 
it has a high DNA affinity due to electrostatic interactions and hydrogen bonding with the 
DNA bases.
49
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Figure 1.20 Structure of tri-platinum BBR3464.49 
 
1.2.5.4 Platinum(IV) prodrugs  
Platinum(IV) prodrugs can be used to overcome the problems of cisplatin as they are 
relatively inactive and kinetically inert when compared to their platinum(II) analogues.
50
 
They must be activated by reduction and this occurs mainly in the acidic conditions of the 
tumour cell.
50
 The axial ligands also offer the potential to functionalise the drug with 
bioactive ligands, allowing targeting of specific tumour types. 
 
A very promising example of platinum(IV) prodrugs are two trans-diammine  platinum 
complexes (Fig. 1.21) developed by Sadler.
51
 The platinum(IV) complexes are relatively 
inert and are non-toxic in the dark. However, upon UV irradiation they are photoactivated 
to their platinum(II) analogues whereby they can form adducts with DNA and exert a 
potent cytotoxicity.
51
 It is known that platinum drugs with leaving groups trans to one 
another, as in transplatin, are usually inactive
52
 however these compounds have very 
similar activity to that of cisplatin in a human cancer cell line.
51
  
 
 
 
Figure 1.21 Structure of platinum(IV) prodrugs.51  
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1.3 Other, non-platinum based transition metal anticancer agents 
Inspired by the success of the metallo-drug cisplatin, a vast array of other transition metal-
based drugs have been developed as therapeutic agents. Transition metals have a range of 
coordination numbers and geometries and can consequently be used as scaffolds to obtain 
architectures not possible with organic molecules.
50
 The metal centre can impart a cationic 
charge to the molecule which is very favourable for DNA binding.
39
 Some transition metal 
complexes also have photophysical properties such as luminescence and so metallo-drugs 
can be used for diagnostic applications as well as therapeutic ones.
53
  
 
1.3.1 Ruthenium drugs 
Ruthenium complexes are often less toxic than platinum drugs and have a different mode 
of action due to being octahedral in geometry rather than square planar.
54
 It is thought that 
they are taken up into cells via transferrin receptor-mediated endocytosis.
54,55 
Two 
ruthenium drugs are currently undergoing clinical trials, NAMI-A and KP1019 (Fig. 1.22).  
 
 
 
Figure 1.22 Structure of ruthenium drugs NAMI-A (left) and KP1019 (right).55,56  
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NAMI-A shows very promising activity in vitro and has been found to be less toxic than 
cisplatin and is also less toxic to healthy cells.
56
 It has a different mechanism of action than 
platinum drugs, and other ruthenium drugs, in that it is not cytotoxic to tumour cells.
56
 
However it has strong efficacy in the treatment of solid tumours, even those in an advanced 
stage of growth.
56
 The mechanism for this anti-tumour activity has not been fully 
elucidated as yet.   
 
KP1019 is a potent anti-tumour agent against many different cancers, including colon 
cancer. It rapidly enters tumour cells, causing cell death by apoptosis.
55
 It is thought that 
DNA is not the main target for this drug but that its interaction with cellular proteins is 
responsible for its activity.
55
 
 
1.3.2 Rhodium drugs 
Rhodium-based metallo-drugs show potential as anticancer agents as many have potent 
anticancer activity and show limited side effects.
57
 They are attractive due to their possible 
photophysical properties and many rhodium(III) complexes have been found to perform 
photoinduced DNA cleavage.
58
  
 
A rhodium(III)-polypyridyl complex (Fig. 1.23) was found to be very cytotoxic against 
breast and colon cancer cell lines, with an activity greater than that of cisplatin.
57
 The 
complex was also found to affect cellular oxygen consumption, and therefore cell 
respiration, indicating an anti-mitochondrial mode of action.
57
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Figure 1.23 Structure of rhodium(III)-polypyridyl complex.57  
 
 
One example of a photoactivated rhodium-based drug is a rhodium(III)-dipyridophenazine 
complex (Fig. 1.24).
59
 It has been found to penetrate tumour cell membranes and is 
phototoxic when irradiated with UVA light.
59
 The complex forms adducts with DNA and 
acts as a photonuclease, cleaving the DNA strands.
59
 This rhodium(III) complex can also 
penetrate the protein shell of the Sindbis alphavirus and after photoactivation renders the 
viral genome non-infectious.
59
 
 
 
Figure 1.24 Structure of rhodium(III)-dipyridophenazine complex.59 
 
1.3.3 Rhenium drugs 
Luminescent rhenium-based drugs are also of great interest as they have many possible 
applications in diagnostic and therapeutic medicine.
60
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One example is a luminescent rhenium(I)-polypyridine complex (Fig. 1.25) designed as a 
biological sensor for cadmium(II) and zinc(II) ions.
61
 Studies showed that the compound 
was taken up by a human cervix epithelioid carcinoma cancer cell line and was far more 
cytotoxic than cisplatin.
61
 The compound could be used as a cellular stain, with increased 
luminescence emission upon addition of zinc(II) or cadmium(II) ions indicating its 
potential use as a biological probe.
61
 
 
 
 
Figure 1.25 Structure of rhenium(I)-polypyridine complex.61 
 
 
Other examples of rhenium complexes developed as anticancer compounds are two 
rhenium(IV) compounds with bipyridine and dimethyl-bipyridine ligands (Fig. 1.26).
62
 
These mononuclear complexes show potent cytotoxicity towards breast, ovarian and 
prostate cancer cell lines, with a higher anti-proliferative activity than cisplatin.
62
 It was 
also found that the bipyridine-rhenium(IV) complex causes cell death by apoptosis.
62
 
 
 
 
Figure 1.26 Structure of rhenium(IV)-bipyridine complexes.62 
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1.3.4 Iridium drugs 
Iridium metallo-complexes are often designed as biological probes due to their luminescent 
properties.
63
   
 
One example of a luminescent iridium complex that also possesses anticancer activity is an 
iridium(III)-polypyridine-indole complex (Fig. 1.27).
63
 Excitation of this complex gave 
rise to long-lived luminescence in the visible region, which makes it suitable for biological 
applications.
63
 In vitro studies confirmed that the complex has potent cytotoxicity, 
significantly greater than that of cisplatin, in a human cervix epithelioid carcinoma cancer 
cell line.
63
 Cellular uptake and microscopy studies indicated good uptake and localisation 
of the complex in the perinuclear area of the cell.
63
  
 
 
 
Figure 1.27 Structure of iridium(III)-polypyridyl-indole complex.63  
 
 
 
One recently developed iridium(III) complex (Fig. 1.28) has been found to act as a kinase 
inhibitor and possesses light-activated cytotoxicity.
64
 The complex inhibits vascular 
endothelial growth factor kinases, a possible novel anticancer target, which may lead to 
tumour growth inhibition.
64
 Cytotoxic activity of the compound was assessed in a human 
cervix epithelioid carcinoma cancer cell line and was found to be light dependent.
64
 In the 
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dark the compound was not cytotoxic, whereas when irradiated with UV light the 
compound was found to reduce cellular survival to 12.5%.
64
 
 
 
Figure 1.28 Structure of iridium(III) complex.64  
 
 
 
1.3.5 Iron drugs 
Metallo-complexes containing iron are of great interest, as iron is found abundantly in the 
body and is essential for many biological processes.
65
 
 
One example is an iron(II) complex with a pentadentate pyridyl ligand (Fig. 1.29) that is 
cytotoxic in breast and human cervix epithelioid carcinoma cancer cell lines with activity 
greater than that of cisplatin.
65
 This cell death is caused by DNA damage by the 
compound. The complex is also able to cleave DNA, inducing single strand cleavage of 
supercoiled DNA.
65
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Figure 1.29 Structure of iron(II) complex with pentadentate pyridyl ligand.65  
  
 
 
A bis(Fe(II)-EDTA-distamycin)fumaramide complex (Fig. 1.30) can bind to DNA with 
sequence preference for A/T rich regions of DNA and can also cleave DNA.
66
 
 
 
 
Figure 1.30 Structure of bis(Fe(II)-EDTA-distamycin)fumaramide complex.66 
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1.4 Targeting other DNA structures  
Although the majority of classical drugs bind to duplex DNA, a greater understanding of 
DNA processes has shown that DNA structures other than duplex DNA are often involved 
in DNA replication, transcription and recombination.
67,68
 These DNA structures are 
exciting new targets for therapeutic agents.  
 
1.4.1 Targeting the Holliday junction 
A Holliday junction, or four-way junction, is formed from two intertwined DNA duplexes 
that have exchanged strands (Fig. 1.31).
3
 The Holliday junction is an integral intermediate 
in homologous recombination; the process in which DNA is repaired.
69
 Targeting the 
Holliday junction may provide a new class of drugs with a different method of action to 
those of conventional duplex DNA binding drugs. 
 
 
Figure 1.31 Structure of Holliday junction. [Reproduced from Ref 70]  
 
A bis-acridine compound that can bind across the centre of this junction has been 
developed (Fig. 1.32).
69
 The molecule can interact with the junction in several ways, with 
the two acridine moieties extensively π-π stacking with the DNA bases of the crossover 
DNA strands.
69
 The hydrophobic side chains of the compound are positioned in the minor 
grooves of the junction and the positive charge of the compound neutralises the high 
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negative charge density of the junction, stabilising the structure by electrostatic 
interactions.
69
   
 
 
Figure 1.32 Structure of bis-acridine compound (top); Crystal structure of bis-acridine compound binding to 
Holliday junction (PDB 2GWA)69 (bottom). 
 
1.4.2 Targeting the three-way junction 
Three-way, or Y-shaped, junctions are another type of junction and are found in DNA and 
RNA.
71
 They are formed, like the four-way Holliday junction, from duplex DNA strands 
that converge at a point.
71
 Y-shaped junctions are thought to be the most abundant 
junctions and play important roles in DNA replication, RNA translation and are present in 
several diseases such as myotonic dystrophy type I and Huntington’s disease.72,73,74 
Consequently they may be an interesting target for the design of new therapeutic agents 
with a different mode of activity than conventional drugs.  
 
Chapter 1: Introduction 
 
29 
 
One known compound that can bind to DNA three-way junctions is a dinuclear iron(II) 
triple stranded complex (Fig. 1.33) developed by Hannon.
71
 The cylindrical complex is of 
the correct size and shape to fit neatly into the cavity in the centre of the three-way 
junction.
71
 The phenyl rings of the compound π-π stack with the DNA bases, and 
electrostatic interactions between the cationic compound and the negatively charged DNA 
help to stabilise the non-covalent binding interactions.
71
 The iron(II) complex is a potent 
cytotoxic agent, however this has yet to be directly linked to this DNA binding mode.
71
 
This compound, and its analogues, will be further discussed in Section 1.5.4. 
 
 
Figure 1.33 Structure of iron(II) triple stranded complex [Reproduced from Ref 75] (left); Crystal structure of 
iron(II) complex bound in the heart of a DNA three-way junction (PDB 2ET0)71 (right). 
 
1.4.3 Targeting G-quadruplexes 
Recently there has been much interest in G-quadruplex DNA structures. These are another 
example of non-classical DNA that may be targeted with more specificity and may provide 
a new mode of action for therapeutic agents.  
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G-quadruplexes are found at the telomere ends of chromosomes and are formed of several 
stacked G-tetrads, which are themselves formed of four guanine DNA bases interacting by 
Hoogsteen base pairing in a planar arrangement (Fig. 1.34).
9
 
 
 
 
Figure 1.34 G-tetrad where M+ = K+, Na+ or NH4
+ (left); Tetrameric, dimeric and monomeric G-
quadruplexes composed of three G-tetrads (right). [Reproduced from Ref 9] 
 
 
In normal cells telomeric DNA shortens after every cell division and when the telomeres 
get too short, the cells stop dividing and commit suicide.
50
 This is to maintain the DNA and 
prevent mutations. Telomerase is an enzyme that catalyses the synthesis of telomeric DNA 
and is overexpressed in cancerous cells, allowing indefinite replication and so a high 
proliferation rate.
9
 The formation of G-quadruplexes at the telomere ends of DNA stops 
telomerase action, and so if these G-quadruplexes can be induced or stabilised, cancer cell 
replication may be inhibited.
76
 Therefore, many small molecules have been designed to 
bind to and stabilise G-quadruplexes.  
 
One example is a manganese(III) porphyrin (Fig. 1.35) which has been found to 
preferentially bind to G-quadruplexes over duplex DNA.
76
 The complex interacts by π-π 
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stacking with the last G-tetrad and the four cationic arms interact with the loops of the G-
quadruplex.
76
 Electrostatic interactions occur between the positively charged complex and 
the negative G-quadruplex, strengthening the interaction.
76
 
 
 
 
Figure 1.35 Structure of manganese(III) porphyrin.76 
 
Another example is that of a tetra-substituted naphthalene diimide compound (Fig. 1.36), 
which binds to the terminal G-tetrad of G-quadruplexes and thermally stabilises the 
structure.
77
 Extensive π-π stacking can be observed between the compound and the G-
tetrad, and the four side chains are positioned within the G-quadruplex groove regions and 
can hydrogen bond to the guanine bases.
77
 The compound has been found to be a potent 
inhibitor of cell growth, however this has not been formally linked to the stabilisation of 
the G-quadruplex structure.
77
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Figure 1.36 Structure of naphthalene diimide compound (left); Crystal structure of naphthalene diimide 
compound (purple) interacting with G-quadruplex (turquoise spheres are potassium ions) (PDB 3T5E)77; side 
view (top right) and top view (bottom right). 
 
 
An N,N’-bis(quinolinyl)pyridine-2,6-dicarboxamide compound (Fig. 1.37) has been found 
to stabilise a human telomeric G-quadruplex, while no stabilisation was found for double 
stranded DNA, showing high selectivity.
78
 The compound could induce long-term 
inhibition of cell growth in several cancer cell lines.
78
 
 
 
 
Figure 1.37 Structure of N,N’-bis(quinolinyl)pyridine-2,6-dicarboxamide compound.78 
Chapter 1: Introduction 
 
33 
 
1.5 Supramolecular chemistry 
Supramolecular chemistry was defined as the ‘chemistry of molecular assemblies and of 
the intermolecular bond’ by its founder J.M. Lehn.79 It is the study of highly-organised and 
sometimes extremely complex molecular species that are formed from several discrete 
chemical components through intermolecular, non-covalent interactions rather than 
covalent bonds.
80,81
 Supramolecular chemistry involves the self-assembly of carefully 
designed molecular components, forming large highly functional molecular architectures 
with novel properties.
82
 The most impressive examples of supramolecular assembly can be 
seen in nature. For example, ferritin is a large and complex iron storage protein which is 
composed of many subunits that contain the inherent information that allows the formation 
of the whole supermolecule by self-assembly.
83
 
 
Supramolecular chemistry involves the formation of molecular architectures through non-
covalent interactions, including hydrogen bonding, electrostatics, π-π stacking, van der 
Waals and hydrophobic interactions.
81
 These interactions are weaker than covalent bonds, 
however collectively they are strong enough to allow the formation of large and complex 
structures.
81
  
 
1.5.1 Supramolecular helicates  
Supramolecular chemistry encompasses a broad range of architectures, but one area of 
particular interest is that of supramolecular helicates as many helical motifs appear in 
nature and important biological molecules.
84
 Supramolecular helicates are formed from the 
spontaneous self-assembly of organic ligands and metal ions, with one or more ligands 
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wrapping around and coordinating to one or more central metal ions.
85
 It is the intrinsic 
structural information encompassed within these components that allows the formation of a 
specific, directed architecture.
86
 The specific stereochemical requirements of the metal ion 
and the position of the binding sites on the ligand dictate the structure of the helicate that is 
formed.
84,86
  
 
The helicate ligand is made up of several metal ion polydentate binding sites with spacer 
groups between these units.
85
 The spacer must be flexible enough to allow the formation of 
the helical complex, yet rigid enough to prevent coordination of one metal ion to several 
binding units.
85
 Helicates can be classed as homotopic; if the metal binding units of the 
ligand are the same, or heterotopic; if the ligand contains different metal binding units (Fig. 
1.38).
85
 Heterotopic helicates exist as two isomeric forms, head-to-head (HH) or head-to-
tail (HT).
85
  
 
 
 
 
Figure 1.38 Configurations of homotopic and heterotopic helicates. [Adapted from Ref 85] 
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1.5.2 Chirality of helicates 
Supramolecular helicates are intrinsically chiral due to the way the ligands are wrapped 
around the central metal ions. If the ligands are wound in a clockwise direction, when 
viewed down the helical axis, they are right handed (P or plus) and if they are wound in an 
anti-clockwise manner they are left handed (M or minus) (Fig. 1.39).
86
  
 
 
 
Figure 1.39 P (left) and M (right) helicity of a dinuclear helicate. [Reproduced from Ref 87] 
 
If the helicate is formed from achiral ligands, a racemic mixture of M and P enantiomers 
will result.
87
 These may be separated by chiral resolving agents or chiral 
chromatography.
87
 However, there are many examples of enantiopure helicates synthesised 
from chiral, enantiopure ligands.
87
 Stereoselectivity can be forced by the rigidity of the 
ligand, the length of the ligand spacer or by introducing chiral moieties on the ligand 
coordinating units or spacer.
87,88
  
 
One example of an enantiopure helicate is a trinuclear triple stranded titanium(IV) complex 
synthesised from a chiral ligand (Fig. 1.40).
89
 The introduction of chiral groups to the 
Chapter 1: Introduction 
 
36 
 
ligand spacer allowed the complete control of the stereochemistry of the resulting 
helicate.
89
 
 
 
Figure 1.40 Structure of chiral ligand used to form enantiopure Ti(IV) helicate.89 
 
 
 
1.5.3 Applications of supramolecular helicates  
Although a vast array of supramolecular helicates have been developed, research into their 
applications is less established. One application of helicates is for the recognition and 
capture of anions, with helicates being designed to include an anion binding cavity. An 
example of this is a triple stranded dinuclear iron(II) helicate which has a cavity in which 
chloride ions can bind (Fig. 1.41).
90
  
 
 
 
 
Figure 1.41 Structure of ligand of iron(II) triple stranded helicate (top); Molecular model of chloride anions 
(green) bound in anion cavities of helicate [Reproduced from Ref 90] (bottom). 
 
Helicates have also been developed for use as catalysts. A chiral dinuclear silver(I) helicate 
(Fig. 1.42) was synthesised to be used as a catalyst for an asymmetric allylation reaction.
91
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The helicate afforded the desired product of the reaction in good yield but with low 
enantiomeric excess.
91
  
 
Figure 1.42 Structure of chiral dinuclear Ag(I) helicate.91 
 
Hannon et al have developed double and triple stranded metallo-helicates that are potent 
cytotoxic
75
 and anti-microbial 
92
 agents for use in therapeutic applications, as discussed in 
the next section.  
 
1.5.4 Supramolecular cylinders with anticancer activity 
Over the past decade supramolecular metallo-cylinders have been developed as potential 
anticancer agents in the Hannon group. These helicates are formed of pyridylimine ligands 
wrapped around two central metal ions (Fig. 1.43).
93
 The ligand is synthesised from 
commercially available, inexpensive starting materials and can be complexed with a range 
of metal salts to yield double or triple stranded dinculear helicates.
93
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Figure 1.43 Synthesis of iron(II) triple stranded supramolecular cylinder from pyridylimine ligand, L. 
[Reproduced from Ref 75] 
 
Modelling and DNA binding studies revealed that the triple stranded iron(II) cylinder, 
[Fe2L3]
4+
 (Fig. 1.43), is of the correct size and shape, 2 nm in length by 1 nm diameter, to 
bind in the major groove of DNA.
94
 This DNA binding is with some sequence preference 
for A/T rich regions and induces bending and intramolecular coiling of the DNA helix.
94,95
 
Atomic force microscopy (AFM) images of the cylinder with linearized plasmid DNA 
show dramatic intramolecular coiling of the DNA at moderate cylinder loading (Fig. 
1.44).
94
   
 
Figure 1.44 AFM images of linearized plasmid DNA in absence and presence of iron(II) triple stranded 
cylinder. [Reproduced from Ref 94] 
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Further studies revealed that the cylinder can also unwind duplex DNA, with an unwinding 
angle of 27°, and can do so rather extensively compared to other non-intercalative 
compounds.
95
 This indicates that the cylinder could have an effect on any cellular 
processes that require opening of the DNA helix, such as DNA transcription and 
replication.
96
  
 
Attempts to crystallise the iron(II) cylinder with a DNA palindromic hexanucleotide led to 
the discovery of an unprecedented mode of non-covalent DNA recognition. The crystal 
structure revealed a DNA three-way junction with the cylinder bound in its central cavity 
(Fig. 1.45) (as discussed in Section 1.4.2).
71
 
             
 
Figure 1.45 Crystal structure of [Fe2L3]
4+ bound in heart of DNA three-way junction (PDB 2ET0)71; front 
view (left) and side view (right). 
 
Further studies revealed that the cylinder can bind to and stabilise a variety of three-way 
junction, and other Y-shaped junction, structures formed from palindromic and non-
palindromic oligonucleotide sequences of varying lengths.
97
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This novel DNA recognition has many applications, as three-way junctions and other Y-
shaped junctions play a role in many biological processes, as previously discussed. 
 
Perhaps unsurprisingly, for a molecule that exhibits such strong DNA binding, the cylinder 
has been found to be a potent inhibitor of cellular proliferation in several cancer cell lines, 
with an activity IC50 (the drug concentration needed to inhibit cellular proliferation by fifty 
percent) only five times less than that of cisplatin.
75
  
 
Interestingly the cylinder is not genotoxic or mutagenic, properties that cause severe side 
effects in existing anti-cancer compounds such as cisplatin.
75,98
 The iron(II) complex also 
possesses antimicrobial activity
92
 and has been shown to inhibit the DNA binding of 
proteins involved in DNA replication.
99
 
 
These supramolecular cylinders are a racemic mixture of M and P enantiomers (Fig. 1.46), 
which can be separated by cellulose column chromatography with sodium chloride 
solution as the eluent.
100
 Studies have revealed that the two enantiomers have different 
DNA binding modes, with the M enantiomer having a stronger binding affinity for  DNA 
due to its ability to partially insert one of its chelates between the DNA bases in the major 
groove.
95
 The M enantiomer has been found to be more efficient at DNA coiling and 
unwinding, and can stabilise DNA three-way junctions more effectively than the P 
enantiomer.
95,97,101
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Figure 1.46 Structure of M and P enantiomers of [Fe2L3]
4+. [Reproduced from Ref 95] 
 
 
Double stranded dinuclear cylinders can also be formed, using tetrahedral metal ions such 
as copper(I) and silver(I). The copper(I) cylinder [Cu2L
1
2]
2+
 (Fig. 1.47) binds to DNA, 
although less strongly compared to the iron(II) triple stranded cylinder, likely due to its 
reduced charge.
102
 However, it can act as an artificial nuclease in the presence of peroxide, 
causing unusual double strand DNA cleavage at the same site.
102
 
 
 
Figure 1.47 Structure of ligand L1 in double stranded complex [Cu2L
1
2]
2+.102 
 
A luminescent triple stranded ruthenium(II) cylinder, [Ru2L3]
4+
, has also been developed 
that is highly stable due to its inert ruthenium centres.
103
 This cylinder can bind to DNA, 
induce intramolecular coiling and is cytotoxic, with IC50 values only 2-5 times less than 
cisplatin, against several cancer cell lines.
103
 More excitingly, this complex can cleave 
DNA in a sequence dependent manner upon irradiation with visible or UVA light.
104
 This 
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observed DNA photocleavage activity makes the ruthenium(II) cylinder a potential 
candidate for use in photodynamic therapy applications.
104
 
 
1.6 Summary and thesis aims 
There has been a vast amount of research conducted to try to understand the structure and 
function of DNA, to investigate the action of natural therapeutic agents and to develop 
synthetic agents with similar or enhanced efficacy.  
 
The work undertaken and presented in this thesis is an extension of the research on 
supramolecular helicates with anticancer activity, discussed in section 1.5.4. The aim of the 
work herein is to develop novel helicates, functionalised with a variety of DNA binding 
groups and biomolecules, to further probe the DNA binding activity of this class of 
metallo-drugs. In order to achieve a range of functionalised cylinders, a new 
functionalisation route is needed for the easy modification of the cylinder. Helicates with 
tumour-targeting steroid and sugar vectors will also be designed and synthesised in order 
to improve the specificity of these metallo-cylinders for their target, cancerous tissue. Their 
DNA binding and activity will be assessed using circular and linear dichroism, and agarose 
and polyacrylamide gel electrophoresis.  
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2.1 Introduction and aims 
As detailed in Chapter 1 (Section 1.5.4), double and triple stranded di-nuclear metallo-
cylinders (Fig. 2.1) have been developed as potential anticancer agents in the Hannon 
group.
1
  
 
Figure 2.1 Structure of triple stranded supramolecular cylinder [Reproduced from Ref 2] (left); Model of 
cylinder bound in major groove [Reproduced from Ref  3] (middle); Crystal structure of cylinder  bound in the 
heart of a DNA three-way junction (PDB 2ET0)4 (right). 
 
These cylindrical structures are of the correct size and shape to bind in the major groove of 
DNA
5
 and in the centre of DNA three-way junctions.
4
 They are able to unwind duplex 
DNA
6
 and are cytotoxic against several cancer cell lines.
2
 
 
Inspired by the successes of the parent cylinder, the aim of the work described herein was 
to design and synthesise functionalised supramolecular helicates (Fig. 2.2) that could be 
used to further probe, and possibly improve, the DNA recognition properties of this 
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exciting class of anticancer agents. Modification of these cylinders, by the addition of a 
variety of functional groups, R, may give further insight into the structural requirements of 
the DNA sites that these cylinders preferentially bind.  
 
Figure 2.2 Functionalised supramolecular cylinder. [Adapted from Ref 
2
] 
 
To achieve a range of functionalised cylinders, a novel functionalisation route was needed 
to allow the easy and varied modification of the cylinder, over few reaction steps. 
Functionalisation of these supramolecular helicates has been accomplished in the past, 
however the synthetic route used is less than ideal due to the many reaction steps needed.
7
 
 
2.2 Novel functionalisation route  
To synthesise these modified cylinders, a simple coupling procedure was needed so that 
many different functional groups could be attached using the same reaction conditions, 
over few reaction steps. Sonogashira cross-coupling is a well-known and documented 
procedure for the coupling of terminal alkynes and aryl/alkenyl halides, catalysed by 
palladium(0) and copper(I) catalysts, under mild conditions.
8
 The proposed synthesis 
(Scheme 2.1) involves Sonogashira coupling of the new functional moiety, R, to 
commercially available 5-bromopyridine-2-carboxaldehyde over one step.   
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Scheme 2.1 Sonogashira coupling of functional moiety, R, to 5-bromopyridine-2-carboxaldehyde. 
 
The triple stranded iron(II) cylinder can then be synthesised from the functionalised 
pyridine carboxaldehyde in a one-pot reaction (Scheme 2.2). 
 
 
Scheme 2.2 One-pot synthesis of functionalised iron(II) helicate. 
 
This synthesis route allows a variety of chemical groups to be conjugated to the cylinder, 
and many compounds containing an alkyne functional group are commercially available. 
However these compounds can also be easily synthesised. An alkyne group can be added 
in many ways, including via a palladium catalysed cross-coupling reaction (Scheme 2.3). 
 
 
 
Scheme 2.3 Proposed synthetic route for addition of an alkyne group, via a palladium catalysed cross-
coupling reaction, and subsequent silyl deprotection. 
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2.2.1 Sonogashira cross-coupling 
Sonogashira cross coupling involves the use of a palladium catalyst, either a Pd(0) catalyst 
such as [Pd(PPh3)4] or alternatively a Pd(II) pre-catalyst such as [Pd(PPh3)2Cl2], and a 
copper(I) catalyst such as CuI.
9
 The presence of an organic base such as triethylamine or 
diisopropylamine is also needed.
9
 The proposed mechanism of the cross-coupling reaction 
proceeds via a dual catalytic cycle (Scheme. 2.4) with the first step being an oxidative 
addition (A) of Pd(0) (f) into the C-X bond of an aryl or vinyl halide (b) to form the Pd(II) 
species (j).
9
 Transmetallation (B) then occurs, where the Pd(II) electron deficient metal 
centre accepts a terminal alkyne donor ligand, to form (k).
9
 It is thought that a copper 
catalytic cycle is responsible for the formation of copper acetylide (e), which transfers the 
alkyne to the palladium, from the alkyne reactant (a) via an intermediate (d).
9
 The 
reductive elimination step (C) produces the disubstituted alkyne (c), the reaction product, 
by forming a new carbon-carbon bond and at the same time regenerates the catalyst Pd(0).
9
  
 
If a palladium(II) pre-catalyst (g) is used, this must first be activated by phosphine or 
excess alkyne to form Pd(0) species (f).
9
 This is facilitated by a copper cycle that aids the 
sequential transfer of two alkyne ligands (a), and then reductive carbon-carbon bond 
formation to expel the diacetylene side product (i).
9
 An organic base is needed to remove 
the acid formed in the reductive elimination step of the palladium cycle.
9
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Scheme 2.4 Outline of reaction scheme and proposed catalytic cycles of Sonogashira coupling. [Adapted 
from Ref 9] 
 
2.3 Molecular design 
Several iron(II) cylinders functionalised with simple chemical groups were designed. The 
5-position of the pyridine carboxaldehyde was used as it is known that modification at this 
site, which has the effect of increasing the length of the cylinder, has the least effect on its 
DNA recognition properties.
10
 Widening of the cylinder by modification at the 3-position 
was found to weaken the DNA binding strength of the cylinder
10
 and this may also be the 
case for the 4-position. Modification at the 6-position of the pyridine ring was also ruled 
out due to possible steric hindrance of the iron coordination site, or inhibition of the 
formation of the triple stranded cylinder.  
 
The first cylinder to be synthesised, [Fe2L
TB
3]
4+
, was functionalised with an alkyne group 
only (Fig. 2.3). The DNA binding studies of this cylinder would indicate whether or not the 
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alkyne linker, present in all of the functionalised cylinders, would adversely affect the 
DNA recognition properties of these cylinders.  
 
 
Figure 2.3 Structure of LTB ligand of complex [Fe2L
TB
3]
4+. 
 
Two iron(II) cylinders, [Fe2L
PA
3]
4+
 and [Fe2L
Hex
3]
4+
, functionalised with alcohol groups at 
different distances from the helicate core were then designed (Fig. 2.4). It was hoped that 
these hydroxyl groups would increase solubility and may be able to hydrogen-bond with 
the DNA, increasing the interaction between the complex and the DNA. A flexible alkyl 
linker was incorporated into the hexyn-ol complex, [Fe2L
Hex
3]
4+
, which may have some 
effect on the interaction of the alcohol group with the DNA. 
 
 
Figure 2.4 Structures of LPA (top) and LHex (bottom) ligands of complexes [Fe2L
PA
3]
4+ and [Fe2L
Hex
3]
4+. 
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Finally, a cylinder functionalised with aromatic phenyl groups, [Fe2L
Phen
3]
4+
, (Fig. 2.5) was 
designed. It was thought that this group would allow any effects on the DNA binding of 
introducing aromatic substituents onto the cylinder to be explored. 
 
 
Figure 2.5 Structure of ligand LPhen of complex [Fe2L
Phen
3]
4+. 
 
2.4 Synthesis 
2.4.1 Synthesis of parent cylinder, [Fe2L
P
3][BF4]4 
11
 
The parent cylinder with tetrafluoroborate counterions has previously been synthesised
11
 
however the synthesis method described herein has not been reported. A one-pot synthesis 
was employed between the commercially available starting materials 2-
pyridinecarboxaldehyde, 4,4’-methylenedianiline and iron(II) tetrafluoroborate 
hexahydrate (Scheme 2.5) in a 6:3:2 stoichiometry. The reaction was performed in ethanol, 
with the starting materials added sequentially and dropwise, and an immediate colour 
change from pale yellow to deep purple was observed. Although this colour change signals 
the formation of the iron(II) complex, the reaction mixture was stirred at room temperature 
for 12 hours, to make sure that as much of the starting materials had reacted as possible. 
The product, which had precipitated from the reaction solution, was then collected by 
filtration. Washing with copious amounts of chloroform resulted in a light purple solid in 
81% yield.  
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Scheme 2.5 Synthetic route for preparation of [Fe2L
P
3][BF4]4. 
 
 
In the 
1
H NMR spectrum (Fig. 2.6), assigned using a 2D-COSY (see Appendix), a peak 
corresponding to the imine (Him) proton is observed, giving evidence for the formation of 
the product. The four phenyl protons give rise to two peaks in the spectrum corresponding 
to HPha and HPhb due to rotation of the phenylene rings at room temperature.  
 
 
 
 
Figure 2.6 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
P
3][BF4]4. 
 
The ESI mass spectrum (see Appendix) shows several multiply charged peaks with an 
isotopic distribution pattern corresponding to the species [Fe2(C25H20N4)3]
4+
,
 
[Fe2(C25H20N4)3]
3+
 and [Fe2(C25H20N4)3]
2+
.  
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2.4.2 Synthesis of triple bond cylinder, [Fe2L
TB
3][BF4]4 
2.4.2.1 Synthesis of 5-ethynyl-2-pyridinecarboxaldehyde (2) 
12
 
As 5-ethynyl-2-pyridinecarboxaldehyde (2) is not commercially available, it was 
synthesised in two steps from 5-bromo-2-pyridinecarboxaldehyde (Scheme 2.6) according 
to literature procedure.
12
  
 
 
Scheme 2.6 Synthetic route for preparation of 5-ethynyl-2-pyridinecarboxaldehyde (2). 
 
A Sonogashira coupling reaction was employed to couple trimethylsilylacetylene with the 
bromo-pyridine starting material in the presence of the catalysts 
bis(triphenylphosphine)palladium(II) dichloride and copper iodide in basic conditions. 
This was achieved by heating the reaction mixture at 80°C for 5 hours under an argon 
atmosphere. The triphenylphosphine oxide impurity from this reaction was removed by 
protonating the product with hydrochloric acid, partitioning the product and impurity using 
water and diethyl ether, neutralising the aqueous phase and extracting with ethyl acetate. 
The product (1) could then be purified using column chromatography on silica. In the 
second step of the synthesis, potassium carbonate was used to deprotect the silyl group of 
5-[(trimethylsily)ethyny])-2-pyridinecarboxaldehyde (1) to give the expected product (2) in 
an overall yield of 56%.  
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The off-white solid was characterised by 
1
H NMR (Fig. 2.7), high resolution EI mass 
spectrometry and elemental analysis which confirm the formation of the triple bond 
aldehyde (2) and are consistent with the literature.
12
 
 
 
 
Figure 2.7 1H NMR (300 MHz, CDCl3, 298 K) of 5-ethynyl-2-pyridinecarboxaldehyde (2). 
 
 
2.4.2.2 Synthesis of [Fe2L
TB
3][BF4]4 
To prepare the functionalised cylinder, a one-pot reaction using six equivalents of 5-
ethynyl-2-pyridinecarboxaldehyde (2), three equivalents of the spacer 4,4’-
methylenedianiline and two equivalents of iron(II) tetrafluoroborate hexahydrate, mixed 
sequentially and dropwise, was stirred for 12 hours in ethanol (Scheme 2.7). An immediate 
colour change from pale yellow to purple after addition of the starting materials was 
observed, indicating the formation of the iron(II) helicate. The resulting purple precipitate 
was collected by filtration and purified by washing with a large volume of chloroform. A 
yield of 73% was obtained for this synthesis. 
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Scheme 2.7 Synthetic route for preparation of [Fe2L
TB
3][BF4]4. 
 
 
The product was characterised using ESI mass spectrometry, in which peaks corresponding 
to multiply charged species [Fe2(C29H20N4)3]
4+ 
and [Fe2(C29H20N4)3]
3+ 
were observed
 
with 
the expected isotopic distribution patterns (see Appendix). In the 
1
H NMR spectrum (Fig. 
2.8), assigned using a 2D-COSY (see Appendix), characteristic peaks corresponding to the 
imine (Him), spacer (Hsp) and phenyl (HPha,Phb) protons are observed with the expected 
integration. The proton of the triple bond moiety is also observed.   
 
 
 
 
 
Figure 2.8 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
TB
3][BF4]4. 
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An overall yield of 41% was obtained, with respect to the 5-bromo-2-
pyridinecarboxaldehyde starting material, for the synthesis of the triple bond cylinder, 
[Fe2L
TB
3][BF4]4. 
 
 2.4.3 Synthesis of propargyl alcohol cylinder, [Fe2L
PA
3][BF4]4 
2.4.3.1 Synthesis of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3) 
As 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3) is not commercially available, 
it was synthesised in one step (Scheme 2.8). A Sonogashira coupling, with catalysts 
bis(triphenylphosphine)palladium(II) dichloride and copper iodide, between 5-bromo-2-
pyridinecarboxaldehyde and propargyl alcohol was performed in basic conditions under an 
argon atmosphere. The reaction mixture was heated to 80°C for 5 hours, after which time 
the crude product was purified by column chromatography on silica, to remove unreacted 
starting materials. The triphenylphosphine oxide impurity was removed by protonation of 
the product with hydrochloric acid, partitioning of the product and impurity, and 
subsequent neutralisation and extraction of the solution of 5-(3-hydroxyprop-1-ynyl)-2-
pyridinecarboxaldehyde. An off-white solid was produced, in a yield of 58%.  
 
 
Scheme 2.8 Synthetic route for preparation of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3). 
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High resolution EI mass spectrometry data was consistent with the formation of the 
product. The 
1
H NMR spectrum (Fig. 2.9) provides further evidence for the formation of 
the compound, as peaks corresponding to the aldehyde (Hald) and H7 protons are observed 
at the correct integration.  
 
 
  
Figure 2.9 1H NMR (300 MHz, CDCl3, 298 K) of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3). 
 
2.4.3.2 Synthesis of [Fe2L
PA
3][BF4]4 
A one-pot reaction between the propargyl alcohol aldehyde (3), 4,4’-methylenedianiline 
and iron(II) tetrafluoroborate hexahydrate with stoichiometry of 6:3:2 (Scheme 2.9) 
yielded the desired product in a very good yield of 96%.  
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Scheme 2.9 Synthetic route for preparation of [Fe2L
PA
3][BF4]4. 
 
The purple solid was purified simply by washing with copious volumes of chloroform. 
Characterisation by ESI mass spectrometry confirmed the cylinder had been formed, with 
species [Fe2(C31H24N4O2)3]
4+
, [Fe2(C31H24N4O2)3]
3+ 
and [Fe2(C31H24N4O2)3]
2+
 being 
identified (see Appendix). The 
1
H NMR spectrum (Fig. 2.10), assigned using 2D-COSY 
(see Appendix), contains the characteristic peaks corresponding to the imine (Him), spacer 
(Hsp) and phenyl (HPha,Phb) protons at the expected chemical shifts and integrations. The 
propargyl alcohol moiety can be identified by the peak corresponding to the H1 protons.  
 
 
 
Figure 2.10 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
PA
3][BF4]4. 
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An overall yield of 56% was obtained, with respect to the 5-bromo-2-
pyridinecarboxaldehyde starting material, for the synthesis of the propargyl alcohol 
cylinder, [Fe2L
PA
3][BF4]4. 
 
2.4.4 Synthesis of hexyn-ol cylinder, [Fe2L
Hex
3][BF4]4 
2.4.4.1 Synthesis of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4) 
As 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4) is not commercially available it was 
synthesised by coupling 5-bromo-2-pyridinecarboxaldehyde and 5-hexyn-1-ol using a 
Sonogashira procedure (Scheme 2.10). In the presence of the catalysts 
bis(triphenylphosphine)dichloropalladium(II) and copper iodide, the reaction was stirred 
for seventy two hours under an inert atmosphere. The triphenylphosphine oxide impurity, 
introduced by the palladium catalyst, was removed by a short silica column with diethyl 
ether as eluent. The product could then be purified further using column chromatography 
on silica to remove unreacted starting materials, yielding an off-white solid in 42% yield.  
 
 
Scheme 2.10 Synthetic route for preparation of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4). 
 
 
Characterisation by high resolution EI mass spectrometry confirmed the expected product, 
5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4), had been formed. The 
1
H NMR spectrum 
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(Fig. 2.11) shows peaks corresponding to the pyridine-carboxaldehyde and also to the 
hexyn-ol moiety. The H10 proton is found furthest downfield as it is closest to the 
electronegative oxygen, and one peak is observed for the H8 and H9 protons due to their 
similar chemical environments. 
 
 
 
Figure 2.11 1H NMR (300 MHz, CDCl3, 298 K) of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4). 
 
 
 
2.4.4.2 Synthesis of [Fe2L
Hex
3][BF4]4 
As with the previously synthesised alkyne cylinders, a one-pot reaction was used with the 
sequential and dropwise addition of six equivalents of 5-(hex-5-yn-1-ol)-2-
pyridinecarboxaldehyde (4), three equivalents of 4,4’-methylenedianiline and two 
equivalents of iron(II) tetrafluoroborate hexahydrate in ethanol (Scheme 2.11). An 
immediate precipitation of a purple species was observed which is consistent with the 
formation of an iron(II) cylinder. The reaction mixture was stirred overnight to allow the 
maximum amount of starting materials to react, and then the resulting precipitate was 
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collected by filtration and washed with chloroform. A 58% yield was obtained for this one-
pot reaction.   
 
 
 Scheme 2.11 Synthetic route for preparation of [Fe2L
Hex
3][BF4]4. 
 
 
The cylinder [Fe2L
Hex
3][BF4]4 was characterised by ESI mass spectrometry, in which three 
species corresponding to the multiply charged [Fe2(C37H36N4O2)3]
4+ 
,
 
[Fe2(C37H36N4O2)3]
3+ 
and [Fe2(C37H36N4O2)3]
2+
 were observed with the correct isotopic pattern (see Appendix). 
The 
1
H NMR (Fig. 2.12), assigned using a 2D-COSY (see Appendix), has peaks 
characteristic of these types of metallo-cylinders, including those corresponding to the 
imine (Him), spacer (Hsp) and phenyl (HPha,Phb) protons at expected chemical shifts and 
integrations. 
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Figure 2.12 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
Hex
3][BF4]4. 
 
An overall yield of 24% was obtained, with respect to the 5-bromo-2-
pyridinecarboxaldehyde starting material, for the synthesis of the hexyn-ol cylinder, 
[Fe2L
Hex
3][BF4]4. 
 
2.4.5 Synthesis of phenylacetylene cylinder, [Fe2L
Phen
3][BF4]4 
2.4.5.1 Synthesis of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5) 
As 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5) is not commercially available it was 
synthesised by Sonogashira coupling of 5-bromo-2-pyridinecarboxaldehyde and 
phenylacetylene (Scheme 2.12). The catalysts bis(triphenylphosphine)-
dichloropalladium(II) and copper iodide were used, as well as basic conditions and an inert 
atmosphere. The reaction mixture was stirred for 72 hours at room temperature. The 
triphenylphosphine oxide impurity, resulting from the palladium catalyst, was removed by 
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a short silica column with diethyl ether as eluent. Unreacted starting materials were then 
removed by column chromatography on silica, to yield a pale brown solid in 72% yield.  
 
 
Scheme 2.12 Synthetic route for preparation of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5). 
 
 
The compound was characterised by high resolution EI mass spectrometry, which 
confirmed the formation of the product. The 
1
H NMR spectrum (Fig. 2.13) also confirms 
the formation of the desired product, 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5). The 
pyridine-carboaxaldehyde peaks can be observed, as well as the peaks corresponding to the 
attached aromatic ring moiety at the expected chemical shifts and integration.  
 
 
Figure 2.13 1H NMR (300 MHz, CDCl3, 298 K) of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5). 
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2.4.5.2 Synthesis of [Fe2L
Phen
3][BF4]4 
The synthesis of [Fe2L
Phen
3][BF4]4 was achieved using a one-pot reaction with six 
equivalents of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5), three equivalents of 4,4’-
methylenedianiline and two equivalents of iron(II) tetrafluoroborate hexahydrate being 
mixed sequentially and dropwise in ethanol (Scheme 2.13). An immediate colour change 
from pale yellow to deep purple indicated the formation of an iron(II) cylinder, however 
the reaction mixture was stirred at room temperature overnight to ensure maximum yield 
of the product. The purple precipitate was collected by filtration and purified by washing 
with a large volume of chloroform to yield the desired product in 21% yield. 
 
 
 
Scheme 2.13 Synthetic route for preparation of [Fe2L
Phen
3][BF4]4. 
 
 
The [Fe2L
Phen
3][BF4]4 cylinder was characterised by ESI mass spectrometry, in which one 
peak corresponding to the species [Fe2(C41H28N4)3]
4+ 
was observed with the correct 
isotopic pattern (see Appendix). Observation of the characteristic cylinder peaks, in the 
1
H 
NMR spectrum (Fig. 2.14), corresponding to the imine (Him), spacer (Hsp) and phenyl 
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(HPha,Phb) protons is evidence of the desired product being formed. Peaks originating from 
the phenyl ring are also apparent, with the H2 and H3 protons overlapping. 
 
 
 
Figure 2.14 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
Phen
3][BF4]4. 
 
An overall yield of 15% was obtained, with respect to the 5-bromo-2-
pyridinecarboxaldehyde starting material, for the synthesis of the phenylacetylene cylinder, 
[Fe2L
Phen
3][BF4]4. 
 
2.5 Properties of synthesised alkyne cylinders 
2.5.1 Complex counterions  
The novel alkyne cylinders synthesised in this chapter are all dinuclear triple stranded 
cylinders with tetrafluoroborate counterions. The most favoured counterion would be 
chloride for these complexes, as the majority of the parent and later generation iron(II) 
cylinders have chloride counterions,
1,7
 however synthesis of these cylinders with chloride 
counterions was unsuccessful. One-pot syntheses with iron(II) chloride tetrahydrate, as 
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used in the formation of the parent cylinder,
1
 gave an immediate green precipitate which 
could not be identified by mass spectrometry or NMR spectroscopy. This observation 
suggests that the triple-stranded iron(II) helicate with chloride counterions is unstable and 
therefore does not form. This theory was further investigated by the addition of 
tetrabutylammonium chloride, a compound often used in the ion exchange of the parent 
cylinder, to a solution of the tetrafluoroborate alkyne cylinders. The deep purple solution 
immediately became a pale yellow colour, indicating degradation of the iron(II) cylinder. 
The addition of a solution of sodium chloride to the tetrafluoroborate alkyne cylinders had 
the same effect. These studies indicate that the chloride counterions somehow destabilise 
these alkyne triple-stranded cylinders, whereas the tetrafluoroborate counterions do not. 
 
2.5.2 Solubility of synthesised complexes 
Due to the nature of the desired application of these metallo-cylinders, as anti-cancer 
drugs, solubility is an important factor. The therapeutic effectiveness of a drug is linked to 
its ability to reach its target site in the body at an appropriate dose, and this is dependent on 
the aqueous solubility of the drug.
13
 However, there are many water-insoluble therapeutic 
drugs in development and therefore much research is on-going into methods of improving 
their bioavailability. Numerous drug carriers have been developed, such as water soluble 
polymers, microcapsules, liposomes and micelles, that can solubilise poorly soluble 
drugs.
14
 
 
The parent cylinder with chloride counterions, [Fe2L
P
3][Cl]4, is soluble in water as is the 
tetrafluoroborate complex, [Fe2L
P
3][BF4]4, (both in millimolar concentrations). This 
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aqueous solubility is very advantageous as DNA binding studies are carried out in aqueous 
solutions. Unfortunately none of the alkyne cylinders synthesised in this chapter are water 
soluble. The triple bond, propargyl alcohol and hexyn-ol cylinders, [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 respectively, are very soluble in methanol and 
acetonitrile. The phenylacetylene cylinder, [Fe2L
Phen
3][BF4]4, is only soluble in acetonitrile. 
This solubility in water-miscible solvents allows these complexes to be dissolved in water, 
with the assistance of a small percentage of methanol or acetonitrile, and so DNA binding 
studies can be carried out.  
 
2.5.3 UV-Vis stability studies 
When designing a metallo-drug, one pharmacokinetic consideration must be its stability 
when administered into the body. After entering the bloodstream, metallo-drugs will 
undergo some hydrolysis leading to unwanted metabolites that could cause side effects.
15
 
The stability of the synthesised cylinders is also important when investigating their DNA 
binding activity, as any degradation of the complex will affect the results of the DNA 
binding studies. The stability of the cylinders synthesised in this chapter were assessed 
using UV-Vis spectroscopy.  
 
The UV-Vis absorption of solutions of these cylinders in water (and sometimes a small 
percentage of methanol due to solubility issues) was measured every hour for twelve hours 
at room temperature. As the stability of metallo-cylinders has been known to improve in 
the presence of DNA,
16
 this was also measured, using a ct-DNA:complex ratio of 6:1, over 
Chapter 2: Novel Alkyne Metallo-Cylinders 
 
73 
 
a twelve hour period at room temperature. Any loss of absorbance over time indicates 
degradation of the complex. 
 
Firstly, the stability of the parent cylinder in water was investigated. As the cylinders 
synthesised in this work have tetrafluoroborate counterions, the stabilities of the parent 
complex with both chloride and tetrafluoroborate counterions was investigated to see if the 
counterion has any effect. It was found that the complexes [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4 have remarkably different stabilities at room temperature (Fig. 2.15). Over 
a 12 hour period the tetrafluoroborate complex loses 10% of its original absorbance, 
compared to only 2% for the chloride complex. However, in the presence of ct-DNA (calf 
thymus DNA) the complexes have a much greater and more comparable stability, with 
hardly any degradation for either compound. This is evidence that although the counterion 
has an effect on the complex stability at room temperature, in the presence of DNA the 
tetrafluoroborate counterion has no significant disadvantages. 
 
Figure 2.15 Normalised UV-Vis stability studies of complexes [Fe2L
P
3][Cl]4 and [Fe2L
P
3][BF4]4 at room 
temperature (10 μM, water) and in presence of ct-DNA in 6.7 mM NaCl and 0.33 mM Na(CH2)2AsO2.3H2O 
(pH 6.8)  (ratio 6:1 ct-DNA:complex). λmax = 573 nm. 
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The stability of the alkyne cylinders synthesised in this chapter was also explored. Due to 
these complexes not being completely water soluble, a small percentage of methanol or 
acetonitrile was needed to solubilise them. All four complexes showed degradation at room 
temperature, with [Fe2L
PA
3][BF4]4 being the most stable with a loss of  8% of absorbance 
over 12 hours. The [Fe2L
Phen
3][BF4]4 cylinder was the least stable, with a loss of 54% of its 
original absorbance and a half-life of 11 hours (Fig. 2.16). The stability of all of the 
complexes, apart from [Fe2L
Phen
3][BF4]4, was greatly improved in the presence of ct-DNA. 
The complex with the greatest stability improvement was [Fe2L
TB
3][BF4]4, with a loss of 
only 2% of its original absorbance in the presence of DNA over 12 hours, compared to a 
loss of 49% without DNA. 
 
 
 
Figure 2.16 Normalised UV-Vis stability studies of (left) complexes [Fe2L
TB
3][BF4]4 and [Fe2L
PA
3][BF4]4 at 
room temperature (10 μM, 3% MeOH:water) and in presence of ct-DNA in 6.7 mM NaCl and 0.33 mM 
Na(CH2)2AsO2.3H2O (pH 6.8)  (ratio 6:1 ct-DNA:complex, 1.9% MeOH:water). λmax = 591 nm. 
And (right) complexes [Fe2L
Hex
3][BF4]4 and [Fe2L
Phen
3][BF4]4 at room temperature (8 μM, 2.4% 
MeOH:water, 2.4% MeCN:water respectively) and in presence of ct-DNA in 6.7 mM NaCl and 0.33 mM 
Na(CH2)2AsO2.3H2O (pH 6.8)  (ratio 6:1 ct-DNA:complex, 1.9% MeOH:water and 1.9% MeCN:water 
respectively). λmax 589 nm and 605 nm respectively. 
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This apparent stabilising effect of DNA to these complexes has previously been observed 
with other iron(II) supramolecular cylinders.
16
 As these types of cylinders are known to 
bind in the major groove of DNA,
5,16
 it is possible that the DNA groove shields or protects 
the cylinders from attack by solvent molecules, slowing down their degradation. This may 
explain why the stability of [Fe2L
Phen
3][BF4]4 with and without ct-DNA is very similar. As 
this cylinder is more bulky in shape than the other alkyne cylinders described, it may not 
fit into the major groove of the DNA as well and therefore will not be as shielded to 
solvent attack.  
 
Taking into account that the DNA binding studies detailed herein involve maximum 
experimental times of 5 hours, it can be concluded that the stabilities of these alkyne 
cylinders should not significantly affect any conclusions that may be drawn from them, 
except perhaps for [Fe2L
Phen
3][BF4]4.   
 
2.6 DNA binding studies  
Four novel iron(II) supramolecular cylinders functionalised with small chemical groups 
have been synthesised and characterised. The DNA binding properties of these novel 
cylinders were investigated by several techniques. DNA binding studies of the parent 
cylinder with tetrafluoroborate counterions, [Fe2L
P
3][BF4]4, were also carried out for 
comparison as this complex had not been investigated previously. 
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2.6.1 Circular dichroism 
Circular dichroism (CD) is a highly sensitive spectroscopic technique used to investigate 
DNA conformation in solution and drug-DNA interactions.
17
 CD measures the difference 
in absorption of left (Al) and right (Ar) circularly polarised light: 
CD = Al - Ar 
Circularly polarised light consists of two linearly polarised light beams oscillating 
perpendicularly to each other.
18
 The rotating electric field vector maintains a constant 
magnitude but rotates about the propagation direction in the form of a helix (Fig. 2.17).
18
 If 
the vector forms a right-handed helix the light is right-circularly polarised, whereas a left-
handed helix is left-circularly polarised. At each point in space and time the magnetic field 
vector is perpendicular to the electric field.
19
   
 
Figure 2.17 a) Left-circularly polarised light, propagating in z direction. Arrows show rotating electric field 
vector, the magnetic field vector is perpendicular to the electric field vector. [Reproduced from Ref 20]  
b) Left- and right-circularly polarised light. [Reproduced from Ref 18] 
 
Circular dichroism is used to study chiral molecules. Chiral molecules, defined as being 
non-superimposable on their mirror image, do not have a plane of reflection therefore any 
rearrangement of electrons occurs in a helical nature.
19
 As CD uses circularly polarised 
light, with electric field vectors propagating in a helical manner, the molecule will interact 
a)                                                        b) 
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differently with left and right handed circularly polarised light.
19
 This difference in 
absorption of left and right circularly polarised light is plotted against wavelength, 
resulting in a CD spectrum.
18
   
 
DNA is a chiral molecule, due to the chiral sugar units that make up the sugar-phosphate 
backbone, and therefore has its own CD spectrum (Fig. 2.18). The CD spectrum of the B-
form of ct-DNA exhibits positive and negative bands of nearly equal magnitudes between 
200-300 nm. The CD signals in the UV region do not result from the chiral sugar-
phosphate backbone, as it has no important transitions in this region, but from transitions 
of the purine and pyrimidine bases that are in a chiral environment created by the sugar-
phosphate backbone.
19
  
 
 
Figure 2.18 CD spectrum of ct-DNA (B-conformation). 
 
As mentioned previously, circular dichroism is a valuable technique in probing drug-DNA 
interactions. Many DNA-binding molecules are achiral and so do not have a CD spectrum 
of their own. However by binding to DNA, the drug acquires an induced chirality from its 
environment, giving rise to an induced CD (ICD) signal.
19
 The resulting CD spectrum 
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gives information about the conformation of DNA, if it is retained or altered due to the 
drug binding, and gives an insight into the binding mode of the drug, indicated by 
characteristic ICD signals.
19
 
 
In the work detailed in this thesis, CD titrations with calf thymus DNA are carried out in an 
aqueous buffered solution, keeping a constant DNA concentration and decreasing the ratio 
of ct-DNA:complex by adding aliquots of a stock solution of complex. CD spectra are 
measured after each addition of complex and overlaid to give a CD titration spectrum as 
shown in figure 2.19. 
 
2.6.1.1 Circular dichroism studies of the parent cylinder, [Fe2L
P
3]
4+
, with different 
counterions 
In recent work, the DNA binding activity of the parent iron(II) metallo-cylinder, 
[Fe2L
P
3][Cl]4, as studied by circular dichroism was reported.
5,21
 The CD spectrum of the 
titration of [Fe2L
P
3][Cl]4 with ct-DNA (Fig. 2.19) has several features which show that the 
cylinder is binding to DNA without perturbing its B-conformation. There are several 
induced CD (ICD) signals in the MLCT region of the metal complex, at 315 nm, 375 nm, 
541 nm and 610 nm, which show that the cylinder is binding to the DNA. As the 
concentration of complex in solution increases, so too does the ICD signal suggesting an 
additive effect.
5,21
 In the DNA region of the spectrum (200-300 nm) there is no significant 
change to the CD signal showing that the binding of [Fe2L
P
3][Cl]4 does not alter the DNA 
geometry.
5,21
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Figure 2.19 CD spectrum of 500 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of [Fe2L
P
3][Cl]4. Legend shows ct-DNA:complex ratios. [Reproduced from Ref 
21] 
 
 
The parent cylinder with tetrafluoroborate counterions, [Fe2L
P
3][BF4]4 has previously been 
synthesised,
11
 however its DNA binding activity had not been investigated. As the 
functionalised cylinders presented in this thesis have tetrafluoroborate counterions the 
DNA binding activity of the parent cylinder with tetrafluoroborate counterions, and its 
comparison with the parent cylinder with chloride counterions, is of great interest.  
 
As already discussed (Section 2.5.3) the stability of [Fe2L
P
3][Cl]4 is significantly greater 
than that of [Fe2L
P
3][BF4]4, however in the presence of ct-DNA the stabilities of these 
complexes are very similar. This allows comparison of the results of DNA binding studies 
carried out for both cylinders, as their degradation is very similar in an environment where 
DNA is present. 
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CD titrations with ct-DNA were carried out for the complexes [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4 and the resulting CD titration spectra were found to be almost identical as 
expected. The spectrum for [Fe2L
P
3][BF4]4 is shown below (Fig. 2.20). As previously 
discussed, characteristic ICD signals in the MLCT region of the complexes are observed 
which indicate binding to ct-DNA, with no change to the DNA B-conformation.             
   
 
Figure 2.20 CD of 295 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
P
3][BF4]4. Legend shows ct-DNA:complex ratios. Analysed in a 
1cm pathlength cuvette.   
 
When the ICD signals at 338 nm and 622 nm are plotted against complex concentration 
(Fig. 2.21), it is apparent that both complexes have a very similar behaviour towards DNA. 
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Figure 2.21 Normalised ICD signal vs complex concentration for complexes [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4 at 338 nm and 622 nm. 
 
These CD studies provide evidence that the counterion of these iron(II) helicates does not 
significantly alter their DNA binding activity.  
 
2.6.1.2 Circular dichroism studies of synthesised alkyne cylinders 
CD titrations analogous to those performed with the parent cylinder were carried out for 
the synthesised alkyne cylinders in order to assess their DNA binding activity. Due to their 
poor solubility in water, concentrated stock solutions of the alkyne cylinders in methanol, 
or acetonitrile for [Fe2L
Phen
3][BF4]4, were made. These were then diluted with water to 
achieve the final complex solutions used in the CD titration experiments. The percentage 
of methanol, or acetonitrile, at the end of each titration was calculated to be 6% at most. 
Control experiments were carried out to assess whether the solvent had any effect on the 
CD spectroscopy of ct-DNA. The titration was performed as usual, but instead of titrating 
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in a stock solution of complex, a solution of water with the corresponding percentage of 
methanol or acetonitrile was added. The resulting CD spectra showed that the small 
percentage of solvent had no effect on the ct-DNA.  
 
For each complex, two equal titrations were carried out using the same stock solutions of 
DNA and complex. One titration was performed in a 1cm pathlength cuvette, so as to 
analyse the less intense MLCT region. However as more complex is titrated into the DNA-
complex solution, the concentration increases, and so the CD signal in the UV region 
becomes saturated. This is usually observed when a DNA:complex ratio of 10:1 is reached. 
To study the UV region at higher complex concentrations, the titration is also carried out in 
a 0.1 cm pathlength cuvette. This can be explained using the Beer Lambert law: 
A= ε c l 
Where A = absorbance, ε = molar absorption coefficient (mol-1dm3cm-1), c = concentration 
(moldm
3
) and l = pathlength (cm). 
 
If the pathlength, l, is shortened the absorbance, and consequently the saturation, of the 
sample will be lower.   
 
None of the alkyne cylinders has an intrinsic CD signal as they exist as a racemic mixture 
of M and P enantiomers. As a result, the CD signals that are observed in the spectroscopic 
regions of the complex are due to interaction with DNA.  
 
The CD titration spectra of the triple bond cylinder, [Fe2L
TB
3][BF4]4, (Fig. 2.22) reveal an 
ICD signal at 312 nm. This indicates that the cylinder is binding to ct-DNA. The B-
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conformation of DNA is retained upon cylinder binding. However at higher complex 
loading, with a ratio of DNA:complex of 6:1 (0.1 cm pathlength spectrum), a new peak 
arises at approximately 241 nm, overlapping the DNA signature. This is most likely due to 
the complex in-ligand spectroscopy.   
 
Figure 2.22 CD of 266 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
TB
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.3% max. 
MeOH. Analysed in 1cm (a) and 0.1cm (b) pathlength cuvettes.  
 
An induced CD signal at 326 nm can be observed in the CD titration spectra of the 
propargyl alcohol cylinder, [Fe2L
PA
3][BF4]4, (Fig. 2.23). This ICD signal arises from the 
interaction between the cylinder and DNA, and indicates a binding event. The 
characteristic B-DNA signal between 200-300 nm is unaffected by this binding, apart from 
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small decreases in its intensity. At the lowest DNA:complex ratio of 4:1, an extra band 
arises at 241 nm due to in-ligand complex spectroscopy, which overlaps the DNA 
spectroscopy.  
 
Figure 2.23 CD of 295 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
PA
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.9% max. 
MeOH. Analysed in 1cm (a) and 0.1cm (b) pathlength cuvettes.  
 
The CD titration spectra for the hexyn-ol cylinder, [Fe2L
Hex
3][BF4]4, (Fig. 2.24) indicate 
that the complex binds to ct-DNA as an ICD signal at 330 nm can be observed.  The B-
conformation of ct-DNA is retained throughout the titration and is not affected by the 
cylinder binding.  From a ratio of DNA:complex of 10:1 a band corresponding to the in-
ligand spectroscopy appears at approximately 246 nm, overlapping the DNA transitions.  
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Figure 2.24 CD of 285 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Hex
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.7% max. 
MeOH. Analysed in 1cm (a) and 0.1cm (b) pathlength cuvettes.  
 
Induced CD signal at 348 nm is apparent in the CD titration spectra of the phenylacetylene 
cylinder, [Fe2L
Phen
3][BF4]4, (Fig. 2.25) giving evidence that the complex binds to ct-DNA. 
As more and more complex binds to the ct-DNA, the shape of the DNA signal remains 
unchanged therefore the B-conformation of DNA is retained upon cylinder binding. As the 
ICD signal for this complex is less intense than for the other cylinders, it cannot be 
observed in the 0.1 cm pathlength cuvette.   
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Figure 2.25 CD of 241 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex  [Fe2L
Phen
3][BF4]4. Legend shows ct-DNA:complex ratios. 6% max. 
MeCN. Analysed in 1cm (a) and 0.1cm (b) pathlength cuvettes. 
 
2.6.2 Linear Dichroism 
Linear dichroism (LD) is another technique used to study DNA conformation and drug-
DNA interactions. LD measures the difference in absorption of light linearly polarised 
parallel and perpendicular to an orientation axis: 
LD = Aparallel -Aperpendicular 
In linearly polarised light the electric field vector oscillates in the same plane (Fig. 2.26).
19
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Figure 2.26 Linearly polarised light. [Reproduced from Ref 19] 
 
LD is used to probe molecules that are long enough to be oriented, such as DNA. A couette 
cell can be used to orient a sample by viscous drag.
22
 Linearly polarised light can interact 
with the oriented DNA molecules producing an LD spectrum (Fig. 2.27). The DNA bases 
are situated perpendicular to the helix axis and therefore the transitions of the bases are 
also perpendicular to the helix axis, giving rise to a negative signal in the DNA absorbance 
region, between 200-300 nm.
22
   
 
Figure 2.27 LD spectrum of ct-DNA (B-conformation). 
 
As most DNA-binding molecules are too small to be oriented themselves they do not have 
their own LD spectrum. However when these molecules bind to DNA they become 
oriented and an induced LD signal (ILD) results from the interaction.
22
 The LD spectrum 
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gives information about the conformation of DNA and how it is affected by the binding of 
a drug molecule, and characteristic ILD signals can provide evidence of a specific binding 
mode.   
 
In the work detailed in this thesis, LD titrations with ct-DNA were carried out in aqueous 
buffered solution, keeping a constant DNA concentration and decreasing the ratio of ct-
DNA:complex by adding aliquots of a stock solution of complex. LD spectra are measured 
after each addition of complex and overlaid to give an LD titration spectrum as shown in 
figure 2.28. 
 
2.6.2.1 Linear dichroism studies of the parent cylinder, [Fe2L
P
3]
4+
, with different 
counterions 
The DNA binding activity of the parent cylinder, [Fe2L
P
3][Cl]4, as investigated by linear 
dichroism was recently reported.
5,21
 The LD spectrum for the titration between ct-DNA 
and [Fe2L
P
3][Cl]4 (Fig. 2.28) shows an induced LD (ILD) signal at 569 nm in the MLCT 
region of the complex. As the concentration of complex increases, the ILD signal also 
increases confirming that the cylinder is binding to the DNA, not at random sites but in a 
specific orientation.
5,21
 The DNA LD signal at 260 nm, arising from the DNA bases, 
decreases in magnitude as cylinder concentration increases, showing that the cylinder is 
binding to the DNA and kinking or coiling it.
5,21
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Figure 2.28 LD spectrum of 500 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of [Fe2L
P
3][Cl]4. Legend shows ct-DNA:complex ratios. [Reproduced from Ref 
21]  
 
 
Although previously synthesised,
11
 the DNA binding of the parent cylinder with 
tetrafluoroborate counterions, [Fe2L
P
3][BF4]4, had not been studied by LD. Due to the 
synthesised complexes in this work having tetrafluoroborate counterions, it was deemed 
very important to compare the DNA binding of [Fe2L
P
3][Cl]4 and [Fe2L
P
3][BF4]4 by linear 
dichroism, to see if altering the counterion can affect the DNA binding activity in any way. 
 
LD titrations with ct-DNA were carried out for both [Fe2L
P
3][Cl]4 and [Fe2L
P
3][BF4]4 
complexes and the results compared. The spectra were found to be very similar for both 
complexes. The spectrum of the LD titration of [Fe2L
P
3][BF4]4 (Fig. 2.29) shows, as 
previously detailed, an ILD signal in the MLCT region that increases with increasing 
complex concentration, indicating oriented binding. The magnitude of the DNA band at 
260 nm decreases with increasing complex concentration, showing kinking or coiling of 
the DNA upon cylinder binding.   
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Figure 2.29 LD of 295 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
P
3][BF4]4. Inset shows expansion of MLCT region. Legend shows 
ct-DNA:complex ratios.  
 
To compare the DNA interaction of these complexes, the ILD can be plotted against 
complex concentration (Fig. 2.30). It is observed that the complexes [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4 induce a very similar effect on the DNA when they bind.  
 
 
Figure 2.30 Normalised LD signal at 260 nm vs complex concentration for complexes [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4. 
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These LD studies demonstrate that the counterion of these iron(II) helicates has no 
significant effect on the DNA binding. 
 
2.6.2.2 Linear dichroism studies of synthesised alkyne cylinders 
Linear dichroism titrations analogous to those performed with the parent cylinder were 
carried out for the complexes synthesised in this chapter. As these complexes are not water 
soluble, concentrated stock solutions of the alkyne cylinders in methanol, or acetonitrile for 
[Fe2L
Phen
3][BF4]4, were made and then diluted with water to achieve the final complex 
solutions used in the titrations. Maximum percentages of 6% methanol and 7% acetonitrile 
were used and control LD titrations were carried out in order to ensure that these solvents 
had no effect on the ct-DNA. 
 
As these iron(II) cylinders are too small to be oriented by the couette cell, no intrinsic LD 
signal can arise from the cylinders. Consequently any ILD signal observed must come 
from the interaction between the complex and ct-DNA. 
 
The LD titration spectrum with complex [Fe2L
TB
3][BF4]4 (Fig. 2.31) shows a strong ILD 
signal between 500-650 nm in the MLCT region of the complex. As the concentration of 
complex increases so too does the magnitude of this LD signal. This shows that the 
complex is binding to the DNA in a specific orientation and not just randomly. There is 
also induced LD signal apparent at 298 nm, but only at higher complex loading. It is 
observed that the magnitude of the negative DNA band at 260 nm decreases as the 
complex concentration increases. This indicates that the complex is binding to the DNA 
and causing a loss of orientation by coiling or bending the DNA. Even on addition of a 
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very small concentration of complex there is an immediate effect on this negative DNA 
band, showing that this coiling occurs at very low complex loading.  
 
Figure 2.31 LD of 252 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
TB
3][BF4]4. Inset shows expansion of MLCT region. Legend 
shows ct-DNA:complex ratios. 5% max. MeOH. 
 
In the LD titration spectrum (Fig. 2.32) of the propargyl alcohol cylinder, [Fe2L
PA
3][BF4]4, 
an ILD signal between 500-650 nm, with a maximum at 599 nm, can be observed. The 
magnitude of this LD signal increases as the cylinder concentration increases revealing 
oriented binding of the complex to the ct-DNA. At higher complex loading, with ratios of 
DNA:complex of 10:1 to 4:1,  an induced LD signal at 310 nm can also be seen. The 
negative DNA LD band decreases in magnitude with increasing cylinder loading. This 
means that complex binding induces bending or coiling of the DNA, even at very low 
complex loading.  
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Figure 2.32 LD of 262 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
PA
3][BF4]4. Inset shows expansion of MLCT region. Legend 
shows ct-DNA:complex ratios. 5.2% max. MeOH. 
 
In the LD titration spectrum of [Fe2L
Hex
3][BF4]4 (Fig. 2.33), an induced LD signal can be 
observed in the MLCT region of the complex, with a maximum at 598 nm. This ILD signal 
increases in intensity as the cylinder concentration is increased, indicating that the complex 
binds to the DNA in a specific orientation and not just randomly. Another ILD signal can 
be seen at 305 nm at higher complex loading. Upon increasing complex concentration, the 
magnitude of negative DNA LD band decreases, indicating coiling or bending of the DNA 
induced by the hexyn-ol functionalised cylinder.   
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Figure 2.33 LD of 286 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Hex
3][BF4]4. Inset shows expansion of MLCT region. Legend 
shows ct-DNA:complex ratios. 5.7% max. MeOH. 
 
There is no detectable ILD signal in the LD titration spectrum for complex 
[Fe2L
Phen
3][BF4]4 (Fig. 2.34). Even at high complex loading, with a DNA:complex ratio of 
4:1, no signals are observed that would suggest oriented binding of this complex. However 
the magnitude of the negative DNA LD band at 260 nm can be observed to decrease as the 
concentration of the complex is increased, even at low cylinder loading. This confirms that 
although no induced LD signal is apparent, the complex is binding to the DNA and causing 
the dramatic coiling or bending observed for other iron(II) cylinders.    
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Figure 2.34 LD of 274 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Phen
3][BF4]4. Legend shows ct-DNA:complex ratios. 6.9% max. 
MeCN. 
 
The DNA binding activities of the alkyne cylinders discussed can be compared to each 
other and to the parent cylinder by calculating the percentage loss of LD signal of the 
negative DNA band at 260 nm (Table 2.1) and also by plotting the magnitude of this LD 
DNA band versus complex concentration (Fig. 2.35). It can be observed that all of the 
complexes induce dramatic DNA coiling/bending on binding, even at low complex 
concentration. At the highest complex loading, corresponding to a DNA:complex ratio of 
4:1, a loss of 99% of the LD signal is induced by the parent cylinder with tetrafluoroborate 
counterions. The complexes [Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 have a 
similar effect, especially at high complex loading. The phenylacetylene complex induces 
the least coiling of the DNA, with a 59% loss of LD signal for the DNA band. This is 
likely due to its bulky inflexible nature which perhaps does not allow such close proximity 
to the DNA as the other cylinders.  
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DNA:complex 
ratio 
% Loss of LD signal at 260nm upon interaction with complexes 
 
4:1 [Fe2L
P
3][BF4]4 [Fe2L
TB
3][BF4]4 [Fe2L
PA
3][BF4]4 [Fe2L
Hex
3][BF4]4 [Fe2L
Phen
3][BF4]4 
99 97 87 91 59 
 
Table 2.1 Comparison of the percentage loss of LD signal at 260 nm upon interaction with complexes at a 
ratio of DNA:complex 4:1. 
 
 
Figure 2.35 Normalised LD signal at 260 nm vs complex concentration for parent and alkyne complexes. 
 
2.6.3 Gel electrophoresis 
Agarose gel electrophoresis is a widely used technique for the separation of biomolecules, 
such as DNA fragments, based on their size, charge or conformation.
23
 In this work, a 
small bacterial plasmid pBR322 is used as a model system for probing the interaction 
between DNA-binding drug molecules and supercoiled DNA.
24
 Supercoiled DNA is found 
extensively in living cells, and is important in any process that requires opening of the 
double helix of DNA, such as replication and transcription.
25,26 
The pBR322 plasmid exists 
as two forms in solution, supercoiled and circular (relaxed) forms. The supercoiled form is 
negatively supercoiled (Fig. 2.36), which means that it is under wound, as are most circular 
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DNA’s found in nature (mitochondrial, viral and bacterial).26 As this negatively 
supercoiled structure is under wound it exerts a force that helps to separate the strands of 
duplex DNA, assisting the processes of replication and transcription.
26
 
 
 
Figure 2.36 Negatively supercoiled DNA (left); Relaxed circular form; loss of supercoiling due to unwinding 
by DNA helicases or DNA-binding drug (middle); Positive supercoiling of relaxed form due to further strand 
separation (right). [Reproduced from Ref 24] 
 
Agarose gel electrophoresis is employed in this work to study the interaction between the 
metallo-helicates synthesised and supercoiled pBR322 plasmid DNA. Gel electrophoresis 
studies are performed by loading the agarose gel with samples of mixtures of pBR322 
DNA and the metal complexes at different ratios. When an electric field is applied, the 
negatively charged DNA migrates through the gel towards the positive electrode separating 
the two forms of DNA, circular and supercoiled, due to their difference in size and 
therefore migration speed (Fig. 2.37).   
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Figure 2.37 Schematic representation of an agarose gel showing different migration speeds of circular and 
supercoiled DNA. 
 
The different bands in the gel corresponding to the two forms of DNA are visualised using 
ethidium bromide as a stain, which intercalates into the DNA and is visible under UV 
light.
23
 
 
If a drug does bind to the supercoiled form of plasmid DNA, this will cause the supercoiled 
DNA to unwind and therefore increase in size or volume (Fig.2.36). This can be observed 
as a slowing down of the speed of migration of the supercoiled band through the gel, from 
the negative to positive electrode. Therefore if the supercoiled DNA is observed to be 
unwound by the metal complex, it suggests that the complex is binding to the DNA.
6
  
 
If the circular and supercoiled bands co-migrate then the unwinding angle, Φ, defined as 
the number of degrees by which the DNA is unwound about its helical axis per molecule 
bound, can be calculated using the formula: 
Φ = 
    
    
 
where, Φ = DNA unwinding angle, σ = superhelicity constant and r(c) = ratio of DNA 
base:complex bound at which the circular and supercoiled bands co-migrate. 
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The superhelicity constants for plasmids pBR322 and pUC19, determined using cisplatin 
which has a known unwinding angle of 13°, were found to be -0.059 and -0.058 
respectively.
6,27
 
 
In the studies detailed in this thesis agarose gel electrophoresis was performed using DNA 
plasmids pUC19, for parent complex [Fe2L
P
3][Cl]4, and pBR322, for all other complexes. 
Solutions containing different ratios of plasmid DNA:metal complex are loaded onto a 1% 
agarose gel and the gel is run by applying an electric current. The DNA bands in the gel 
are visualised using ethidium bromide as a stain. If the bands corresponding to the circular 
and supercoiled forms of DNA co-migrate the unwinding angle, Φ, can be calculated.  
 
2.6.3.1 Gel electrophoresis studies of the parent cylinder, [Fe2L
P
3]
4+
, with different 
counterions 
In recent work, it was reported that the parent iron(II) cylinder, [Fe2L
P
3][Cl]4, was able to 
bind to duplex DNA and to unwind it.
6
 The band corresponding to the supercoiled form of 
the pUC19 plasmid DNA can be observed to migrate at an increasingly slower speed 
through the gel as the cylinder concentration is increased (lanes 2 to 8, Fig. 2.38).
6
 This 
shows that as the cylinder concentration increases, more and more complex is binding to 
the supercoiled form of DNA, unwinding it and increasing its size or volume, and therefore 
causing it to run at a slower speed through the gel. At a DNA:complex ratio of 26:1 all of 
the supercoiled form has been unwound to the circular relaxed form (lane 8, Fig. 2.38).  
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As the cylinder concentration is increased further, a band corresponding to positively 
supercoiled DNA becomes apparent, with a faster migration rate through the gel. This 
shows that the cylinder is continuing to bind to the relaxed circular form of DNA, winding 
and supercoiling it up again.    
         
 
Figure 2.38 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of circular (C) 
and supercoiled (SC) forms of pUC19 plasmid DNA incubated at 25°C for 30 minutes with different ratios of 
complex [Fe2L
P
3][Cl]4. Lanes 2-11: DNA:complex ratio = 125:1, 67:1, 44:1, 37:1, 33:1, 29:1, 26:1, 22:1, 
19:1 and 16:1 respectively). Control lanes: 1 and 12 = non-modified DNA. [Reproduced from Ref 6] 
 
For [Fe2L
P
3][Cl]4, the supercoiled and circular forms of the plasmid DNA co-migrate at a 
DNA:complex ratio of 26:1.
6
 Using this ratio, the unwinding angle, Φ, is calculated to be 
27°±3.
6
  
 
Gel electrophoresis was also performed using the parent cylinder with tetrafluoroborate 
counterions, [Fe2L
P
3][BF4]4, so as to compare the unwinding ability of both complexes.  
The gel for the [Fe2L
P
3][BF4]4 complex (Fig. 2.39) shows that, as for [Fe2L
P
3][Cl]4, the 
mobility of the supercoiled DNA band decreases as the cylinder concentration increases, 
giving evidence for the unwinding of the supercoiled form of DNA by the cylinder. As 
cylinder concentration increases further, positive supercoiling of the DNA occurs. 
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Figure 2.39 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
P
3][BF4]4. Lanes 2-13: DNA:complex ratio = 100:1, 50:1, 40:1, 20:1, 15:1, 10:1, 8:1, 6:1, 5:1, 4:1, 3:1 
and 2:1 respectively). Control lane: 1 = non-modified DNA. 
 
The two forms of DNA co-migrate at a DNA:complex ratio of 20:1, allowing the 
unwinding angle,  Φ, to be calculated as 21°.  
 
When comparing the unwinding angles of the two complexes, [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4, the different ratios of DNA:complex used when performing the experiment 
must be taken into account. However the unwinding angles, 27°±3 and 21° respectively, 
are quite similar, therefore their unwinding activities can be said to be similar and not 
significantly affected by the difference in counterion.  
 
The unwinding angle of 27° observed for [Fe2L
P
3][Cl]4 shows that the parent cylinder has 
very good DNA unwinding activity, especially when compared to other non-intercalative 
compounds such as the minor groove binder Hoechst which has an unwinding angle of 
1°.
6,28
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2.6.3.2 Gel electrophoresis studies of synthesised alkyne cylinders 
Gel electrophoresis experiments analogous to those performed with the parent cylinder 
were also carried out for the alkyne cylinders synthesised. Due to the insolubility of the 
complexes in water, a small percentage of methanol or acetonitrile was used to dissolve the 
compounds. In each experiment control lanes containing samples of DNA with and 
without solvent were compared to ensure the solvent used had no effect on the DNA or the 
gel. Samples containing different plasmid DNA:complex ratios (Table 2.2) were incubated 
at room temperature for two hours before being run on a 1% agarose gel.  
 
Lanes 1 2 3 4 5 6 7 
DNA:complex 
ratio 
MeOH/MeCN 
control 
50:1 40:1 30:1 20:1 15:1 10:1 
Lanes 8 9 10 11 12 13 14 
DNA:complex 
ratio 
8:1 6:1 5:1 4:1 3:1 2:1 control 
 
Table 2.2 Ratios of plasmid DNA:complex used in gel electrophoresis experiments. Control lane 1: untreated 
DNA with max. percentage of solvent used. Control lane 14: untreated DNA without solvent. 
 
The agarose gel (Fig. 2.40) for the triple bond cylinder, [Fe2L
TB
3][BF4]4, indicates that the 
complex is binding to the supercoiled form of DNA. From a DNA:complex ratio of 10:1 
the supercoiled (SC) band can be seen to be migrating at a slower pace through the gel. As 
the complex concentration increases, the band slows down even more. This means that the 
complex is binding to the DNA and unwinding it, causing an increase in the size or shape 
of the DNA, and so it migrates at a slower rate through the gel. At a ratio of 8:1 the circular 
(C) band of DNA begins to migrate at a faster speed through the gel. This is due to the 
complex binding to and shortening or condensing the helical form of the circular DNA. At 
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a 5:1 DNA:complex ratio, the supercoiled and circular bands co-migrate indicating that all 
of the supercoiled DNA has been unwound to the relaxed circular form. At higher complex 
loading, lanes 11-13, the supercoiled band has reappeared and can be seen to migrate faster 
through the gel as the complex concentration is increased. This indicates that the DNA has 
decreased in size, due to positive supercoiling of the DNA.   
          
 
Figure 2.40 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
TB
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex. 7% 
max. MeOH. 
 
DNA binding can be seen in the agarose gel (Fig. 2.41) for the propargyl alcohol complex, 
[Fe2L
PA
3][BF4]4. The migration of the supercoiled band is observed to slow down at a 
DNA:complex ratio of 15:1. This is due to the complex binding to the supercoiled plasmid 
and unwinding it by lengthening or stiffening it. The circular and supercoiled bands can be 
seen to co-migrate at a ratio of 6:1, due to all of the supercoiled DNA being unwound to 
the relaxed circular form. As the cylinder concentration is increased further, lanes 10-13, 
the supercoiled band reforms and begins to migrate faster through the gel. This indicates 
that the complex is causing the plasmid to wind up again, this time in a positive supercoil.  
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Figure 2.41 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
PA
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex. 7% 
max. MeOH. 
 
The agarose gel (Fig. 2.42) for the hexyn-ol cylinder, [Fe2L
Hex
3][BF4]4, does not show any 
DNA unwinding. There is no change in the mobility of the plasmid bands with increasing 
complex concentration, showing that the cylinder has no effect. This result is surprising as 
the CD and LD studies show good DNA binding activity of this complex. 
 
         
Figure 2.42 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
Hex
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex. 7% 
max. MeOH. 
 
 
DNA binding is not observed in the agarose gel for the phenylacetylene cylinder, 
[Fe2L
Phen
3][BF4]4 (Fig. 2.43). No effect on the mobility of the bands can be observed even  
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at high complex concentration. This indicates that no DNA unwinding is observed.  
         
Figure 2.43 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
Phen
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex. 7% 
max. MeCN. 
 
As co-migration of the circular and supercoiled forms of the pBR322 plasmid was induced 
by the triple bond and propargyl alcohol cylinders, [Fe2L
TB
3][BF4]4 and [Fe2L
PA
3][BF4]4, 
unwinding angles could be calculated for these compounds and compared to that of the 
parent cylinder (Table 2.3). The triple bond cylinder is able to unwind the supercoiled 
DNA by 5°±1 and the propargyl alcohol complex by 6°±1. When compared to the value 
for the parent cylinder these values seem rather small. However compared to the 
unwinding value calculated for cisplatin, which is 13°,
27
 these complexes do show 
promising DNA unwinding activity.  
 
Complexes [Fe2L
P
3][Cl]4 [Fe2L
TB
3][BF4]4 [Fe2L
PA
3][BF4]4 
Φ values 27° ±3 5° ±1 6° ±1 
 
Table 2.3 Unwinding angles (Φ) of complexes calculated from gel electrophoresis experiments. 
  
- 
+ 
    C 
SC 
   1     2     3      4      5     6     7      8     9    10    11    12   13    14 
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2.6.4 PAGE studies 
Polyacrylamide gel electrophoresis (PAGE) is a similar technique to that of agarose gel 
electrophoresis (Section 2.6.3), and is employed for the separation of smaller DNA 
fragments than those separated by agarose gels, due to a smaller pore size in the gel.
29
 
Polyacrylamide gel electrophoresis is used to separate complex mixtures of 
macromolecules, such as DNA fragments, by size.
30
 PAGE studies are advantageous as 
only very low concentrations of the macromolecule to be investigated are needed, as 
radiolabelling allows highly sensitive detection of the bands in the gel, corresponding to 
the separated fragments.
31
    
 
PAGE studies investigating the interaction between supramolecular helicates and DNA 
three-way junctions have recently been reported
31
 and were employed herein. In these 
studies three oligonucleotide strands that are able to form a DNA three-way junction are 
employed and one of these strands is labelled with 
32
P. Mixtures of the three 
oligonucleotide strands and the metallo-cylinder at different ratios are incubated and then 
loaded onto the polyacrylamide gel (Fig. 2.44). A control consisting of the three DNA 
strands with magnesium chloride is also used, as it is known that magnesium dications can 
stabilise three-way junctions at low to medium ionic strengths.
32
 As with the agarose gels, 
an electric current is then applied which causes migration of the negatively charged DNA 
fragments through the gel towards the positive electrode. The smaller single strands have a 
faster migration rate through the gel than the larger three-way junction, and so the different 
species are separated. An autoradiogram is then obtained that allows visualisation of the 
bands corresponding to these different species. 
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Figure 2.44 Schematic representation of a polyacrylamide gel showing different migration speeds of single 
strand oligonucleotides and DNA three-way junction. One strand is radiolabelled with 32P (blue circle). 
 
In the absence of cylinder, or magnesium ions, the three-way junction is not stabilised and 
so cannot form. Therefore, only bands corresponding to the single strands will be observed 
in the polyacrylamide gel. If the cylinder being investigated can promote the formation and 
stabilisation of the three-way junction, a band corresponding to the three-way junction will 
be observed.  
 
2.6.4.1 PAGE studies of the parent cylinder, [Fe2L
P
3]
4+
, and bulky cylinder, [Fe2L
CF3
3]
4+ 
31
 
Recently, three-way junction polyacrylamide gel electrophoresis studies of the parent 
cylinder and a bulky substituted cylinder, [Fe2L
CF3
3]
4+
, were reported.
31
 A PAGE 
experiment was carried out with three 14-mer non-palindromic oligonucleotide DNA 
strands which could form a three-way junction with arms of seven base pairs long (Fig. 
2.45).
31
 These three strands were incubated with [Fe2L
P
3][Cl]4 at different mixing ratios.
31
 
The autoradiogram of the gel (Fig. 2.45) shows that the three oligonucleotide strands do 
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not form a three-way junction structure unless in the presence of the iron(II) cylinder.
31
 An 
increase in the concentration of the cylinder (lanes 6 and 7) did not further enhance the 
formation of the three-way junction.
31
 Interestingly, the presence of a very high 
concentration of magnesium chloride did not afford stabilisation of the three-way junction 
under the experimental conditions used (lane 8) as would be expected, indicating the 
highly stabilising nature of the iron(II) cylinder to the three-way junction structure.
31
  
   
Figure 2.45 Structure of DNA three-way junction formed from three 14-mer nonpalindromic oligonucleotide 
strands (left); Autoradiogram of polyacrylamide gel (right) run at 25 °C. Lanes 1-3: controls containing one, 
two and three oligonucleotide strands. Lanes 4-7: all three strands with [Fe2L
P
3]
4+ at mixing ratios of 
strand:cylinder of 6:1, 3:1, 3:2 and 3:10 respectively (blue triangle indicates increasing concentration of 
cylinder). Lane 8: all three strands with 10 mM MgCl2. Asterisk indicates 
32P labelled strand. [Adapted from 
Ref 31] 
 
Further studies with different oligonucleotide sequences confirmed that this stabilisation is 
also apparent for other three-way junction and Y-shaped junction structures, including 
those with palindromic and non-palindromic sequences.
31
 The M and P enantiomers of the 
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parent cylinder were also investigated and both were shown to promote the formation and 
stabilisation of DNA three-way junctions, with the M enantiomer having a greater efficacy 
than the P.
31
  
 
To study the importance of the size and shape of the cylinder on its ability to stabilise 
DNA three-way junctions, a bulky cylinder, [Fe2L
CF3
3]
4+
, (Fig. 2.46) was also employed.
31
 
It was found that no three-way junction was formed, confirming the theory that the 
stabilisation of the three-way junction is afforded by the interactions induced by the perfect 
fit of the cylinder in the heart of the junction structure.
31
  
 
Figure 2.46 Structure of LCF3 ligand of bulky cylinder, [Fe2L
CF3
3]
4+.31 
 
2.6.4.2 PAGE studies of the parent cylinder, [Fe2L
P
3]
4+
, with different counterions and 
alkyne cylinders 
To assess the ability of these cylinders to bind to and stabilise DNA three-way junctions, 
they were studied by PAGE. These studies were carried out by co-worker N. Calle Alonso 
from the University of Birmingham. The results are briefly described herein for 
completeness. 
 
Oligonucelotide strands of the same sequence as those used for the experiments reported 
and discussed previously (Section 2.6.4.1) were used (Fig. 2.45).
3,31
 Due to the insolubility 
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of the alkyne complexes in water, a small percentage of methanol or acetonitrile was used 
to dissolve the compounds. In each experiment control lanes containing one, two and three 
DNA strands and magnesium chloride were incorporated. The parent and alkyne cylinders 
were mixed with the three non-palindromic oligonucleotide strands to give a ratio of three-
way-junction:cylinder of 1:1, incubated for one hour and run on a 15% polyacrylamide gel.  
 
The autoradiogram of the polyacrylamide gel (Fig. 2.47, cropped image; for whole gel see 
Appendix) indicates that the individual oligonucleotide strands cannot form a DNA three-
way junction under these experimental conditions. Only a band corresponding to the 
individual strands can be seen at the bottom of the gel, due to the fast migration rate of 
these small fragments. Magnesium chloride did not promote the formation of a three-way 
junction, as was observed in the previous PAGE studies with the parent cylinder (Section 
2.6.4.1). However, when the oligonucleotide strands were incubated with the parent, 
[Fe2L
P
3][Cl]4 and [Fe2L
P
3][BF4]4, and alkyne, [Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4 and 
[Fe2L
Hex
3][BF4]4, cylinders, a three-way junction was formed. A small difference in the 
migration rate of these bands through the gel can be seen and this is due to the molecular 
weight of the cylinders. The lower molecular weight cylinders, [Fe2L
P
3][Cl]4 and 
[Fe2L
P
3][BF4]4, run through the gel with higher electrophoretic mobility, whereas as the 
molecular weight increases, from [Fe2L
TB
3][BF4]4 to [Fe2L
Hex
3][BF4]4, the migration rate 
decreases. The phenyl cylinder, [Fe2L
Phen
3][BF4]4, did not promote the formation of a DNA 
three-way junction.  
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Figure 2.47 Autoradiogram of polyacrylamide gel run at 25 °C. Lanes 1-3: S3*, S3*+S2, S3*+S2+S1 
respectively; Lane 4: S3*+S2+S1+MgCl2; Lanes 5-10: S3*+S2+S1 with [Fe2L
P
3][Cl]4, [Fe2L
P
3][BF4]4, 
[Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4, [Fe2L
Hex
3][BF4]4 and [Fe2L
Phen
3][BF4]4 respectively. Ratio of three-way 
junction (S1+S2+S3*):complex of 1:1. Asterisk indicates 32P labelled strand.  
 
As the PAGE experiments were carried out in duplicate, only a preliminary comparison of 
the three-way junction promotion and stabilisation ability of the parent and functionalised 
cylinders can be noted. Quantification of the band in the gel corresponding to the three-
way junction (Fig. 2.48) indicates that the parent cylinders with chloride and 
tetrafluoroborate counterions have a similar promotion and stabilisation effect. 
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The [Fe2L
PA
3][BF4]4 cylinder appears to be less able to promote the formation of a three-
way junction than the parent cylinder.  
 
Figure 2.48 Bar graph showing percentage of three-way junction formed by complexes. Data based on two 
repeats; error bars shown demonstrate the two data points (not standard deviation), and the bar their average.  
 
2.7 Conclusions 
In this chapter, a novel cylinder functionalisation route has been presented which allows 
the easy and efficient modification of metallo-cylinders. It has been demonstrated that 
different groups can be attached to the edges of the cylinder via this route, in few reaction 
steps.  
 
Using this synthesis route, four novel iron(II) cylinders functionalised with chemical 
groups have been designed and synthesised in only two or three steps with overall yields of  
15-56%, with respect to the 5-bromo-2-pyridinecarboxaldehyde starting material. As the 
substituent attached to the cylinder gets larger and bulkier, the yield of the cylinder 
formation step decreases, likely due to steric hindrance. 
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Unfortunately these complexes are insoluble in water, however their solubility in water-
miscible solvents allowed DNA binding studies to be carried out. The stability of these 
complexes in DNA binding experimental conditions, at room temperature in aqueous 
solution in the presence of DNA, was evaluated. The majority of the complexes showed 
very good stabilities in these conditions, however [Fe2L
Phen
3][BF4]4 was less stable with a 
degradation of one third over a period of five hours. 
 
DNA binding studies, including circular and linear dichroism with ct-DNA and gel 
electrophoresis with plasmid DNA, were carried out for the parent cylinder and novel 
functionalised cylinders. The DNA binding activity of the parent cylinder with 
tetrafluoroborate counterions was found to be very similar to that of the chloride version, 
[Fe2L
P
3][Cl]4. Both complexes were able to bind to ct-DNA, and to bend or coil it, and also 
to bind to and unwind supercoiled plasmid DNA. PAGE studies revealed the ability of the 
cylinders to promote the formation of a DNA three-way junction with similar efficiency. 
 
The triple bond, propargyl alcohol and hexyn-ol cylinders, [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4, were found to be DNA binders when evaluated 
using circular dichroism. In the LD titration experiments the [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 cylinders all induced significant DNA 
bending/coiling. Gel electrophoresis studies found the triple bond and propargyl alcohol 
functionalised helicates unwound supercoiled plasmid DNA with unwinding angles of 
5°±1 and 6°±1 respectively. However the hexyn-ol functionalised cylinder showed no 
DNA unwinding. PAGE studies revealed that these three complexes could all promote the 
formation of a DNA three-way junction.  
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The phenylacteylene complex, [Fe2L
Phen
3][BF4]4, seems to behave differently to the other 
three novel functionalised compounds. CD and LD studies indicated that the complex 
could bind to ct-DNA, however far less DNA coiling/bending was observed for this 
complex when compared to the other three, unwinding of supercoiled DNA by this 
compound was not observed in the gel electrophoresis experiment, and the complex did not 
promote the formation of a DNA three-way junction as observed by polyacrylamide gel 
electrophoresis. This is likely due to the bulky inflexible nature of the phenylacetylene 
moiety that is attached at the ends of this cylinder, which somehow inhibits close 
proximity to the DNA or possibly does not allow the complex to bind in the major groove 
of the DNA.  
 
Unfortunately, in vitro studies could not be undertaken with these alkyne functionalised 
cylinders due to their insolubility in the solvent systems required.  
 
These investigations indicate that modification of the iron(II) parent cylinder can be 
achieved without complete loss of its inherent DNA binding properties. However the 
functionalisation moiety to be attached has to be chosen carefully to avoid a significant 
loss of DNA affinity or water solubility; it appears that directly linked aryl groups on the 
alkyne may present problems.  
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2.8 Experimental: synthesis 
2.8.1 Materials and methods 
All reagents and solvents were purchased from Aldrich, Fisher, Apollo Scientific and 
Fluorochem and used without further purification. Deuterated NMR solvents were 
purchased from Goss Scientific. NMR spectra were recorded on Brüker AVIII300 and 
AVIII400 spectrometers and processed using standard Brüker software. Electrospray 
Ionisation (ESI) spectra were recorded on a Micromass LCT Time of flight mass 
spectrometer in positive ionisation mode. IR spectra were recorded on a PerkinElmer 
Spectrum 100 FT-IR spectrometer. Microanalyses data were obtained using a CE 
Instruments EA1110 elemental analyser. UV-Vis spectra were performed using a Varian 
Cary 5000 UV-Vis spectrometer. CD and LD spectra were recorded on a Jasco J-810 
spectropolarimeter. 
 
2.8.2 Synthesis of Parent cylinder, [Fe2L
P
3][BF4]4
11 
 
 
[Fe2(C25H20N4)3][BF4]4 
FW: 1588.29 
 
To a solution of 2-pyridinecarboxaldehyde (0.021 g, 0.20 mmol) in ethanol (1 ml) was 
added a solution of 4,4’-methylenedianiline (0.019 g, 0.10 mmol) in ethanol (1.5 ml) 
dropwise. A solution of iron(II) tetrafluoroborate hexahydrate (0.022 g, 0.07 mmol) in 
Chapter 2: Novel Alkyne Metallo-Cylinders 
 
116 
 
ethanol (0.5 ml) was then immediately added dropwise and the reaction mixture stirred 
overnight at room temperature. The resulting purple precipitate was collected by vacuum 
filtration, washed with chloroform (1 L), diethyl ether (200 ml) and dried for 12 hours over 
silica, yielding a light purple solid (0.042 g, 81% yield). 
1
H NMR (300 MHz, CD3CN): δ 8.90 (s, 2H, Him), 8.55 (dd, J = 7.7, 0.7 Hz, 2H, HPy3), 
8.38 (td, J = 7.7, 1.2 Hz, 2H, HPy4), 7.78 – 7.70 (m, 2H, HPy5), 7.32 (d, J = 5.4 Hz, 2H, 
HPy6), 6.95 (br s, 4H, HPha/ Phb), 5.52 (br s, 4H, HPha/ Phb), 4.01 (s, 2H, Hsp). 
Mass spectrum (ESI): m/z = 310.5 [Fe2(C25H20N4)3]
4+ 
, 414.4 [Fe2(C25H20N4)3]
3+
, 621.1 
[Fe2(C25H20N4)3]
2+
. 
IR (ν) = 3040 (m, C-H), 2908 (m, C-H), 1614 (m, C≡C), 1585 (m, C=C), 1034 (s, br, BF4). 
UV-Vis (H2O): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 236 (47,400), 277 (46,100), 324 (20,000), 
525 sh (8,000), 573 (10,800). 
 
2.8.3 Synthesis of Triple Bond cylinder, [Fe2L
TB
3][BF4]4 
2.8.3.1 Synthesis of 5-[(trimethylsily)ethynyl]-2-pyridinecarboxaldehyde (1)
 12
 
 
C11H13NOSi 
FW: 203.32 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.401 g, 2.16 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.058 g, 0.08 mmol), copper iodide 
(0.033 g, 0.17 mmol) and triphenylphosphine (0.047 g, 0.18 mmol). Anhydrous THF (8 
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ml), triethylamine (8 ml) and trimethylsilylacetylene (0.42 ml, 2.97 mmol) were added, 
and the reaction mixture stirred under an argon atmosphere with light exclusion at 80°C for 
5 hours. The resulting dark brown crude mixture was evaporated to dryness in vacuo and 
purified by column chromatography on a silica column (DCM). To remove the 
triphenylphosphine oxide impurity, diethyl ether and 2 M HCl were added to the pale 
yellow solid, the layers were separated and the aqueous layer washed again with diethyl 
ether. The aqueous layer was neutralised with aqueous saturated NaHCO3 and extracted 
with ethyl acetate. The ethyl acetate was dried over Na2SO4 and evaporated in vacuo 
yielding an off-white solid (0.399g, 91% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.05 (s, 1H, Hald), 8.79 (t, J = 1.4 Hz, 1H, H6), 7.89 - 7.88 
(m, 2H, H3, H4), 0.26 (s, 9H, HMe).  
HRMS (EI): m/z = calculated for C11H13NOSi [M]
+
 203.0766; Found 203.0773. 
IR (ν) = 3039 (m, C-H), 2964 (m, C-H), 2824 (m, C-H), 2158 (s, C≡C), 1709 (s, C=O), 
1576 (m, C=C).  
 
2.8.3.2 Synthesis of 5-ethynyl-2-pyridinecarboxaldehyde (2) 
12
 
 
C8H5NO 
FW: 131.13 
 
To a solution of 5-[(trimethylsily)ethynyl]-2-pyridinecarboxaldehyde (1) (0.254 g, 0.12 
mmol) in methanol (15 ml) was added potassium carbonate (0.021 g, 0.15 mmol) and the 
reaction mixture was stirred for 5 hours at room temperature. Ethyl acetate was added and 
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the solution was washed twice with water, twice with brine and dried over MgSO4. After 
evaporation of the solvent, the crude mixture was purified by column chromatography on a 
silica column (DCM) yielding an off-white solid (0.102 g, 62% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.04 (s, 1H, Hald), 8.84 – 8.80 (m, 1H, H6), 7.91 - 7.90 
(m, 2H, H3, H4), 3.43 (s, 1H, H7). 
13
C NMR (100 MHz, CDCl3): δ192.4 (Cald), 153.0 (C6), 151.4 (Cq), 140.0 (C3/4), 120.8 
(C3/4), 84.0 (C7), 79.7 (Cq). 
HRMS (EI): m/z = calculated for C8H5NO [M]
+
 131.0371; Found 131.0368. 
IR (ν) = 3210 (s, C≡C-H), 3086 (m, C-H), 2104 (s, C≡C), 1689 (s, C=O), 1580 (m, C=C). 
Elemental analysis (%) calculated for C8H5NO: C: 73.3; H: 3.8; N: 10.7; Found: C: 73.1; 
H: 3.7; N: 10.6. 
 
2.8.3.3 Synthesis of [Fe2L
TB
3][BF4]4 
 
[Fe2(C29H20N4)3][BF4]4 
FW: 1732.42 
 
To a solution of 5-ethynyl-2-pyridinecarboxaldehyde (2) (0.040 g, 0.31 mmol) in ethanol 
(1 ml) was added a solution of 4,4’-methylenedianiline (0.030 g, 0.15 mmol) in ethanol 
(1.5 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate (0.034 g, 0.10 
mmol) in ethanol (0.5 ml) was then immediately added dropwise and the reaction mixture 
stirred overnight at room temperature. The resulting purple precipitate was collected by 
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vacuum filtration, washed with chloroform (1 L), diethyl ether (200 ml) and dried for 12 
hours over silica, yielding a light purple solid (0.064 g, 73% yield). 
1
H NMR (300 MHz, CD3CN): δ 9.13 (s, 2H, Him), 8.61 (d, J = 7.9 Hz, 2H, HPy3), 8.44 (d, 
J = 7.9 Hz, 2H, HPy4), 7.57 (s, 2H, HPy6), 6.94 (br s, 4H, HPha/ Phb), 5.50 (br s, 4H, HPha/ Phb), 
4.05 (s, 2H, Hsp), 3.98 (s, 2H, H1). 
Mass spectrum (ESI): m/z = 346.2 [Fe2(C29H20N4)3]
4+ 
, 461.9 [Fe2(C29H20N4)3]
3+ 
. 
IR (ν) = 3041 (w, C-H), 2116 (s, C≡C), 1597 (m, C=C), 1546 (m, C=C), 1051 (s, br, BF4). 
UV-Vis (MeOH): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 276 sh (51,900), 302 (78,000), 533 sh 
(10,200), 591 (14,400). 
 
2.8.4 Synthesis of Propargyl Alcohol cylinder, [Fe2L
PA
3][BF4]4 
2.8.4.1 Synthesis of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3) 
 
C9H7NO2 
FW: 161.16 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.801 g, 4.31 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.115 g, 0.16 mmol), copper iodide 
(0.061 g, 0.32 mmol) and triphenylphosphine (0.085 g, 0.32 mmol). Anhydrous THF (11 
ml), triethylamine (16 ml) and propargyl alcohol (0.29 ml, 4.98 mmol) were added, and the 
reaction mixture stirred under an argon atmosphere with light exclusion at 80°C for 5 
hours. The resulting dark brown crude mixture was evaporated to dryness in vacuo and 
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purified by column chromatography on a silica column (MeOH:DCM 5:95). To remove 
the triphenylphosphine oxide impurity, diethyl ether and 2 M HCl were added to the pale 
yellow solid obtained, the layers were separated and the aqueous layer washed again with 
diethyl ether. The aqueous layer was neutralised with aqueous saturated NaHCO3 and 
extracted with ethyl acetate. The ethyl acetate was dried over Na2SO4 and evaporated in 
vacuo yielding an off-white solid (0.404 g, 58% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.05 (s, 1H, Hald), 8.82 - 8.81 (m, 1H, H6), 7.92 – 7.85 
(m, 2H, H3, H4), 4.55 (s, 2H, H7). 
13
C NMR (100 MHz, CDCl3): δ192.2 (Cald), 152.4 (C6), 139.6 (C3/4), 121.1 (C3/4), 51.2 
(C7). 
HRMS (EI): m/z = calculated for C9H7NO2 [M]
+
 161.0477; Found 161.0472. 
IR (ν) = 3229 (br, OH), 2854 (m, C-H), 2242 (s, C≡C), 1707 (s, C=O), 1582 (m, C=C). 
 
2.8.4.2 Synthesis of [Fe2L
PA
3][BF4]4 
 
 
[Fe2(C31H24N4O2)3][BF4]4 
FW: 1912.58 
 
To a solution of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3) (0.030 g, 0.19 
mmol) in ethanol (1 ml) was added a solution of 4,4’-methylenedianiline (0.018 g, 0.09 
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mmol) in ethanol (1.5 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate 
(0.021 g, 0.06 mmol) in ethanol (0.5 ml) was then immediately added dropwise and the 
reaction mixture stirred overnight at room temperature. The resulting purple precipitate 
was collected by vacuum filtration, washed with chloroform (1 L), diethyl ether (200 ml) 
and dried for 12 hours over silica, yielding a light purple solid (0.057 g, 96% yield). 
1
H NMR (300 MHz, CD3CN): δ  9.00 (s, 2H, Him), 8.55 (d, J = 7.9 Hz, 2H, HPy3), 8.37 (d, 
J = 7.9 Hz, 2H, HPy4), 7.48 (s, 2H, HPy6), 6.94 (br s, 4H, HPha/ Phb), 5.49 (br s, 4H, HPha/ Phb), 
4.40 (d, J = 5.5 Hz, 4H, H1), 4.03 (s, 2H, Hsp). 
Mass spectrum (ESI): m/z = 391.4 [Fe2(C31H24N4O2)3]
4+ 
, 521.5 [Fe2(C31H24N4O2)3]
3+ 
, 
781.8 [Fe2(C31H24N4O2)3]
2+
. 
IR (ν) = 3322 (br, OH), 2221 (s, C≡C), 1594 (m, C=C), 1543 (m, C=C), 1016 (s, br, BF4). 
UV-Vis (MeOH): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 235 (56,500), 277 sh (39,000), 311 
(55,600), 538 sh (4,700), 591(6,300). 
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2.8.5 Synthesis of Hexyn-ol Cylinder, [Fe2L
Hex
3][BF4]4 
2.8.5.1 Synthesis of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4) 
 
C12H13NO2 
FW: 203.24 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.200 g, 1.08 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.030 g, 0.04 mmol) and copper 
iodide (0.017 g, 0.09 mmol). 5-Hexyn-1-ol (0.11 ml, 1.00 mmol), anhydrous THF (35 ml) 
and diisopropylamine (0.63 ml) were added, and the reaction mixture stirred under an 
argon atmosphere with light exclusion, at room temperature, for 72 hours. The resulting 
dark brown crude mixture was evaporated to dryness in vacuo and purified by column 
chromatography on a silica column (MeOH:DCM 2:98). The resulting off-white solid was 
dissolved in diethyl ether and purified by column chromatography on a short silica column 
(diethyl ether) to remove the triphenylphosphine oxide impurity. Evaporation of the 
solvent yielded an off-white solid (0.092 g, 42% yield). 
1
H NMR (300 MHz, CDCl3): δ10.04 (s, 1H, Hald), 8.74 - 8.73 (m, 1H, H6), 7.89 – 7.79 (m, 
2H, H3, H4), 3.73 – 3.69 (m, 2H, H10), 2.54 – 2.48 (m, 2H, H7), 1.76 – 1.71 (m, 4H, H8, 
H9). 
13
C NMR (100 MHz, CDCl3): δ 192.6 (Cald), 152.5 (C6), 139.5 (C3), 120.7 (C4), 61.8 (C7), 
31.7 (C8/9), 24.6 (C8/9), 19.4 (C10). 
HRMS (EI): m/z = calculated for C12H13NO2 [M]
+
 203.0946; Found 203.0945. 
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IR (ν) = 3164 (br, OH), 2945 (m, C-H), 2861 (m, C-H), 2222 (s, C≡C), 1710 (s, C=O), 
1580 (m, C=C). 
 
2.8.5.2 Synthesis of [Fe2L
Hex
3][BF4]4 
 
[Fe2(C37H36N4O2)3][BF4]4 
FW: 2165.06 
 
To a solution of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4) (0.138 g, 0.68 mmol) in 
ethanol (2.5 ml) was added a solution of 4,4’-methylenedianiline (0.068 g, 0.34 mmol) in 
ethanol (4 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate (0.076 g, 0.23 
mmol) in ethanol (1.5 ml) was then immediately added dropwise and the reaction mixture 
stirred overnight at room temperature. The resulting purple precipitate was collected by 
vacuum filtration, washed with chloroform (1.5 L), diethyl ether (200 ml) and dried for 12 
hours over silica, yielding a dark purple solid (0.143 g, 58% yield). 
1
H NMR (300 MHz, CD3CN): δ 8.95 (s, 2H, Him), 8.50 (d, J = 7.9 Hz, 2H, HPy3), 8.30 (d, 
J = 7.9 Hz, 2H, HPy4), 7.34 (s, 2H, HPy6), 6.92 (br s, 4H, HPha/Phb), 5.50 (br s, 4H, HPha/Phb), 
4.02 (s, 2H, Hsp), 3.54 – 3.52 (m, 4H, H4), 2.68 (s, 2H, HOH), 2.49 (t, J = 6.2 Hz, 4H, H1), 
1.63 – 1.61 (m, 8H, H2, H3). 
Mass spectrum (ESI): m/z = 454.6 [Fe2(C37H36N4O2)3]
4+ 
,
 
605.8 [Fe2(C37H36N4O2)3]
3+ 
, 
908.2 [Fe2(C37H36N4O2)3]
2+
. 
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IR (ν) = 3365 (br, OH), 2934 (w, C-H), 2225 (s, C≡C), 1594 (m, C=C), 1542 (m, C=C), 
1016 (s, br, BF4). 
UV-Vis (MeOH): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 237 (121,800), 276 sh (53,700), 318 
(116,200), 534 sh (11,400), 589 (16,500). 
 
2.8.6 Synthesis of Phenyl Cylinder, [Fe2L
Phen
3][BF4]4 
2.8.6.1 Synthesis of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5) 
 
C14H9NO 
FW: 207.23 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.201 g, 1.08 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.031 g, 0.04 mmol) and copper 
iodide (0.016 g, 0.08 mmol). Phenylacetylene (0.12 ml, 1.06 mmol), anhydrous THF (35 
ml) and diisopropylamine (0.63 ml) were added, and the reaction mixture stirred under an 
argon atmosphere with light exclusion, at room temperature, for 72 hours. The resulting 
dark brown crude mixture was evaporated to dryness in vacuo and purified by column 
chromatography on a silica column (DCM). The resulting pale brown solid was dissolved 
in diethyl ether and purified by column chromatography on a short silica column (diethyl 
ether) to remove the triphenylphosphine oxide impurity. Evaporation of the solvent yielded 
an off-white solid (0.161 g, 72% yield). 
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1
H NMR (300 MHz, CDCl3): δ 10.1 (s, 1H, Hald), 8.91 – 8.87 (m, 1H, H6), 7.96 – 7.95 (m, 
2H, H3, H4), 7.59 – 7.56 (m, 2H, H7), 7.43 – 7.36 (m, 3H, H8, H9). 
13
C NMR (100 MHz, CDCl3): δ 192.5 (Cald), 152.4 (C6), 139.2 (C3/4), 131.8 (C7), 129.4 
(C8/9), 128.5 (C8/9), 120.9 (C3/4). 
HRMS (EI): m/z = calculated for C14H9NO [M]
+
 207.0684; Found 207.0673. 
IR (ν) = 3000 (w, C-H), 2821 (w, C-H), 2215 (s, C≡C), 1703 (s, C=O), 1576 (m, C=C). 
 
2.8.6.2 Synthesis of [Fe2L
Phen
3][BF4]4 
 
 
[Fe2(C41H28N4)3][BF4]4 
FW: 2189.00 
 
To a solution of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5) (0.107 g, 0.52 mmol) in 
ethanol (3 ml) was added a solution of 4,4’-methylenedianiline (0.051 g, 0.26 mmol) in 
ethanol (2 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate (0.058 g, 0.17 
mmol) in ethanol (2 ml) was then immediately added dropwise and the reaction mixture 
stirred overnight at room temperature. The resulting purple precipitate was collected by 
vacuum filtration, washed with chloroform (1 L), diethyl ether (200 ml) and dried for 12 
hours over silica, yielding a dark purple solid (0.039 g, 21% yield). 
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1
H NMR (300 MHz, CD3CN): δ 9.07 (s, 2H, Him), 8.62 (d, J = 7.9 Hz, 2H, HPy3), 8.49 (d, 
J = 7.9 Hz, 2H HPy4), 7.67 (s, 2H, HPy6), 7.57 (d, J = 6.8 Hz, 4H, H1), 7.50 – 7.47 (m, 6H, 
H2, H3), 6.97 (br s, 4H, HPha/ Phb), 5.55 (br s, 4H, HPha/ Phb), 4.06 (s, 2H, Hsp). 
Mass spectrum (ESI): m/z = 460.3 [Fe2(C41H28N4)3]
4+
. 
IR (ν) = 3035 (w, C-H), 2219 (s, C≡C), 1597 (m, C=C), 1545 (m, C=C), 1056 (s, br, BF4). 
UV-Vis (MeCN): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 231 (106,700), 261 sh (107,000), 354 
(148,100), 596 (17,400). 
 
2.9 Experimental: DNA binding studies 
2.9.1 Materials and methods 
All DNA binding studies were carried out using Ultrapure water (18.2 MΩ) purchased 
from Fisher Scientific. Calf thymus (ct-) DNA, highly polymerised, was purchased from 
Sigma Aldrich and pBR322 plasmid DNA was purchased from New England Biolabs. 
Both were used without further purification and kept frozen. Tris-acetate-EDTA buffer was 
purchased from Fisher and agarose from USB Corporation. 
 
2.9.2 Circular and Linear Dichroism Experiments 
CD and LD measurements were recorded using a Jasco J-810 spectropolarimeter. CD 
measurements were carried out in quartz cuvettes of 1cm (750-200 nm) or 0.1 cm (450-200 
nm) pathlength. LD experiments were recorded in a flow couette cell (Krometek) with a 
0.1 cm pathlength. 
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Stock solutions of ct-DNA (3000 μM) in water were prepared and kept frozen until the day 
of the experiment. Sodium chloride (1 M) and sodium cacodylate (Na(CH2)2AsO2.3H2O) 
(100 mM) buffer stock solutions were used to prepare final ct-DNA solutions of 300 μM 
with 20 mM NaCl and 1 mM sodium cacodylate (pH 6.8). DNA concentrations were 
determined by UV-Vis measurements using the known molar extinction coefficient of ε258 
= 6600 mol
-1
dm
3
cm
-1
 per DNA base.  
 
CD and LD titrations were carried out using three solutions; solution A (a 300 μM ct-DNA 
solution, containing  NaCl (20 mM) and sodium cacodylate (1 mM)); solution B (a 500 μM 
complex solution) and solution C (a 600 μM ct-DNA solution, containing 40 mM NaCl 
and sodium cacodylate (2 mM)). Firstly solution A was recorded, then equal aliquots of 
solutions B and C were added, keeping the concentration of ct-DNA constant throughout 
the titration. The titration was carried out to obtain an initial ct-DNA:complex ratio of 60:1 
decreasing to 4:1. The stock solution of complex was stored in ice during the experiment.  
 
2.9.3 Agarose Gel Electrophoresis 
Agarose gels were prepared by warming agarose (2 g) in 1x Tris-acetate-EDTA buffer 
which was then poured into a gel tray (210 x 150 mm) fitted with a 15 toothed comb, to 
produce sample wells. The gel was left to set for 40 minutes. Sample solutions (16 μl) were 
prepared containing 96.3 µM pBR322 plasmid DNA and different concentrations of 
complexes (from 60 µM stock solution in water and up to 7% MeOH or MeCN) to obtain 
plasmid:complex ratios ranging from 100:1 to 2:1. These sample solutions were incubated 
for 2 hours at room temperature. Before loading , 4 μl loading buffer (30% glycerol, 0.25% 
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bromophenol blue) was added, the samples were mixed and then 16 μl of the samples 
loaded into the gel wells. The gel was run for 2.5 hours in an Amersham Biosciences 
HE99X Maxi submarine kit with an electrophoresis Power Supply-EPS 301 system, at a 
constant voltage of 120 V and 400 mA, in 1x Tris-acetate-EDTA running buffer. The gel 
was then stained with an ethidium bromide solution (0.5 mg.ml
-1
) in 200 ml of water for 20 
minutes and visualised using a UVtec–uvipro platinum 2.0 system (UVidoc, Cambridge, 
UK) at 312 nm.  
 
2.9.4 Polyacrylamide Gel Electrophoresis (PAGE) 
Procedure provided by S. Phongtongpasuk 
3
 and carried out by N. Calle Alonso, both of 
the Hannon group, University of Birmingham. 
2.9.4.1 Radioactive labelling 
Oligonucleotides (sequences S1: CGGAACGGCACTCG, S2: CGAGTGCAGCGTGG, 
S3: CCACGCTCGTTCCG) were purchased from MWG Eurofin. One strand was labelled 
with 
32P at the 5’ terminus using T4 polynucleotide kinase (New England Biolabs) and [γ-
32P] adenosine 5’-triphosphate (Perkin Elmer). First ultrapure water (4.8 µl), 10x 
bacteriophage T4 polynucleotide kinase buffer (1 µl), oligonucleotide S3 (1.2 µl of 100 
µM), bacteriophage T4 polynucleotide kinase (1 µl) (New England Biolabs) and γ-32P ATP 
(2 µl of 6000 Ci/mmol) (Perkin Elmer) were incubated in an eppendorf at 37°C for 40 
minutes. To deactivate the polynucleotide kinase, the solution was then heated to 80°C for 
3 minutes.  
 
To purify the radioactive-labelled DNA fragments from any unreacted ATP a QIAquick 
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nucleotide removal kit (QIAGEN) was employed. 10 volumes of PN buffer were added to 
1 volume of reaction sample and this solution was loaded onto a QIAquick spin column 
with a 2ml collection tube, centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. A new collection tube was then fitted to the column, PE buffer (500 µl) was 
added and this solution was centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. Again, PE buffer (500 µl) was added and the solution was centrifuged at 13000 
rpm for 1 minute to remove residual buffer. The column was then put into a fresh 
eppendorf, ultrapure water (30 µl) was added to the column and this was left for 5 minutes. 
After centrifuging at 13000 rpm for 2 minutes a radiolabelled DNA stock solution (8 µM) 
was obtained. 
 
2.9.4.2 Polyacrylamide gel preparation 
A 15% native polyacrylamide gel was prepared by mixing 52.5 ml of ultra pure water, 10 
ml of 10x TB buffer (890 mM tris(hydroxymethy)amino methane and 890 mM boric acid) 
(pH 8.3), 37.5 ml of 40% acrylamide (29:1) (Geneflow), 500 µl of 10% (w/v) ammonium 
persulfate and 75 µl tetramethylenediamine (TEMED). This was then poured onto a set of 
glass plates and left to set for 40 minutes. The wells of the polymerised gel were washed 
with running buffer (TB buffer) and the gel was pre-run at 200 V for 5 minutes before 
sample loading.  
 
2.9.4.3 PAGE electrophoresis experiment  
Sample solutions were prepared by mixing solutions of the complexes with stoichiometric 
amounts of oligonucleotides in TBN buffer (89 mM tris(hydroxymethy)amino methane, 89 
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mM of boric acid and 100 µM NaCl) (pH 8.3) to give final concentrations of 0.4 µM for 
each single strand (1.2 µM total concentration of DNA) and 0.4 µM of complex. This gives 
a three-way junction:complex ratio of 1:1. The sample solutions were incubated for 1 hour 
at room temperature and then in ice for 15 minutes. To prepare the samples for loading, 5 
µl of 30% glycerol was added to each eppendorf. 13 µl of each sample was then loaded 
onto the 15% polyacrylamide gel. The gel was run for 4 hours at 120 V using Gel System 
equipment (Thermo Scientific UK). It was then exposed on a phosphor imaging plate for 
1-16 hours depending on how fresh the radioactive ATP used was. A radiogel image was 
obtained using a Molecular Imager FX (Bio-Rad) and the gel was quantified using 
Quantity One software.  
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Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
3.1 Introduction and aims 
In chapter 2, a novel cylinder functionalisation route was developed which allows the easy 
and efficient modification of iron(II) cylinders. Several complexes functionalised with 
simple chemical groups were synthesised and the DNA binding studies of these proved 
that functionalisation at the ends of the cylinder does not result in a significant loss of 
DNA binding affinity. 
 
Although the parent and the majority of the second generation cylinders described show 
DNA binding activity, they all have an inherent disadvantage; their activity and 
cytotoxicity is not specific to cancerous tissue. In vitro studies with the iron(II) parent 
cylinder and the immortalised non-tumour cell line MRC5 indicated no sensitivity to 
cancerous tissue, and cytotoxicity to normal cells.
1
 It is well known that the anticancer 
agent cisplatin causes severe side effects such as nephrotoxicity, neurotoxicity, nausea and 
vomiting.
2
 These side effects are due to the non-targeting nature of cisplatin which leads to 
non-cancerous cells and tissues being damaged.
2
 Therefore it can be supposed that if these 
metallo-cylinders were to be used therapeutically in the clinic, they would also cause side-
effects due to their non-specific nature. To overcome this problem the specificity of 
metallo-cylinders to tumour cells must be improved. 
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3.1.1 Drug targeting strategies 
Many strategies have been developed to target therapeutic drugs to cancerous tissues. 
Passive targeting is common, with the development of drugs bound to polymers, 
liposomes, dendrimers or other macromolecular carriers to allow concentration and 
retention of the drug in tumour tissue.
3
 Receptor mediated targeting is another strategy, in 
which receptors that are overexpressed can be used to deliver drugs to specific cancerous 
tissues and organs.
3
  Known biomolecules with receptors overexpressed by cancerous cells 
include folic acid, oncofoetal proteins, peptides, carbohydrates and steroids (Fig. 3.1).
3,4
 
Drug-biomolecule conjugates that retain a high affinity for the corresponding receptor will 
be preferentially delivered and accumulated into the cells that overexpress this receptor, by 
endocytosis.
4
  
 
 
Figure 3.1 Structure of (a) folic acid; (b) arginine; (c) D-glucose; (d) estrogen. 
 
3.1.1.1 Biomolecule conjugated supramolecular cylinders 
Peptides are one type of biomolecule that can be used in the targeted delivery of drugs. 
Cell-penetrating peptides are short sequences of peptides that can cross the plasma 
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membrane and cell-targeting peptides have specificity to certain cell lines and enter the cell 
via receptor mediated endocytosis.
5
 
 
Several metallo-cylinders conjugated to short peptide fragments have been developed by 
Cardo of the Hannon group.
6,7
 These cylinders were designed to have enhanced cellular 
uptake and increased specificity towards certain DNA base sequences.
6,7
 The first peptide 
conjugated cylinders to be developed were functionalised with a glycine-glycine-serine 
tripeptide sequence (Fig. 3.2).
6
 Both the iron(II) cylinder, [Fe2L
a
3]
4+
, and the copper(I) 
cylinder, [Cu2L
a
2]
2+
, showed that the inherent DNA binding activity of the cylinder had 
been retained.
6
  
 
 
 
Figure 3.2 Structure of La ligand of complex [Fe2L
a
3]
4+.6 
 
An iron(II) cylinder conjugated to arginine, [Fe2L
b
3]
4+ 
(Fig. 3.3), was also developed and 
was found to have good DNA binding activity and could stabilise DNA three-way 
junctions.
7
 The complex was also shown to have potent cytotoxicity in an ovarian cancer 
cell line.
7
 
 
 
Figure 3.3 Structure of Lb ligand of complex [Fe2L
b
3]
4+.7 
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These peptide functionalised helicates show promising DNA binding activity and the 
arginine conjugate shows potent cytotoxicity, however the synthesis of these complexes 
has many reaction steps and the iron(II) cylinders possess very poor stability, with the 
[Fe2L
a
3]
4+ 
complex only being stable for two hours.
6
   
 
Steroid hormones can also be used to facilitate the delivery of cytotoxic drugs, as many 
hormone-dependant cancers overexpress steroid receptors, and these can be targeted by 
steroid-drug conjugates. The estrogen receptor (ER) is overexpressed in 60-75% of breast 
cancer tumours
8
 and the androgen receptor, for testosterone conjugates, is overexpressed in 
approximately 80% of breast
9,10,11
, 74-90% of ovarian
12,13,14
 and in all prostate 
tumours.
15,16,17
 
 
Steroid functionalised anticancer agents have previously been reported by the Hannon 
group.
18,19
 Examples include an estrogen-functionalised platinum(II) terpyridine complex 
and a platinum(II)-testosterone conjugate (Fig. 3.4).
18,19
 Cellular uptake and cytotoxicity 
studies showed that the steroid conjugates retained their receptor binding affinities and 
were delivered across the cell membrane into tumour cells with the corresponding steroid 
receptor.
18,19
 The uptake of these complexes was much higher than their non-steroidal 
analogues. 80-100% of the estrogen-Pt(II)-terpyridine complex was taken up by cells 
displaying the estrogen receptor (ERα+) compared to only 25% for the non-steroidal 
analogue.
18,19
 Both complexes showed potent cytotoxicity against ovarian and breast 
cancer cell lines, with the platinum(II)-testosterone conjugate showing better activity than 
its non-steroidal analogue.
18,19
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Figure 3.4 Structure of platinum(II)-testosterone conjugate (left) and estrogen-functionalised platinum(II) 
terpyridine complex (right).18,19 
 
3.1.2 Conjugation of chiral substituents and biomolecules 
As previously mentioned (Section 1.5.2, Chapter 1), the introduction of chiral substituents 
onto helicate ligands can force the stereoselectivity of the helicate, known as chiral 
induction.
20,21
 Many biomolecules have stereogenic centres and so functionalisation with 
these moieties might lead to enantiopure helicates. 
 
The inducement of chirality to these iron(II) helicates by chiral substituents has previously 
been observed in the development of Cardo’s peptide-conjugated cylinders (Section 
3.1.1.1).
6,7
 The conjugation of L-arginine (Fig. 3.5) to the cylinder resulted in the 
formation of a diastereoisomerically pure helicate of the P configuration and the 
conjugation of D-arginine resulted in a diastereoisomerically pure helicate of the M 
configuration.
7
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Figure 3.5 Structure of ligands conjugated to L-arginine (top) and D-arginine (bottom).7 
 
The chirality of a DNA-binding agent will influence its ability to bind to DNA, as DNA is 
also chiral. This was observed with the peptide cylinders, as both diastereoisomers were 
found to bind to and stabilise DNA three-way junctions more than the parent cylinder, and 
the D-arginine conjugate (M helical isomer) showed stronger binding than the L-arginine 
conjugate (P helical isomer).
7
 
 
3.2 Molecular design 
As the steroid hormone-platinum(II) conjugates described previously (Section 3.1.1.1) 
showed good activity and selectivity, it was thought that a supramolecular cylinder 
functionalised with steroid hormones may also possess the same properties. To synthesise 
these biomolecule-conjugated cylinders the novel functionalisation route, detailed and 
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employed in chapter 2, offers a straightforward synthesis route with few reaction steps. As 
estrogen and testosterone steroid hormones conjugated with alkyne groups, estradiol and 
ethisterone respectively, are already commercially available, the synthesis route will have 
fewer steps. Two iron(II) cylinders were designed that were functionalised with 
testosterone and estrogen hormones, [Fe2L
Test
3]
4+
 and [Fe2L
Estro
3]
4+
 respectively (Fig. 3.6). 
The 5-position of the pyridine ring was chosen as the modification site, as for the 
functionalised cylinders developed in Chapter 2, so as not to effect the cylinder formation 
or significantly reduce the DNA affinity of the synthesised cylinders. By positioning the 
hormones at the ends of the cylinder, and attaching them at the 17α position, it was hoped 
that the hormone-receptor binding affinity would be retained, allowing delivery of the 
conjugates across the cell membrane.  
 
 
Figure 3.6 Structure of ligands LTest (top) and LEstro (bottom). 
 
As these steroid hormones have multiple stereogenic centres, their effect on the chirality of 
the cylinder when conjugated must be considered. Once synthesised, the chirality of the 
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designed steroid-functionalised cylinders will be investigated to see whether any chiral 
induction is observed.  
 
3.3 Synthesis  
3.3.1 Synthesis of testosterone cylinder, [Fe2L
Test
3][BF4]4 
3.3.1.1 Synthesis of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) 
As 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) is not commercially 
available it was synthesised, with the synthesis based on a literature procedure.
22
 
Sonogashira coupling was employed to couple 5-bromo-2-pyridinecarboxaldehyde to 17-
ethynyltestosterone using the catalysts copper iodide and 
bis(triphenylphosphine)dichloropalladium(II) (Scheme 3.1). Basic conditions were used 
and the reaction mixture was stirred under an argon atmosphere at room temperature for 
seventy two hours. The crude product was then purified by removal of the 
triphenylphosphine oxide impurity, with use of a short silica column with diethyl ether as 
eluent, and removal of unreacted starting materials using column chromatography on 
silica. A pale brown solid was produced in 44% yield.    
 
 
Scheme 3.1 Synthetic route for preparation of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6). 
 
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
142 
 
The product was characterised using high resolution EI mass spectrometry and elemental 
analysis, which both confirmed the formation of the desired product, 17α-[(2-
pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) of formula [C27H31NO3]. Characteristic 
peaks in the 
1
H NMR spectrum (Fig. 3.7), assigned using a 2D-COSY (see Appendix), 
corresponding to the steroid H4’ and methyl (H18’ and H19’) protons and the pyridine-
carboxaldehyde aldehyde proton ( Hald) at the expected integration confirm the product has 
been formed.  
 
 
 
Figure 3.7 1H NMR (300 MHz, CDCl3, 298 K) of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone 
(6). 
 
 
3.3.1.2 Synthesis of [Fe2L
Test
3][BF4]4 
The testosterone cylinder, [Fe2L
Test
3][BF4]4, was synthesised using a one-pot procedure 
with six equivalents of the testosterone aldehyde (6), three equivalents of the spacer, 4,4’-
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methylenedianiline, and two equivalents of the metal salt, iron(II) tetrafluoroborate 
hexahydrate, added sequentially and dropwise, in ethanol (Scheme 3.2). An immediate 
dark purple precipitate formed on addition of the reactants suggesting the formation of an 
iron(II) cylinder. The product was isolated simply by filtration and washed with copious 
amounts of chloroform, in a yield of 29%.  
 
Scheme 3.2 Synthetic route for preparation of [Fe2L
Test
3][BF4]4. 
 
 
The light purple solid was confirmed to be the desired product, [Fe2L
Test
3][BF4]4, by 
characterisation with ESI mass spectrometry and NMR spectroscopy. Several multiply 
charged peaks in the mass spectrum can be attributed to the species [Fe2(C67H72N4O4)3]
4+ 
and [Fe2(C67H72N4O4)3]
3+ 
(see Appendix). Peaks in the 
1
H NMR spectrum (Fig. 3.8), 
assigned using 2D-COSY (see Appendix), corresponding to the characteristic imine (Him), 
spacer (Hsp) and phenyl protons (Pha/b) as well as peaks originating from the steroid, H18 
and H19, at the correct integration suggest the formation of the product. When analysing the 
spectrum it became clear that some of the peaks appeared to be more split than expected, 
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
144 
 
with some that should be singlet peaks with an integration of two actually being observed 
as two separate peaks with an integration of one each, for example H4 and H4’. This is due 
to the formation of two diastereoisomers as will be discussed in greater depth in the next 
section (Section 3.4.1). 
 
Figure 3.8 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
Test
3][BF4]4. 
 
An overall yield of 13%, with respect to the 5-bromo-2-pyridinecarboxaldehyde starting 
material, was obtained for the synthesis of the testosterone cylinder, [Fe2L
Test
3][BF4]4. 
 
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
145 
 
3.3.2 Synthesis of estrogen cylinder, [Fe2L
Estro
3][BF4]4 
3.3.2.1 Synthesis of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7)  
As 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7) is not commercially available 
it was synthesised, with the synthesis based on a literature procedure.
22
 A Sonogashira 
coupling reaction was employed to couple 5-bromo-2-pyridinecarboxaldehyde to 17α-
ethynylestradiol, at room temperature under an inert atmosphere for seventy two hours 
(Scheme 3.3). Catalysts, copper iodide and bis(triphenylphosphine)dichloropalladium(II), 
were employed. The resulting crude mixture was purified using a short silica column with 
diethyl ether as eluent to remove the triphenylphosphine oxide impurity afforded by the 
palladium catalyst, and any unreacted starting materials were removed by column 
chromatography. A pale brown solid was produced in 49% yield.   
 
 
Scheme 3.3 Synthetic route for preparation of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7). 
 
The product, 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7), was characterised 
by high resolution EI mass spectrometry, with one peak corresponding to the molecular ion 
plus sodium being observed. 
1
H NMR spectroscopy revealed a spectrum (Fig. 3.9) 
containing peaks corresponding to the steroid and pyridine-carboxaldehyde moieties of the 
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desired product at the expected ratios, confirming its formation. The aromatic ring of the 
estrogen steroid, protons H1’, H2’ and H4’, can be seen at high chemical shift with the 
pyridine protons, H3, H4 and H6. One singlet peak corresponding to the methyl group of the 
steroid (HMe) can be observed.  
 
 
 
Figure 3.9 1H NMR (300 MHz, CDCl3, 298 K) of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7). 
 
3.3.2.2 Synthesis of [Fe2L
Estro
3][BF4]4 
The estrogen cylinder was synthesised using a one-pot method, with the starting materials 
17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7), 4,4’-methylenedianiline and 
iron(II) tetrafluoroborate hexahydrate being mixed together, sequentially and dropwise, in 
ethanol in a 6:3:2 ratio (Scheme 3.4). Immediate colour change from pale yellow to deep 
purple, indicative of the formation of the desired cylinder, was observed. The purple 
precipitate was collected by filtration and purified by washing with a large volume of  
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chloroform. The resulting light purple solid was obtained in 25% yield.  
 
 
Scheme 3.4 Synthetic route for preparation of [Fe2L
Estro
3][BF4]4. 
 
The estrogen cylinder [Fe2L
Estro
3][BF4]4 was characterised by ESI mass spectrometry, in 
which several multiply charged species corresponding to [Fe2(C65H64N4O4)3]
4+
, 
[Fe2(C65H64N4O4)3]
3+
, [Fe2(C65H64N4O4)3][BF4]
3+ 
and [Fe2(C65H64N4O4)3]
2+
 could be 
identified with the expected isotopic pattern (see Appendix). A 
1
H NMR spectrum (Fig. 
3.10), assigned using 2D-COSY (see Appendix), was employed to characterise the cylinder 
further. The characteristic peak corresponding to the newly formed cylinder, the imine 
peak (Him), could be observed and peaks originating from the steroid were also evident. 
However most of the peaks observed did not have the splitting or integration expected, 
including the imine and steroid peaks discussed. This is due to a mixture of two 
diastereoisomers, as with the testosterone steroid cylinder, and will be discussed in greater 
depth in the next section (Section 3.4.1). 
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Figure 3.10 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
Estro
3][BF4]4. 
 
An overall yield of 12%, with respect to the 5-bromo-2-pyridinecarboxaldehyde starting 
material, was obtained for the synthesis of the estrogen cylinder, [Fe2L
Estro
3][BF4]4. 
 
3.4 Properties of synthesised steroid cylinders 
3.4.1 Chirality of synthesised helicates, as investigated by 
1
H NMR studies with ∆-
TRISPHAT  
The tetrabutylammonium salt of ∆-TRISPHAT, or tris(tetrachlorobenzenediolato)- 
phosphate(V) (Fig. 3.11), is a commercially available chiral NMR shift reagent developed 
by Lacour and co-workers.
23
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Figure 3.11 Tetrabutylammonium salt of ∆-TRISPHAT.23 
 
Herein, ∆-TRISPHAT was used in order to elucidate the enantiomeric purity of the 
synthesised steroid functionalised helicates. 
 
3.4.1.1  
1H NMR ∆-TRISPHAT studies with the parent cylinder 
1
H NMR ∆-TRISPHAT studies have previously been carried out in the Hannon group, 
exploring the effect of ∆-TRISPHAT on racemic and enantiopure solutions of the parent 
cylinder, [Fe2L
P
3][PF6]4.
7,24,25
 When ∆-TRISPHAT was added to a solution of  racemic 
[Fe2L
P
3][PF6]4, splitting of some of the resonances was observed in the 
1
H NMR spectrum 
(Fig. 3.12) indicating that ∆-TRISPHAT is able to interact with the M and P enantiomers 
differently.
24
  
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
150 
 
 
Figure 3.12 1H NMR (300 MHz, CD3CN, 298 K) of a) a solution of rac-[Fe2L
P
3][PF6]4; b) the same solution 
with 2 equivalents of ∆-TRISPHAT. [Reproduced from Ref 24] 
 
To determine whether one or both enantiomers can interact with ∆-TRISPHAT, an 
enantiopure solution of the M enantiomer was “doped” with 10% of enantiopure P and 
then two equivalents of ∆-TRISPHAT were added.24 In the 1H NMR spectrum (Fig. 3.13) 
it can be observed that the spacer protons (H11) of the M enantiomer are shifted on addition 
of ∆-TRISPHAT, whereas it is the imine (H7) and H6 protons of the P enantiomer that are 
shifted.
24
 This suggests that ∆-TRISPHAT interacts in the area of the central spacer for the 
M enantiomer and at the metal coordination site of the P enantiomer.
24
 
 
 
 
a) 
 
 
 
b) 
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Figure 3.13 1H NMR (300 MHz, CD3CN, 298 K of a) a solution of [Fe2L
P
3][PF6]4 (ratio of enantiomers, M:P 
= 9:1);  b) the same solution with 2 equivalents of ∆-TRISPHAT. [Reproduced from Ref 24] 
 
3.4.1.2 
1
H NMR ∆-TRISPHAT studies with peptide cylinders 
∆-TRISPHAT has also been employed to determine the enantiomeric purity of Cardo’s 
peptide conjugated iron(II) cylinders mentioned previously (Section 3.1.2).
7
 Cylinders 
conjugated to L- or D-arginine form seemingly diastereoisomerically pure isomers (P and 
M respectively) as indicated by 
1
H NMR and CD experiments. This observation was 
further investigated using ∆-TRISPHAT (Fig. 3.14).7 When two equivalents of ∆-
TRISPHAT were added to solutions of the L- and D-arginine conjugated cylinders ([Fe2L
L-
Arg
3][PF6]10 and [Fe2L
D-Arg
3][PF6]10 respectively) only one set of resonances was observed 
for each conjugated cylinder confirming that they are diastereoisomerically pure.
7
 For the 
L-arginine conjugate, [Fe2L
L-Arg
3][PF6]10, the imine (H7) and H6 protons are shifted 
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whereas for the D-arginine conjugate, [Fe2L
D-Arg
3][PF6]10, the spacer protons (H11) are 
shifted.
7
 These results are in agreement with those for the parent cylinder and confirm the 
theory that the L-arginine conjugate is in fact the P helical isomer and the D-arginine 
conjugate is the M helical isomer.
7
 
 
Figure 3.14 1H NMR (300 MHz, CD3CN, 298 K) of a) a solution of [Fe2L
L-Arg
3][PF6]10; b) a solution of 
[Fe2L
D-Arg
3][PF6]10; c) a solution of [Fe2L
L-Arg
3][PF6]10 with 2 equivalents of ∆-TRISPHAT; d) a solution of 
[Fe2L
D-Arg
3][PF6]10 with 2 equivalents of ∆-TRISPHAT. Peaks with crosses correspond to arginine protons. 
[Reproduced from Ref 7]   
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3.4.1.3 
1
H NMR ∆-TRISPHAT studies with novel steroid cylinders 
As the 
1
H NMR characterisation of the steroid cylinders detailed in this chapter was 
ambiguous, ∆-TRISPHAT studies were undertaken to investigate the possible mixture of 
diastereoisomers formed in the steroid cylinder synthesis. To a solution of the steroid 
cylinders, [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, was added increasing equivalents of the 
tetrabutylammonium salt of ∆-TRISPHAT.  
 
The 
1
H NMR spectrum (Fig. 3.15) of the testosterone cylinder alone reveals that some of 
the peaks are already split, for example the H4 peak of the steroid. After the addition of one 
equivalent of ∆-TRISPHAT, the peaks are split into two clear sets of resonances. Upon 
addition of another equivalent of ∆-TRISPHAT the peaks are further split. The ratio of the 
peaks of the two sets of resonances is 1:0.85 providing evidence that the solution of 
[Fe2L
Test
3][BF4]4 is an unequal mixture of the two helical isomers, M and P.  
 
As with the parent and peptide cylinders, the resonances that are particularly shifted are 
those corresponding to the imine (Him), spacer (Hsp) and HPy6 protons. For the parent and 
peptide cylinders, the spacer proton (Hsp) of the M enantiomer is shifted, whereas the imine 
(Him) and H6 protons are shifted for the P enantiomer. This is due to the ∆-TRISPHAT 
anion interacting in different areas of the cylinder for each enantiomer. However for the 
testosterone cylinder the peaks that have shifted are all peaks of lower integration. No 
conclusions may be drawn as to which set of peaks corresponds to which helical isomer 
and therefore it is not known which helical isomer is more abundant.  
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Figure 3.15 1H NMR (300 MHz, CD3CN, 298 K) of a) a solution of [Fe2L
Test
3][BF4]4; b) same solution with 
1 equivalent of ∆-TRISPHAT; c) same solution with 2 equivalents of ∆-TRISPHAT. 
 
1
H NMR ∆-TRISPHAT studies were then carried out with the estrogen cylinder, 
[Fe2L
Estro
3][BF4]4. As for the testosterone cylinder, the spectrum of the cylinder alone (Fig. 
3.16) reveals that some peaks are already split, including the imine (Him) and HPy4 protons.  
It was observed that after the addition of one equivalent of ∆-TRISPHAT, the majority of 
peaks split into two sets of resonances. This splitting is increased upon the addition of 
further equivalents of ∆-TRISPHAT. These observations provide evidence for the solution 
being a mixture of M and P helical isomers. The two helical isomers present in solution are 
not in a 1:1 ratio; a ratio of 1:0.72 is observed for the integration of the two sets of peaks. 
As was observed with the other iron(II) cylinders characterised using this method, the 
peaks corresponding to the imine (Him), spacer (Hsp) and pyridine (Py3 and Py6) protons are 
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split the most by the addition of ∆-TRISPHAT. It is difficult to assign the two sets of 
resonances from these spectra. It would be expected that the spacer proton would be 
shifted for the M helical isomer, and that the pyridine and imine protons would be shifted 
for the P helical isomer as previously observed. However all of the peaks that are shifted 
are of lower integration. Therefore conclusions as to the more abundant helical isomer 
cannot be drawn.  
 
 
Figure 3.16 1H NMR (300 MHz, CD3CN, 298 K) of a) a solution of [Fe2L
Estro
3][BF4]4; b) same solution with 
1 equivalent of ∆-TRISPHAT; c) same solution with 2 equivalents of ∆-TRISPHAT; d) same solution with 3 
equivalents of ∆-TRISPHAT. 
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As the 
1H NMR ∆-TRISPHAT studies do not reveal the more abundant helical isomer for 
the two steroid cylinders, it was hoped that circular dichroism studies may provide an 
answer. 
 
3.4.2 Chirality of helicates, as investigated by circular dichroism  
Circular dichroism can be used to identify the chirality of iron(II) cylinders, as the CD 
signals arising in the visible region are due to the helicate core. CD spectra of enantiopure 
solutions of the M and P enantiomers of the parent cylinder, [Fe2L
P
3]
4+
, reveal identical but 
opposite CD signals (Fig. 3.17). This is also true of the peptide conjugated cylinders. When 
solutions of the diastereoisomerically pure L-arginine and D-arginine conjugated cylinders, 
P and M helical isomers respectively, are analysed by CD, the spectra looks remarkably 
similar to that of the parent cylinder.
7
  
 
 
Figure 3.17 CD spectra of M (solid line) and P (dashed line) enantiomers of [Fe2L
P
3]
4+. [Reproduced from 
Ref 26] 
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CD spectra of the steroid cylinders, [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, were recorded 
to see if they could give any information about the chirality of the complexes (Fig. 3.18). It 
is known that both cylinders are a mixture of diastereoisomers, and that these are not in an 
equal ratio. Comparison of the CD spectra obtained with that of the parent cylinder 
suggests that both the [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4 cylinders have a slightly 
higher ratio of the P helical isomer compared to the M helical isomer, due to the 
observation of the characteristic P shape in the visible region of the CD signal. 
 
 
Figure 3.18 CD spectra of increasing concentrations of complexes: (left) [Fe2L
Test
3][BF4]4; (right) 
[Fe2L
Estro
3][BF4]4. Legend shows complex concentration. 5.9% max. MeOH. 
 
 
3.4.3 Complex counterions  
The steroid functionalised cylinders, [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, synthesised 
herein have tetrafluoroborate as counterions. As discussed previously (Section 2.5.1, 
Chapter 2) the preferred counterion would be chloride for these complexes, as the majority 
of the parent and later generation iron(II) cylinders have chloride counterions.  
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However attempts to synthesise these steroid cylinders with chloride as counterion, to form 
[Fe2L
Test
3][Cl]4 and [Fe2L
Estro
3][Cl]4, were unsuccessful. Addition of iron(II) chloride 
tetrahydrate, instead of iron(II) tetrafluoroborate hexahydrate, into the one-pot synthesis of 
both steroid cylinders resulted in an immediate green precipitate which could not be 
identified by mass spectrometry or NMR spectroscopy. Ion exchange using 
tetrabutylammonium chloride induced a degradation of the steroid cylinder, as did the 
addition of a sodium chloride solution. It is concluded from these studies, and those 
performed with the simple alkyne cylinders, that these iron(II) cylinders are in some way 
destabilised by chloride counterions. As these cylinders all contain an alkyne linking 
group, it is possible that this group is somehow interacting unfavourably with the 
counterions, causing the complexes to be unstable. Alternatively, the effect of the alkyne 
on the electronic properties of the pyridylimine is to weaken the binding to the iron centre.  
  
3.4.4 Solubility of steroid functionalised cylinders 
As previously discussed (Section 2.5.2, Chapter 2), water solubility is an advantageous 
property of potential anti-cancer drugs
27
 and DNA binding studies should be carried out in 
aqueous solutions. Unfortunately the steroid functionalised cylinders synthesised in this 
chapter are not water soluble. However they do possess very good solubility in methanol 
and so can be dissolved in water, with the assistance of a small percentage of methanol. 
This allows the DNA binding, though not the cytotoxicity, of these complexes to be 
studied.   
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3.4.5 UV-Vis stability studies 
As previously discussed (Section 2.5.3, chapter 2) the stability of any drug that is to be 
administered into the body is an important consideration. More importantly for this work, 
the stability of these steroid functionalised cylinders must be established in order to fully 
understand the results of the DNA binding studies carried out.   
 
Steroid cylinder stabilities in the absence and presence of ct-DNA were established using 
UV-Vis spectroscopy experiments analogous to those carried out in Chapter 2 (Section 
2.5.3). Aqueous solutions of the steroid cylinders containing a small percentage of 
methanol were used due to solubility issues.  
 
For both complexes, [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, the λmax of the MLCT band 
decreases with time, indicating some degradation. The stability of both complexes is very 
similar, with losses of absorbance of 31% and 33% for the testosterone and estrogen 
cylinders respectively over the twelve hour period (Fig. 3.19). In the presence of ct-DNA 
both complexes are more stable. The degradation of [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4 
in the presence of DNA is slower with an absorbance loss of 20% for both complexes over 
12 hours. Over a five hour period, the maximum experimental time of the DNA binding 
studies carried out herein, the testosterone functionalised cylinder loses 13% of its original 
absorbance and the estrogen cylinder loses 5%. Although degradation of these complexes 
is observed, it is thought that this should not significantly affect any conclusions drawn 
from the DNA binding studies carried out.    
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Figure 3.19 Normalised UV-Vis stability studies of complexes [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4 at 
room temperature (5 μM, 1.5% MeOH:water) and in presence of ct-DNA in 6.7 mM NaCl and 0.33 mM 
Na(CH2)2AsO2.3H2O (pH 6.8)  (ratio 6:1 ct-DNA:complex, 1.9% MeOH:water). λmax 593 nm. 
 
As observed for the alkyne cylinders detailed previously (Chapter 2) and other analogous 
iron(II) supramolecular cylinders,
24
 the presence of ct-DNA appears to have a stabilising 
effect. One possible explanation for this may be that as these types of iron(II) cylinders 
bind in the major groove of DNA,
28
 this environment protects them in some way from 
solvent attack and so they degrade more slowly.   
 
These steroid functionalised cylinders are less stable than the [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 cylinders (Section 2.5.3, Chapter 2). 
 
 
3.5 DNA binding studies 
Two novel iron(II) supramolecular cylinders functionalised with steroid hormones have  
been synthesised and characterised. The DNA binding properties of these novel cylinders 
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 were investigated by several techniques.  
 
3.5.1 Circular dichroism binding studies 
CD titrations were carried out for the steroid functionalised cylinders, [Fe2L
Test
3][BF4]4 and 
[Fe2L
Estro
3][BF4]4 analogous to those described in chapter 2 (Section 2.6.1). These 
complexes had to be dissolved in a methanol-water solvent mix as they are not water 
soluble. As for the CD titration experiments with the alkyne cylinders, two equal titrations 
were carried out in 1 cm and 0.1 cm pathlength cuvettes.  
 
As the two steroid cylinders, [Fe2L
Test
3][BF4]4  and [Fe2L
Estro
3][BF4]4, are chiral they have 
their own intrinsic CD signal (Fig. 3.20). This must be subtracted from the ct-DNA CD 
titration spectrum so as to see only the ICD signal arising from the interaction with DNA. 
This was achieved by first performing the titration with water instead of DNA solutions 
and subtracting these titration spectra from those of the titration with ct-DNA.  
 
 
Figure 3.20 CD of control titrations of [Fe2L
Test
3][BF4]4  (left) and [Fe2L
Estro
3][BF4]4 (right). Water with 
increasing concentrations of complexes. Legend shows corresponding ct-DNA:complex ratios for titration 
with ct-DNA. 5.9% max. MeOH. 
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The CD titration spectra of the testosterone functionalised cylinder, [Fe2L
Test
3][BF4]4, (Fig. 
3.21) reveal an ICD signal at 346 nm. This indicates that the cylinder is binding to ct-
DNA. The B-conformation of DNA is retained upon cylinder binding. However at higher 
complex loading, with a ratio of DNA:complex of 4:1 (0.1 cm pathlength spectrum), there 
is a change in the DNA signature in the region between 200-250 nm, most likely due to 
overlapping complex in-ligand spectroscopy.   
 
Figure 3.21 CD of 286 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Test
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.7% max. 
MeOH. Analysed in 1cm (a) and 0.1cm (b) cuvettes.  
 
ICD signals at 338 nm in the CD titration spectra (Fig. 3.22) of the estrogen functionalised 
cylinder, [Fe2L
Estro
3][BF4]4, indicates DNA binding. The characteristic signal of the B-form 
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of DNA is observed throughout the titration, showing that cylinder binding does not affect 
DNA conformation. However at higher complex loading, with ratios of DNA:complex of 
8:1 to 4:1 (0.1 cm pathlength spectrum), the formation of a peak at 233 nm overlaps the 
DNA bands. This new peak is most likely due to the complex in-ligand spectroscopy.   
 
Figure 3.22 CD of 293 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Estro
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.9% max. 
MeOH. Analysed in 1cm (a) and 0.1cm (b) cuvettes.  
 
 
3.5.2 Linear dichroism binding studies 
Linear dichroism titrations analogous to those performed with the parent and alkyne 
cylinders (Section 2.6.2, Chapter 2) were carried out for the steroid functionalised 
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complexes synthesised in this chapter. Due to poor aqueous solubility, the steroid cylinders 
were dissolved in a methanol/water solution.  
 
These steroid cylinders are too small to be oriented by viscous drag and so do not have any 
intrinsic LD signal. Consequently any ILD signal observed must come from interaction 
between the complex and ct-DNA. 
 
The LD titration spectrum (Fig. 3.23) for the testosterone functionalised cylinder, 
[Fe2L
Test
3][BF4]4, shows no detectable ILD signals in the complex region. Although 
oriented DNA binding cannot be confirmed by the presence of ILD signals in the 
spectrum, there is evidence of DNA binding. The magnitude of the negative LD band at 
260 nm, corresponding to DNA transitions, decreases as the complex concentration 
increases. This indicates that the cylinder is binding to DNA and coiling or bending it so as 
to induce a loss of DNA orientation, even at low cylinder loading.  
  
 
 
Figure 3.23 LD of 296 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Test
3][BF4]4. Legend shows ct-DNA:complex ratios. 5.7% max. 
MeOH. 
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The LD titration spectrum (Fig. 3.24) of the estrogen functionalised cylinder shows no 
induced LD signal, even at high concentrations of the metal complex. Consequently, 
oriented binding of the complex to DNA cannot be confirmed. DNA binding is occurring, 
however, as observed by the reduced magnitude of the negative LD band at 260 nm 
corresponding to the transitions of the DNA. This shows that the orientation of the DNA is 
being affected by the cylinder. The complex is causing the DNA to coil or bend by binding 
to the DNA and this occurs at low complex loading, and increases with higher 
concentrations of cylinder.  
 
 
Figure 3.24 LD of 296 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
Estro
3][BF4]4. Legend shows ct-DNA:complex ratios. 6% max. 
MeOH. 
 
Comparison of the DNA bending activity of the two steroid functionalised cylinders, 
[Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, with that of the parent and alkyne-functionalised 
cylinders (Table 3.1 and Fig. 3.25) show that the steroid functionalised complexes induce 
less coiling/bending of the DNA. However, the steroid cylinders show a similar 
bending/coiling activity to that of the phenylacetylene cylinder, [Fe2L
Phen
3][BF4]4, which 
has a much smaller substituent compared to the bulky steroid moieties, and so the DNA 
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coiling ability of the testosterone and estrogen functionalised cylinders is surprisingly 
pronounced.  
 
DNA:complex ratio % Loss of LD signal at 260nm upon interaction with complexes 
 
4:1 [Fe2L
P
3][BF4]4 [Fe2L
Test
3][BF4]4 [Fe2L
Estro
3][BF4]4 
99 59 70 
 
Table 3.1 Comparison of the percentage loss of LD signal at 260 nm upon interaction with complexes at a 
ratio of DNA:complex 4:1.  
 
 
 
 
 
Figure 3.25 Normalised LD signal at 260 nm vs complex concentration for parent, alkyne-functionalised and 
steroid-functionalised complexes. 
 
 
 
3.5.3 Gel electrophoresis studies 
Gel electrophoresis experiments analogous to those performed with the parent cylinder and 
alkyne cylinders (Section 2.6.3, Chapter 2) were carried out for the steroid cylinders, 
[Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4. A small percentage of methanol was used to 
dissolve the compounds. Samples containing different plasmid DNA:complex ratios (Table 
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3.2) were incubated at room temperature for two hours before being run on a 1% agarose 
gel.  
 
Lanes 1 2 3 4 5 6 7 
DNA:complex 
ratio 
MeOH 
control 
50:1 40:1 30:1 20:1 15:1 10:1 
Lanes 8 9 10 11 12 13 14 
DNA:complex 
ratio 
8:1 6:1 5:1 4:1 3:1 2:1 DNA 
control 
 
Table 3.2 Ratios of plasmid DNA:complex used in gel electrophoresis experiments. 
 
The agarose gel (Fig. 3.26) for complex [Fe2L
Test
3][BF4]4 shows that the circular and 
supercoiled forms of the pBR322 plasmid are not altered by addition of the complex, even 
at high concentrations. The experiment was repeated with a longer sample incubation time 
of four hours, as it was thought that the bulky steroid cylinder may take longer to correctly 
orient itself with the DNA to allow binding. However this made no difference to the result.  
         
 
Figure 3.26 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of circular (C) 
and supercoiled (SC) forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of 
complex [Fe2L
Test
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of 
complex. 7% max. MeOH. 
 
Similarly, no change in the mobility of either the circular or supercoiled forms of the 
plasmid DNA can be seen in the agarose gel (Fig. 3.27) for complex [Fe2L
Estro
3][BF4]4. As 
  
- 
+ 
    C 
SC 
   1    2     3      4      5     6      7     8     9     10    11   12    13   14 
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for the testosterone version of the cylinder, a longer sample incubation time did not 
improve the DNA binding or unwinding for this complex. 
         
Figure 3.27 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
Estro
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex. 7% 
max. MeOH. 
 
 
The results of the gel electrophoresis assays for the steroid cylinders show that the two 
complexes do not unwind supercoiled plasmid DNA, even at high complex concentration.  
 
3.5.4 PAGE studies 
Three-way junction polyacrylamide gel electrophoresis studies analogous to those 
performed with the parent and alkyne cylinders (Section 2.6.4, Chapter 2) were carried out 
for the steroid cylinders, by co-worker N. Calle Alonso from the University of 
Birmingham, and are briefly described herein for completeness. Due to the insolubility of 
the steroid complexes in water, a small percentage of methanol was used to dissolve the 
compounds. In each experiment control lanes containing one, two and three DNA strands 
and magnesium chloride were incorporated. The steroid cylinders were mixed with the 
three non-palindromic oligonucleotide strands to give a ratio of three-way-
junction:cylinder of 1:1, incubated for one hour and run on a 15% polyacrylamide gel.  
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The autoradiogram of the polyacrylamide gel (Fig. 3.28, cropped image; for whole gel see 
Appendix) shows that no three-way junction is formed by the three oligonucleotide strands 
on their own, as expected. It is also apparent that the steroid functionalised cylinders, 
[Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4, do not promote the formation of a DNA three-way 
junction. This may be due to the size and shape of the steroid substituents and their 
consequent destabilising interaction with the junction structure, which possibly prevents its 
formation. A small amount of precipitated DNA can be observed in the sample wells at the 
top of the gel, indicating some interaction between the single DNA strands and the 
complexes. 
 
Figure 3.28 Autoradiogram of polyacrylamide gel run at 25 °C. Lanes 1-3: S3*, S3*+S2, S3*+S2+S1 
respectively; Lane 4: S3*+S2+S1+MgCl2; Lanes 5-6: S3*+S2+S1 with [Fe2L
Test
3][BF4]4 and 
[Fe2L
Estro
3][BF4]4  respectively. Ratio of three-way junction (S1+S2+S3*):complex of 1:1. Asterisk indicates 
32P labelled strand.  
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
170 
 
3.6 Conclusions 
In this chapter, the novel cylinder functionalisation route detailed in chapter 2 was 
employed to synthesise supramolecular helicates end-functionalised with tumour targeting 
vectors. Iron(II) cylinders conjugated to the steroid hormones testosterone and estrogen 
were synthesised in only two reaction steps with overall yields of 12-13%. These 
complexes were found to be a mixture of diastereoisomers, due to the stereogenic centres 
of the steroid moieties attached, as demonstrated by 
1H NMR ∆-TRISPHAT and circular 
dichroism studies.  
 
Unfortunately these complexes are insoluble in water, however their solubility in a 
methanol-water solvent mix allowed DNA binding studies to be carried out. Evaluation of 
the stability of these complexes in the experimental conditions used for DNA binding 
studies indicated that they were stable enough to investigate.   
 
Comparison of the stability of these steroid functionalised cylinders with that of Cardo’s 
peptide cylinders (with half-lives of 2.5-4 hours 
6,24
) indicates that the bioconjugates 
developed herein are significantly more stable. This may be due to the way in which the 
biomolecules are conjugated to the cylinder. The peptide moieties are linked via amide 
bonds whereas the steroid hormones are linked via alkyne bonds. It may be that the amide 
bonds are more susceptible to hydrolysis, rendering the conjugates less stable in aqueous 
solutions. 
 
DNA binding studies were carried out for the [Fe2L
Test
3][BF4]4 and [Fe2L
Estro
3][BF4]4 
cylinders. Circular dichroism titrations with ct-DNA revealed that both complexes are able 
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to bind to DNA. The two steroid functionalised complexes could also bend/coil DNA 
although less bending/coiling was observed compared to the [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 complexes that have smaller functional groups 
attached. However these compounds were not able to unwind supercoiled plasmid DNA, as 
investigated by agarose gel electrophoresis experiments, or able to promote the formation 
of a DNA three way junction, as investigated by PAGE studies.  
 
Unfortunately, as with the alkyne helicates presented in chapter 2, in vitro studies could not 
be undertaken with these steroid functionalised cylinders due to their insolubility in the 
solvent systems required. 
 
The investigations undertaken indicate that iron(II) supramolecular cylinders can be 
functionalised with a large biomolecule without complete loss of their inherent DNA 
binding properties. However, the biomolecule that is conjugated must to be able to impart 
water solubility to these complexes, as this is a desired and important property of 
anticancer agents.  
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3.7 Experimental: synthesis 
3.7.1 Materials and methods 
All reagents and solvents were purchased from Aldrich, Fisher, Apollo Scientific and 
Fluorochem and used without further purification. Deuterated NMR solvents were 
purchased from Goss Scientific. NMR spectra were recorded on Brüker AVIII300 and 
AVIII400 spectrometers and processed using standard Brüker software. Electrospray 
Ionisation (ESI) spectra were recorded on a Micromass LCT Time of flight mass 
spectrometer in positive ionisation mode. IR spectra were recorded on a PerkinElmer 
Spectrum 100 FT-IR spectrometer. Microanalyses data were obtained using a CE 
Instruments EA1110 elemental analyser. UV-Vis spectra were performed using a Varian 
Cary 5000 UV-Vis spectrometer. CD and LD spectra were recorded on a Jasco J-810 
spectropolarimeter. 
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3.7.2 Synthesis of Testosterone cylinder, [Fe2L
Test
3][BF4]4 
3.7.2.1 Synthesis of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) 
Synthesis based on literature procedure.
22
 
  
C27H31NO3 
FW: 417.55 
 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.375 g, 2.02 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.058 g, 0.08 mmol), copper iodide 
(0.033 g, 0.17 mmol) and 17α-ethynyltestosterone (0.600 g, 1.92 mmol). Anhydrous THF 
(85 ml) and diisopropylamine (1.19 ml) were added, and the reaction mixture stirred under 
an argon atmosphere with light exclusion at room temperature for 72 hours. The resulting 
dark brown crude mixture was evaporated to dryness in vacuo and purified by column 
chromatography on a silica column (MeOH:DCM 2:98). The resulting pale brown solid 
was dissolved in diethyl ether and purified by column chromatography on a short silica 
column (diethyl ether) to remove the triphenylphosphine oxide impurity. Evaporation of 
the solvent yielded a pale brown solid (0.368 g, 44% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.06 (s, 1H, Hald), 8.79 – 8.78 (m, 1H, H6), 7.94 – 7.84 
(m, 2H, H3, H4), 5.74 (s, 1H, H4’), 2.48-1.42 (m, 18H, Htestosterone), 1.22 (s, 3H, H18’/19’), 
1.13-1.00 (m, 1H, Htestosterone), 0.97 (s, 3H, H H18’/19’). 
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13
C NMR (100 MHz, CDCl3): δ 192.5 (Cald), 152.5 (C6), 139.5 (C3/4), 124.0 (C4’), 120.9 
(C3/4), 53.5 (Ctestost), 50.5 (Ctestost), 39.1 (Ctestost), 36.3 (Ctestost), 35.7 (Ctestost), 33.9 (Ctestost), 
32.9 (Ctestost), 32.7 (Ctestost), 31.5 (Ctestost), 23.3 (Ctestost), 20.8 (Ctestost), 17.4 (C18/19), 12.9 
(C18/19). 
HRMS (EI): m/z = calculated for C27H32NO3 [M+H]
+
 418.2382; Found 418.2377. 
IR (ν) = 3287 (br, OH), 2937 (m, C-H), 2858 (m, C-H), 2816 (m, C-H), 2217 (s, C≡C), 
1713 (s, C=O), 1669 (s, C=O), 1616 (m, C=C), 1582 (m, C=C). 
Elemental analysis (%) calculated for C27H31NO3: C: 77.4; H: 7.2; N: 3.7; Found: C: 77.6; 
H: 7.5; N: 3.6. 
 
3.7.2.2 Synthesis of [Fe2L
Test
3][BF4]4 
 
 
[Fe2(C67H72N4O4)3][BF4]4 
FW: 3450.90 
 
To a solution of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) (0.060 g, 0.14 
mmol) in ethanol (2 ml) was added a solution of 4,4’-methylenedianiline (0.014 g, 0.07 
mmol) in ethanol (3 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate 
(0.016 g, 0.05 mmol) in ethanol (1 ml) was then immediately added dropwise and the 
reaction mixture stirred overnight at room temperature. The resulting purple precipitate 
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was collected by vacuum filtration, washed with chloroform (2 L), diethyl ether (200 ml) 
and dried for 12 hours over silica, yielding a light purple  solid (0.024 g, 29% yield). 
1
H NMR (300 MHz, CD3CN): δ  8.91 (s, 2H, Him), 8.47 – 8.39 (m, 2H, HPy3), 8.27 – 8.17 
(m, 2H, HPy4), 7.32 – 7.30 (m, 2H, HPy6), 6.91 (br s, 4H, HPha/ Phb), 5.80 (s, 1H, H4), 5.68 (s, 
1H, H4’), 5.50 (br s, 4H, HPha/ Phb), 4.02 (s, 2H, Hsp), 3.60 – 3.56 (m, 2H, HOH), 2.49 – 1.38 
(m, 38H, Htestosterone + 43H, solvent), 1.23 (s, 6H, H18/19), 0.88 (s, 6H, H18/19). 
Mass spectrum (ESI): m/z = 775.8 [Fe2(C67H72N4O4)3]
4+ 
, 1034.1 [Fe2(C67H72N4O4)3]
3+
. 
IR (ν) = 3384 (br, OH), 2941 (w, C-H), 2218 (s, C≡C), 1655 (s, C=O), 1543 (m, C=C), 
1054 (s, br, BF4). 
UV-Vis (MeOH): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 240 (148,500), 319 (91,200), 534 sh 
(8,900), 593 (13,700). 
 
3.7.3 Synthesis of Estrogen cylinder, [Fe2L
Estro
3][BF4]4 
3.7.3.1 Synthesis of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7)  
Synthesis based on literature procedure.
22
 
 
C26H27NO3 
FW: 401.50 
 
A schlenk flask was charged with 5-bromo-2-pyridinecarboxaldehyde (0.300 g, 1.61 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.024 g, 0.03 mmol), copper iodide 
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(0.020 g, 0.11 mmol) and 17α-ethynylestradiol (0.486 g, 1.64 mmol). Anhydrous THF (24 
ml) and diisopropylamine (10 ml) were added, and the reaction mixture stirred under an 
argon atmosphere with light exclusion at room temperature for 72 hours. The resulting 
dark brown crude mixture was evaporated to dryness in vacuo and purified by column 
chromatography on a silica column (MeOH:DCM 2:98). The resulting pale brown solid 
was dissolved in diethyl ether and purified by column chromatography on a short silica 
column (diethyl ether) to remove the triphenylphosphine oxide impurity. Evaporation of 
the solvent yielded a pale brown solid (0.317 g, 49% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.07 (s, 1H, Hald), 8.82 – 8.81 (m, 1H, H6), 7.92 – 7.90 
(m, 2H, H3, H4), 7.16 (d, J = 8.5, 1.0 Hz, 1H, H1’), 6.72 – 6.52 (m, 1H, H2’), 6.57 (d, J = 2.8 
Hz, 1H, H4’), 4.78 (s, 1H, HOH), 2.86 – 2.81 (m, 2H, Hestrogen), 2.51-1.25 (m, 13H, Hestrogen), 
0.96 (s, 3H, HMe). 
13
C NMR (100 MHz, CDCl3): δ 192.5 (Cald), 152.4 (C6), 139.5 (C3/4), 126.5 (C1’), 120.9 
(C3/4), 115.2 (C4’), 112.7 (C2’), 50.0 (Cestrogen), 43.6 (Cestrogen), 39.4 (Cestrogen), 39.1 (Cestrogen), 
33.2 (Cestrogen), 29.6 (Cestrogen), 27.2 (Cestrogen), 26.4 (Cestrogen), 22.9 (Cestrogen), 12.8 (CMe). 
HRMS (EI): m/z = calculated for C26H27NO3Na [M+Na]
+
 424.1889; Found 424.1890. 
IR (ν) = 3316 (br, OH), 2928 (m, C-H), 2867 (m, C-H), 2224 (s, C≡C), 1707 (s, C=O), 
1611 (m, C=C), 1581 (m, C=C). 
 
 
 
 
Chapter 3: Steroid Functionalised Metallo-Cylinders 
 
177 
 
3.7.3.2 Synthesis of [Fe2L
Estro
3][BF4]4 
 
 
[Fe2(C65H64N4O4)3][BF4]4 
FW: 3354.64 
 
To a solution of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7) (0.060 g, 0.15 
mmol) in ethanol (2 ml) was added a solution of 4,4’-methylenedianiline (0.015 g, 0.08 
mmol) in ethanol (3 ml) dropwise. A solution of iron(II) tetrafluoroborate hexahydrate 
(0.017 g, 0.05 mmol) in ethanol (1 ml) was then immediately added dropwise and the 
reaction mixture stirred overnight at room temperature. The resulting purple precipitate 
was collected by vacuum filtration, washed with chloroform (1 L), diethyl ether (200 ml) 
and dried for 12 hours over silica, yielding a light purple  solid (0.021 g, 25% yield). 
1
H NMR (300 MHz, CD3CN): δ 8.85 – 8.83 (m, 2H, Him), 8.35 – 8.30 (m, 2H, HPy3), 8.07 
(d, J = 7.5 Hz, 1H, HPy4), 7.81 (d, J = 7.5 Hz, 1H, HPy4’), 7.31 – 7.23 (m, 4H, HPy6, H1/2), 
6.89 (br s, 4H, HPha/b), 6.74 – 6.52 (m, 6H, Hestrogen-OH/H1/2, H4), 5.45 (br s, 4H, HPha/b), 3.98 
(s, 2H, Hsp), 3.48 (s, 1H, HOH), 3.36 (s, 1H, HOH), 2.88 – 2.79 (m, 4H, Hestrogen), 2.35 – 1.20 
(m, 26H, Hestrogen + 95H, solvent), 0.87 (s, 6H, HMe). 
Mass spectrum (ESI): m/z = 751.9 [Fe2(C65H64N4O4)3]
4+ 
, 1002.2 [Fe2(C65H64N4O4)3]
3+
, 
1031.6 [Fe2(C65H64N4O4)3][BF4]
3+ 
, 1502.9 [Fe2(C65H64N4O4)3]
2+
. 
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IR (ν) = 3449 (br, OH), 2928 (m, C-H), 2869 (m, C-H), 2221 (s, C≡C), 1610 (m, C=C), 
1587 (m, C=C), 1543 (m, C=C), 1056 (s, br, BF4). 
UV-Vis (MeOH): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 230 sh (117,500), 279 sh (60,200), 321 
(106,000), 542 sh (11,500), 593 (15,500). 
 
3.8 Experimental: DNA binding studies 
3.8.1 Materials and methods 
All DNA binding studies were carried out using Ultrapure water (18.2 MΩ) purchased 
from Fisher Scientific. Calf thymus (ct) DNA, highly polymerised, was purchased from 
Sigma Aldrich and pBR322 plasmid DNA was purchased from New England Biolabs. 
Both were used without further purification and kept frozen. Tris-acetate-EDTA buffer was 
purchased from Fisher and agrose from USB Corporation. 
 
3.8.2 Circular and Linear Dichroism Experiments 
CD and LD measurements were recorded using a Jasco J-810 spectropolarimeter. CD 
measurements were carried out in quartz cuvettes of 1 cm (750-200 nm) or 0.1 cm (450-
200 nm) pathlength. LD experiments were recorded in a flow couette cell (Krometek) with 
a 0.1 cm pathlength. 
 
Stock solutions of ct-DNA (3000 μM) in water were prepared and kept frozen until the day 
of the experiment. Sodium chloride (1 M) and sodium cacodylate (Na(CH2)2AsO2.3H2O) 
(100 mM) buffer stock solutions were used to prepare final ct-DNA solutions of 300 μM 
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with 20 mM NaCl and sodium cacodylate (1 mM) (pH 6.8). DNA concentrations were 
determined by UV-Vis measurements using the known molar extinction coefficient of ε258 
= 6600 mol
-1
dm
3
cm
-1
 per DNA base.  
 
CD and LD titrations were carried out using three solutions; solution A (a 300 μM ct-DNA 
solution, containing  NaCl (20 mM) and sodium cacodylate (1 mM)); solution B (a 500 μM 
complex solution) and solution C (a 600 μM ct-DNA solution, containing 40 mM NaCl 
and sodium cacodylate (2 mM)). Firstly solution A was recorded, then equal aliquots of 
solutions B and C were added, keeping the concentration of ct-DNA constant throughout 
the titration. The titration was carried out to obtain an initial ct-DNA:complex ratio of 60:1 
decreasing to 4:1. The stock solution of complex was stored in ice during the experiment.  
 
3.8.3 Agarose gel electrophoresis 
Agarose gels were prepared by warming agarose (2 g) in 1x Tris-acetate-EDTA buffer 
which was then poured into a gel tray (210 x 150 mm) fitted with a 15 toothed comb, to 
produce sample wells. The gel was left to set for 40 minutes. Sample solutions (16 μl) were 
prepared containing 96.3 µM pBR322 plasmid DNA and different concentrations of 
complexes (from 60 µM stock solution in water and up to 7% MeOH) to obtain 
plasmid:complex ratios ranging from 100:1 to 2:1. Theses sample solutions were incubated 
for 2 hours at room temperature. Before loading , 4 μl loading buffer (30% glycerol, 0.25% 
bromophenol blue) was added, the samples were mixed and then 16 μl of the samples 
loaded into the gel wells. The gel was run for 2.5 hours in an Amersham Biosciences 
HE99X Maxi submarine kit with an electrophoresis Power Supply-EPS 301 system, at a 
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constant voltage of 120 V and 400 mA, in 1x Tris-acetate-EDTA running buffer. The gel 
was then stained with an ethidium bromide solution (0.5 mg.ml
-1
) in 200 ml of water for 20 
minutes and visualised using a UVtec–uvipro platinum 2.0 system (UVidoc, Cambridge, 
UK) at 312 nm.  
 
3.8.4 Polyacrylamide Gel Electrophoresis (PAGE)
 
Procedure provided by S. Phongtongpasuk 
29
 and carried out by N. Calle Alonso, both of 
the Hannon group, University of Birmingham. 
 
3.8.4.1 Radioactive labelling 
Oligonucleotides (sequences S1: CGGAACGGCACTCG, S2: CGAGTGCAGCGTGG, 
S3: CCACGCTCGTTCCG) were purchased from MWG Eurofin. One strand was labelled 
with P
32
 at the 5’ terminus using T4 polynucleotide kinase (New England Biolabs) and [γ-
32P] adenosine 5’-triphosphate (Perkin Elmer). First ultrapure water (4.8 µl), 10x 
bacteriophage T4 polynucleotide kinase buffer (1 µl), oligonucleotide S3 (1.2 µl of 100 
µM), bacteriophage T4 polynucleotide kinase (1 µl) (New England Biolabs) and γ-32P ATP 
(2 µl of  6000 Ci/mmol) (Perkin Elmer) were incubated in an eppendorf at 37°C for 40 
minutes. To deactivate the polynucleotide kinase, the solution was then heated to 80°C for 
3 minutes.  
 
To purify the radioactive-labelled DNA fragments from any unreacted ATP a QIAquick 
nucleotide removal kit (QIAGEN) was employed. 10 volumes of PN buffer were added to 
1 volume of reaction sample and this solution was loaded onto a QIAquick spin column 
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with a 2 ml collection tube, centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. A new collection tube was then fitted to the column, PE buffer (500 µl) was 
added and this solution was centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. Again, PE buffer (500 µl) was added and the solution was centrifuged at 13000 
rpm for 1 minute to remove residual buffer. The column was then put into a fresh 
eppendorf, ultrapure water (30 µl) was added to the column and this was left for 5 minutes. 
After centrifuging at 13000 rpm for 2 minutes a radiolabelled DNA stock solution (8 µM) 
was obtained. 
 
3.8.4.2 Polyacrylamide gel preparation 
A 15% native polyacrylamide gel was prepared by mixing 52.5 ml of ultra pure water, 10 
ml of 10x TB buffer (890 mM tris(hydroxymethy)amino methane and 890 mM boric acid) 
(pH 8.3), 37.5 ml of 40% acrylamide (29:1) (Geneflow), 500 µl of 10% (w/v) ammonium 
persulfate and 75 µl tetramethylenediamine (TEMED). This was then poured onto a set of 
glass plates and left to set for 40 minutes. The wells of the polymerised gel were washed 
with running buffer (TB buffer) and the gel was pre-run at 200 V for 5 minutes before 
sample loading.  
 
3.8.4.3 PAGE electrophoresis experiment  
Sample solutions were prepared by mixing solutions of the complexes with stoichiometric 
amounts of oligonucleotides in TBN buffer (89 mM tris(hydroxymethy)amino methane, 89 
mM of boric acid and 100 µM NaCl) (pH 8.3) to give final concentrations of 0.4 µM for 
each single strand (1.2 µM total concentration of DNA) and 0.4 µM of complex. This gives 
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a three-way junction:complex ratio of 1:1. The sample solutions were incubated for 1 hour 
at room temperature and then in ice for 15 minutes. To prepare the samples for loading, 5 
µl of 30% glycerol was added to each eppendorf. 13 µl of each sample was then loaded 
onto the 15% polyacrylamide gel. The gel was run for 4 hours at 120 V using Gel System 
equipment (Thermo Scientific UK). It was then exposed on a phosphor imaging plate for 
1-16 hours depending on how fresh the radioactive ATP used was. A radiogel image was 
obtained using a Molecular Imager FX (Bio-Rad) and the gel was quantified using 
Quantity One software.  
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4.1 Introduction and aims 
In chapter 3, the design and synthesis of two supramolecular helicates end-functionalised 
with tumour targeting vectors, testosterone and estrogen, were described. The DNA 
binding studies carried out for these compounds showed that aspects of the inherent DNA 
binding of the parent cylinder had been retained, with both complexes binding to DNA and 
causing intramolecular coiling of the DNA. Unfortunately, in vitro studies could not be 
undertaken with these compounds due to their insolubility in water.  
 
These studies show that functionalisation of the cylinder with a biomolecule via an alkyne 
linker can produce relatively stable complexes that retain some of the DNA binding 
properties of the unmodified parent cylinder. Reasoning that attaching a highly water 
soluble biomolecule to the cylinder might produce a water-soluble targeted helicate, with 
enhanced or specific delivery to cancerous tissues, this chapter details the design and DNA 
binding of sugar functionalised cylinders.  
 
4.1.1 Sugar functionalisation 
As previously discussed (Section 3.1.1, Chapter 3), one of the strategies for the delivery of 
anticancer drugs to cancerous tissue is receptor mediated targeting. This involves the 
exploitation of cell surface receptors that are overexpressed by tumour cells to deliver 
biomolecule-drug conjugates across the cell membrane.
1
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Carbohydrates make up one category of biomolecules that can be used in this strategy.
1,2
 
Conjugation of sugars to therapeutic drugs can lead to increased water solubility, 
membrane permeability, molecular targeting and can also introduce chirality.
3,4
 The 
carbohydrate can interact with carbohydrate transporters and metabolic pathways in the 
body if attached to the drug by some kind of linker.
4
 A large and varied range of tissues 
and cells highly express carbohydrate receptors that can be targeted by sugar-conjugates.
5
 
For example, mannose receptors are present on macrophages and so can be targeted to treat 
bacterial infectious diseases, inflammatory diseases and genetic metabolic diseases, and 
galactose and lactose receptors are abundant in a variety of tumour types.
5
 
 
There are many examples of cisplatin and cisplatin derivatives conjugated to sugar 
moieties, for improved cellular targeting. An oxaliplatin analogue functionalised with a 
glucose derivative (Fig. 4.1) was designed to take advantage of the increased glycolytic 
activity observed in all primary and metastatic cancers, and the upregulation of glucose 
transporters.
6
 The complex was found to be cytotoxic in cervical and colon cancer cell 
lines, however enhanced uptake due to the sugar moiety was not proven.
6
 Another cisplatin 
analogue conjugated to glucose (Fig. 4.1) was found to be cytotoxic to human ovarian and 
melanoma cancer cell lines with potency similar to that of cisplatin, and was found to have 
improved water solubility.
7
 
 
 
Chapter 4: Sugar Functionalised Metallo-Cylinders 
 
188 
 
 
 
Figure 4.1 Structure of sugar functionalised oxaliplatin analogue (left) and cisplatin analogue conjugated to a 
glucose derivative (right).6,7 
 
Carbohydrates are also employed to target radiopharmaceuticals such as a 
99m
Tc-
ethylenedicysteine-deoxyglucose complex (Fig. 4.2).
8
 The tumour imaging agent was 
found to have a significantly higher cellular uptake compared with its non-sugar analogue, 
thought to be mediated by a glucose receptor.
8
 The agent was observed to accumulate in 
proliferating tumour tissue due to the increased carbohydrate metabolism of these cells.
8
  
 
 
 
Figure 4.2 Structure of 99mTc-ethylenedicysteine-deoxyglucose complex.8 
 
A metallo-intercalator designed as a luminescent biological probe was conjugated to 
several different sugars including a β-D-glucosaminide (Fig. 4.3).9 The water soluble 
complex binds to DNA by intercalation and has similar cytotoxic potency to that of 
cisplatin in brain, breast and epithelial carcinoma cancer cell lines.
9
 Unfortunately the 
complex was not luminescent.
9
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Figure 4.3 Structure of metallo-intercalator conjugated to a β-D-glucosaminide sugar.9 
 
4.2 Molecular design 
As drug-sugar conjugates show promising targeting activity, helicates functionalised with 
sugars will be developed. The conjugation of a sugar moiety can be achieved using the 
novel functionalisation route described in chapter 2, and may lead to increased water 
solubility of the complexes. The acetyl and hydroxyl analogues of β-D-glucosaminide will 
be conjugated to the ends of the cylinder, at the 5-position of the pyridine-carboxaldehyde 
(Fig. 4.4). 
 
 
Figure 4.4 Structures of ligands functionalised with acetyl β-D-glucosaminide (top) and hydroxyl β-D-
glucosaminide (bottom). 
 
As these sugars have multiple stereogenic centres, their effect on the chirality of the 
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cylinder when conjugated must be considered. This will be investigated to see whether any 
chiral induction is observed.  
 
4.3 Synthesis 
4.3.1 Synthesis of acetyl sugar cylinder, [Fe2L
OAcSug
3][BF4]4  
4.3.1.1 Synthesis of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9) 
 
As 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-glucosaminide)-2- 
pyridinecarboxaldehyde (9) is not commercially available it was synthesised in two steps 
(Scheme 4.1). The first step, to synthesise 2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-
β-D-glucosaminide (8), was carried out according to a literature procedure.9 The sugar 
starting material was coupled to propargyl alcohol using silver trifluoromethane sulfonate 
at low temperature. A Sonogashira coupling, based on literature procedure,
10
 was then used 
to couple this alkyne sugar to 5-bromo-2-pyridinecarboxaldehyde, with 
bis(triphenylphosphine)dichloropalladium(II) and copper iodide as catalysts. After reaction 
for seventy two hours under an argon atmosphere, the triphenylphosphine impurity was 
removed by protonating the product with hydrochloric acid, partitioning the product and 
impurity in immiscible solvents, neutralising the acidic solution and extraction of the 
product with ethyl acetate. After further purification by column chromatography on silica, 
a white solid was obtained in 40% yield.      
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Scheme 4.1 Synthetic route for preparation of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9). 
 
The product (9) was characterised by high resolution EI mass spectrometry and elemental 
analysis, both of which confirmed the formation of the desired product. Peaks in the 
1
H 
NMR spectrum (Fig. 4.5), assigned using a 2D-COSY (see Appendix), corresponding to 
the sugar and pyridine-carboxaldehyde moieties at equal integration gives evidence for the 
formation of the product. The acetyl methyl groups of the sugar can be seen at low 
chemical shift.  
 
 
Figure 4.5 1H NMR (300 MHz, CDCl3, 298 K) of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9). 
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4.3.1.2 Synthesis of [Fe2L
OAcSug
3][BF4]4 
The acetyl sugar cylinder, [Fe2L
OAcSug
3][BF4]4, was synthesised using a one-pot procedure 
with six equivalents of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9), three equivalents of the spacer, 4,4’-
methylenedianiline, and two equivalents of the metal salt, iron(II) tetrafluoroborate 
hexahydrate, added sequentially and dropwise, in ethanol (Scheme 4.2). An immediate 
dark purple precipitate formed on addition of the reactants, suggesting the formation of an 
iron(II) cylinder. The product was isolated by filtration and washed with copious amounts 
of ethanol yielding a purple solid in 31% yield.  
 
Scheme 4.2 Synthetic route for preparation of [Fe2L
OAcSug
3][BF4]4. 
 
The light purple solid was confirmed to be the desired product, [Fe2L
OAcSug
3][BF4]4, by 
characterisation with ESI mass spectrometry and NMR spectroscopy. One multiply 
charged peak in the ESI mass spectrum can be attributed to the species 
[Fe2(C59H62N6O18)3]
4+ 
(see Appendix). The characteristic imine peak (Him) of the cylinder 
observed in the 
1
H NMR spectrum (Fig. 4.6), assigned using 2D-COSY (see Appendix), 
Chapter 4: Sugar Functionalised Metallo-Cylinders 
 
193 
 
shows formation of the product. Peaks corresponding to the spacer (Hsp) and phenyl 
protons (Pha/b) and the protons of the sugar moiety can also be observed. The formation of 
the cylinder has not altered the chemical shift of the sugar protons much, most likely due to 
the metal coordination site being quite a distance from the sugar moiety. The peaks of the 
acetyl methyl protons are partially obscured by the deuterated acetonitrile solvent peak and 
corresponding water peak, however they are observed and at the correct integration (Fig. 
4.7).   
 
 
Figure 4.6 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
OAcSug
3][BF4]4. 
 
 
Figure 4.7 1H NMR (300 MHz, CD3CN, 298 K) of [Fe2L
OAcSug
3][BF4]4; low chemical shift region. 
H
2
O                                                                                                 CD
3
CN 
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An overall yield of 4%, with respect to the sugar starting material, was obtained for the 
synthesis of the acetyl-sugar cylinder, [Fe2L
OAcSug
3][BF4]4. 
 
4.3.2 Attempted synthesis of hydroxyl sugar cylinder, [Fe2L
OHSug
3][BF4]4  
4.3.2.1 Synthesis of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10) 
The acetyl protected aldehyde, 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9) (Section 4.3.1.1), was deprotected with 
sodium methoxide (Scheme 4.3), based on literature procedure.
11
 The starting material was 
stirred with sodium methoxide at room temperature for two hours and then the crude 
product was purified by column chromatography, yielding a white solid in 60% yield.  
 
Scheme 4.3 Synthetic route for preparation of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10). 
 
 
High resolution EI mass spectrometry and NMR spectroscopy were used to confirm the 
formation of the desired product (10). It appears that two species are present in the 
1
H 
NMR spectrum (Fig. 4.8), assigned using a 2D-COSY (see Appendix), due to the aldehyde 
group being in equilibrium with the hydrate form in deuterated water. As such, resonances 
corresponding to the aldehyde pyridine and hydrate pyridine protons can be observed, and 
the resonances of the sugar moiety have contributions from both species and so the 
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 integration of these peaks is doubled.   
 
 
 
Figure 4.8 1H NMR (300 MHz, D2O, 298 K) of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10). 
 
4.3.2.2 Attempted synthesis of [Fe2L
OHSug
3][BF4]4  
The hydroxyl sugar cylinder, [Fe2L
OHSug
3][BF4]4, was synthesised using a one-pot 
procedure with the aldehyde 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10), 4,4’-methylenedianiline and iron(II) tetrafluoroborate, in a 
6:3:2 stoichiometry, added sequentially and dropwise, in a methanol-ethanol solvent mix 
(Scheme 4.4).   
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Scheme 4.4 Synthetic route for preparation of [Fe2L
OHSug
3][BF4]4. 
 
Immediately after addition of the iron salt, a dark purple precipitate formed, indicating 
formation of the iron(II) cylinder. The isolated purple solid was washed with a large 
volume of methanol and diethyl ether and dried overnight. Excitingly it was found that the 
solid was soluble in water, and in fact only water, however when preparing an NMR 
sample in deuterated water it was observed that the hydroxy-sugar cylinder was extremely 
unstable. Immediately after dissolution of the solid, obvious degradation was seen with the 
formation of a pale precipitate, which could not be identified by NMR spectroscopy or 
mass spectrometry. Further problems with stability were encountered when the solution 
was freeze-dried, which gave a dark grey solid that was completely insoluble in water and 
all other solvents. Addition of other solvents to a solution of the cylinder in water caused 
almost immediate degradation of the cylinder, with the deep purple/blue solution turning a 
pale yellow colour.  
 
Although the hydroxyl-sugar cylinder was soluble in water, it was difficult to obtain a clear 
1
H NMR spectrum due to the degradation of the complex. Only broad peaks can be 
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observed in the NMR spectrum (Fig. 4.9), that were difficult to integrate with no 
observable splitting patterns. However, the overall appearance of the spectrum can be 
compared to that of the other iron(II) cylinders synthesised herein and shows the 
characteristic imine peak (Him) confirming that the cylinder has been formed. There are no 
peaks corresponding to the 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10), or 4,4’-methylenedianiline spacer starting materials. The 
resonances of the sugar moiety (between 3-5 ppm and at 2 ppm) are very broad and partly 
obscured by solvent peaks, as is the peak of the spacer (Hsp).    
 
 
 
Figure 4.9 1H NMR (300 MHz, D2O, 298 K) of [Fe2L
OHSug
3][BF4]4. 
 
 
Characterisation by ESI mass spectrometry revealed multiply charged peaks corresponding 
to the species [Fe2(C47H50N6O12)3]
4+ 
and [Fe2(C47H50N6O12)3][BF4]
3+ 
(see Appendix). 
Although purity of the hydroxyl-sugar cylinder could not be confirmed by this 
characterisation, it was thought that preliminary DNA binding studies could be employed 
to assess the DNA binding activity of the complex.  
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4.4 Properties of synthesised sugar cylinders 
4.4.1 Chirality of synthesised helicates, as investigated by 
1H NMR ∆-TRISPHAT 
studies  
As detailed previously (Section 3.4.1, Chapter 3), ∆-TRISPHAT is a commercially 
available chiral NMR shift reagent. It has been used to investigate the enantiopurity of the 
parent and peptide conjugated iron(II) cylinders
12,13
 and also to study the chirality of the 
steroid functionalised cylinders presented in this work.   
 
The [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4 cylinders synthesised herein are 
functionalised with chiral sugar moieties. Therefore, they may be a mixture of 
diastereoisomers, as was observed for the steroid functionalised cylinders (Chapter 3), or 
only one, pure diastereoisomer may have formed due to chiral induction, as was seen 
previously for the peptide cylinders.
14
 As the NMR spectrum of the acetyl-sugar cylinder 
has only one set of resonances this implies that the cylinder may be diastereoisomerically 
pure. To investigate the chirality of the sugar complexes 
1
H NMR ∆-TRISPHAT studies 
were carried out. The chiral NMR shift reagent was added to a solution of the acetyl-sugar 
functionalised cylinder in deuterated acetonitrile. As ∆-TRISPHAT is not soluble in water, 
and the hydroxyl-sugar cylinder is only soluble in water, a solution of ∆-TRISPHAT in 
deuterated acetonitrile was added to a solution of the hydroxyl-sugar cylinder in deuterated 
water. 
 
The 
1
H NMR spectrum (Fig. 4.10) observed for the acetyl-sugar cylinder, 
[Fe2L
OAcSug
3][BF4]4, after addition of one equivalent of ∆-TRISPHAT, shows small 
changes in the chemical shifts of some of the peaks. Upon addition of further equivalents 
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of ∆-TRISPHAT, the peaks corresponding to the imine (Him), and two of the pyridine 
protons (HPy3 and HPy6) can be seen to shift. A shift of the peaks nearest to the metal 
coordination site indicates that the complex has the M helical configuration, as was 
observed for the isomerically pure parent and peptide functionalised cylinders (Section 
3.4.1, Chapter 3).   
 
 
 
 
Figure 4.10 1H NMR (300 MHz, CD3CN, 298 K) of a) a solution of [Fe2L
OAcSug
3][BF4]4; b) same solution 
with 1 equivalent of ∆-TRISPHAT; c) same solution with 2 equivalents of ∆-TRISPHAT; d) same solution 
with 4 equivalents of ∆-TRISPHAT. 
 
 
The 
1
H NMR spectra (Fig. 4.11) from the preliminary ∆-TRISPHAT experiment with the 
hydroxyl-sugar cylinder, [Fe2L
OHSug
3][BF4]4, are very difficult to interpret due to the low 
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concentration of complex that could be obtained in solution. After addition of the ∆-
TRISPHAT chiral shift reagent, some changes can be seen in the resonances although this 
may be due to changes in concentration or precipitation of the complex, and so no 
conclusions may be drawn. Also, the ∆-TRISPHAT had to be added to the cylinder 
solution in acetonitrile, which although is miscible with water may affect its ability to 
interact with the complex in some way.  
 
Figure 4.11 1H NMR (300 MHz, D2O/CD3CN, 298 K) of a) a solution of [Fe2L
OHSug
3][BF4]4; b) same 
solution with 1 equivalent of ∆-TRISPHAT; c) same solution with 2 equivalents of ∆-TRISPHAT. 
 
 
Circular dichroism studies were undertaken to gain more information about the chirality of 
the sugar functionalised cylinders developed. 
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4.4.2 Chirality of helicates, as investigated by circular dichroism  
As previously detailed (Section 3.4.2, Chapter 3), circular dichroism can be used to 
identify the chirality of iron(II) cylinders. CD spectra of enantiopure solutions of the M 
and P enantiomers of the parent cylinder, [Fe2L
P
3]
4+
, reveal identical but opposite CD 
signals (Fig. 4.12).  
 
 
Figure 4.12 CD spectra of M (solid line) and P (dashed line) enantiomers of [Fe2L
P
3]
4+. [Reproduced from 
Ref 15] 
 
 
 
CD spectra of the sugar cylinders, [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4, were 
recorded (Fig. 4.13), and compared to those of the parent cylinder. As the purity of the 
hydroxyl-sugar cylinder cannot be confirmed, solutions of component parts of the complex 
were also measured and were found to have no inherent CD signal. The spectra of the 
sugar cylinders reveal that the complexes are chiral, as they have a strong CD signal. The 
pattern of the CD signals of the sugar cylinders is almost the exact opposite of that of the 
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estrogen steroid cylinder (Section 3.4.2, Chapter 3), which is thought to be a mixture of 
diastereoisomers with a larger proportion of the P helical isomer. Comparison of the 
spectra of the sugar cylinders with those of the M and P enantiomers of the parent cylinder 
(Fig. 4.12) reveals that the sugar complexes have the characteristic CD signal of the M 
helical isomer. Therefore it can be concluded that the acetyl-sugar complex, 
[Fe2L
OAcSug
3][BF4]4, is diastereoisomerically pure, from the 
1
H NMR ∆-TRISPHAT 
studies, and is of the M helical configuration, as shown by the CD studies. Investigation of 
the hydroxyl-sugar cylinder, [Fe2L
OHSug
3][BF4]4, by 
1
H NMR ∆-TRISPHAT studies was 
more ambiguous, however by CD the cylinder is chiral and either has a higher proportion 
of the M helical isomer than the P helical isomer, or is diastereoisomerically pure and of 
the M helical configuration.  
 
 
   
Figure 4.13 CD spectra of increasing concentrations of complexes: (left) [Fe2L
OAcSug
3][BF4]4 (1.2% max. 
MeOH); (right) [Fe2L
OHSug
3][BF4]4. Legend shows complex concentration.  
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4.4.3 Solubility of sugar functionalised cylinders 
Water solubility is an advantageous property for potential anti-cancer drugs 
16
 and DNA 
binding studies are carried out in aqueous solutions. With this in mind, the iron(II) 
helicates synthesised in this chapter were functionalised with sugars which are known for 
their solubilising properties in aqueous medium.
4
 The acetyl-sugar cylinder, 
[Fe2L
OAcSug
3][BF4]4, is unfortunately not soluble in water, which is not surprising as it is 
the hydroxyl groups of the sugar that give aqueous solubility, proven by the observation 
that the hydroxyl-sugar functionalised cylinder is soluble in water. However, the acetyl-
sugar complex is soluble in water miscible methanol, which allows DNA binding studies to 
be carried out.  
 
Although the purity of the hydroxyl-sugar cylinder cannot be confirmed and it is relatively 
unstable in water, this aqueous solubility is exciting as it demonstrates that cylinders 
functionalised via alkyne bonds can be water soluble, if a suitable moiety is attached. Poor 
aqueous stability was observed for the peptide-conjugated cylinders developed by Cardo, 
with the tripeptide complex being stable for only two hours.
17
 The stability of the sugar 
cylinders was further investigated by UV-Vis studies, detailed in the next section.   
 
4.4.4 UV-Vis stability studies 
Studies were carried out with [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4 to determine their 
stability in aqueous solvents. Stabilities in the absence and presence of ct-DNA were 
established using UV-Vis spectroscopy.  The acetyl-sugar complex was dissolved in a 
small amount of methanol as it was not soluble in water alone. Solutions containing 
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complex and ct-DNA in a 6:1 ratio were also monitored.  
 
As the hydroxyl-sugar complex cannot be confirmed as pure and degrades quickly in 
solution, only a preliminary stability study was carried out. As it is the MLCT region of the 
complex that is monitored in this experiment, any component parts of the complex present 
due to degradation would not affect the results. 
 
For both complexes, [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4, the λmax of the MLCT 
band decreases with time, indicating complex degradation (Fig. 4.14). The acetyl-sugar 
cylinder is quite stable with a loss of only 12% of its original absorbance over a period of 
twelve hours. In the presence of ct-DNA there is a great improvement in the stability of the 
complex with only a 4% loss of the original absorbance after twelve hours and a 2% loss 
over a five hour period, the longest duration of the DNA binding experiments carried out 
with the complex. This sugar functionalised cylinder is more stable than the steroid 
functionalised cylinders on their own and in the presence of DNA. Although there is some 
degradation of the complex, it is not expected to significantly affect the DNA binding 
studies.  
 
The hydroxyl-sugar cylinder is much less stable, with a loss of almost one quarter of the 
original absorbance over a five hour period. However there are significant improvements 
to the stability of the complex in the presence of ct-DNA, with a 9% loss of original 
absorbance. This degradation must be taken into account when performing the DNA 
binding experiments and analysing the results. 
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Figure 4.14 Normalised UV-Vis stability studies of complexes [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4 at 
room temperature (5 μM, 2.5% MeOH:water and 8 μM, water respectively) and in presence of ct-DNA in 6.7 
mM NaCl and 0.33 mM Na(CH2)2AsO2.3H2O (pH 6.8)  (ratio 6:1 ct-DNA:complex) (1.9% MeOH:water and 
water respectively). λmax = 591 nm and 595 nm respectively. 
 
 
4.5 DNA binding studies 
Novel sugar-functionalised iron(II) supramolecular cylinders have been synthesised and 
characterised herein. The DNA binding properties of these novel cylinders were 
investigated by several techniques including circular dichroism, linear dichroism and gel 
electrophoresis.  
 
 
4.5.1 Circular dichroism binding studies 
CD titrations were carried out for the sugar functionalised cylinders, [Fe2L
OAcSug
3][BF4]4 
and [Fe2L
OHSug
3][BF4]4 analogous to those described in chapter 2 (Section 2.6.1). The 
acetyl-sugar cylinder was dissolved in a methanol-water solvent mix due to being insoluble 
in water. Due to the instability of the hydroxyl-sugar complex, aliquots of the solution to 
be used in the experiment were kept frozen until the time of addition. It was hoped that the 
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cylinder would degrade more slowly once added to the DNA solution as the presence of ct-
DNA has been found to stabilise the complex. Control experiments were also carried out 
for the components of the cylinder, and these were found to have no inherent CD signal, 
induced CD signal or effect on the DNA.  
 
As the sugar-functionalised cylinders are chiral, their own intrinsic CD signal (Fig. 4.15) 
must be subtracted from the CD titration with DNA so as to only see the induced CD 
signal arising from the interaction between the complex and the DNA.   
 
      
Figure 4.15 CD of control titrations of [Fe2L
OAcSug
3][BF4]4  (1.2% max. MeOH) (left) and [Fe2L
OHSug
3][BF4]4 
(right). Water with increasing concentrations of complexes. Legend shows corresponding ct-DNA:complex 
ratios for titration with ct-DNA.  
 
The CD titration spectrum of the acetyl-sugar functionalised cylinder, [Fe2L
OAcSug
3][BF4]4, 
(Fig. 4.16) reveals negative ICD signals at 316 and 354 nm. This indicates that the cylinder 
is binding to ct-DNA. The B-conformation of DNA is retained upon cylinder binding.  
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Figure 4.16 CD of 226 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
OAcSug
3][BF4]4. Legend shows ct-DNA:complex ratios. 1.2% max. 
MeOH. Analysed in 1cm pathlength cuvette.  
 
 
In the preliminary CD titration spectrum of the hydroxyl-sugar functionalised cylinder, 
[Fe2L
OHSug
3][BF4]4, (Fig. 4.17) similar ICD signals at 316 and 354 nm are also observed 
indicating DNA binding. The induced CD signals are very similar to those of the acetyl-
sugar cylinder. The DNA conformation is unperturbed by this DNA binding as the B-
conformation is retained. 
 
 
Figure 4.17 CD of 251 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
OHSug
3][BF4]4. Legend shows ct-DNA:complex ratios. Analysed in 
1cm pathlength cuvette.  
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Comparison of the ICD signals of the two complexes with ct-DNA allows the response to 
DNA to be compared (Fig. 4.18). Both complexes have an immediate effect on the DNA, 
with DNA binding at low complex loading. At high complex loading the hydroxyl-sugar 
cylinder has a slightly stronger binding response than the acetyl-sugar version.  
    
Figure 4.18 Normalised ICD signal vs complex concentration for complexes [Fe2L
OAcSug
3][BF4]4 and 
[Fe2L
OHSug
3][BF4]4.  
 
 
4.5.2 Linear dichroism binding studies 
Linear dichroism titrations were also performed with the sugar-functionalised cylinders, 
analogous to those carried out in Chapter 2 (Section 2.6.2). As the hydroxyl-sugar cylinder 
is significantly unstable over the duration of the LD experiment, aliquots of the solution 
were frozen and defrosted immediately before each titration. As the cylinder is known to 
be more stable in the presence of ct-DNA, it was thought that degradation of the complex 
would slow down once added to the DNA solution. Control experiments indicated that the 
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component parts of the cylinder did not induce any LD signal. The acetyl-sugar cylinder 
was dissolved in a methanol-water solvent mix due to being insoluble in water. As the 
sugar functionalised cylinders are too small to be oriented by viscous drag they do not have 
any intrinsic LD signal, and so any ILD signal observed must come from the interaction 
between the complex and ct-DNA. 
 
The LD titration spectrum (Fig. 4.19) for the acetyl-sugar functionalised cylinder, 
[Fe2L
OAcSug
3][BF4]4, shows no detectable ILD signals in the complex region. DNA binding 
of the complex is evident, although oriented DNA binding cannot be confirmed. The 
magnitude of the negative LD band at 260 nm, corresponding to DNA transitions, 
decreases as the complex concentration increases. This indicates that the cylinder is 
binding to DNA and coiling or bending it so as to induce a loss of orientation. This occurs 
even at low cylinder loading.  
 
 
Figure 4.19 LD of 273 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
OAcSug
3][BF4]4. Legend shows ct-DNA:complex ratios. 4.5% max. 
MeOH. 
 
The preliminary LD titration spectrum (Fig. 4.20) for the hydroxyl-sugar functionalised 
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 cylinder, [Fe2L
OHSug
3][BF4]4, shows an ILD signal at 322 nm, at higher complex loading, 
indicating oriented DNA binding. DNA binding is also proven by a loss in the magnitude 
of the negative LD band at 260 nm, with increasing concentration of cylinder. This 
indicates loss of orientation of the DNA due to the complex coiling or bending it and 
occurs immediately upon addition of the complex at low cylinder loading.  
 
Figure 4.20 LD of 232 μM ct-DNA in 20 mM NaCl and 1 mM Na(CH2)2AsO2.3H2O (pH 6.8) with 
increasing concentrations of complex [Fe2L
OHSug
3][BF4]4. Legend shows ct-DNA:complex ratios. 
 
 
Comparison of the DNA bending/coiling activity of the sugar functionalised cylinders with 
that of the parent, alkyne and steroid functionalised cylinders (Table 4.1 and Fig. 4.21) 
reveals that the [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4 complexes have similar 
activity. It is apparent that at low complex loading, the bending activity of all of the 
cylinders is very similar. At high complex concentration it can be observed that the sugar 
functionalised cylinders have a slightly greater activity than the steroid functionalised 
cylinders and a similar activity to the [Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4 and 
[Fe2L
Hex
3][BF4]4 complexes. This may be due to the size differences of the substituents 
functionalising the cylinders. 
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DNA:complex ratio % Loss of LD signal at 260 nm upon interaction with complexes 
 
8:1 [Fe2L
P
3][BF4]4 [Fe2L
OAcSug
3][BF4]4 [Fe2L
OHSug
3][BF4]4 
80 63 52 
 
Table 4.1 Comparison of the percentage loss of LD signal at 260 nm upon interaction with complexes at a 
ratio of DNA:complex 8:1. 
 
 
  
 
Figure 4.21 Normalised LD signal at 260 nm vs complex concentration for parent and alkyne, steroid and 
sugar functionalised complexes. 
 
 
4.5.3 Gel electrophoresis studies 
The DNA unwinding activity of the sugar-functionalised cylinders [Fe2L
OAcSug
3][BF4]4 and 
[Fe2L
OHSug
3][BF4]4 was investigated by agarose gel electrophoresis analogous to those 
carried out in chapter 2 (Section 2.6.3). As the acetyl-sugar complex is not soluble in water 
alone, a small percentage of methanol was used to dissolve the compound. As the 
hydroxyl-sugar complex is fairly unstable, control gel electrophoresis experiments were 
carried out with the component parts of the complex and these were found to have no 
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effect. Samples containing different plasmid DNA:complex ratios (Table 4.2) were 
incubated at room temperature for two hours before being run on a 1% agarose gel.  
 
Lanes 1 2 3 4 5 6 7 
DNA:complex 
ratio 
MeOH 
or DNA 
control 
50:1 40:1 30:1 20:1 15:1 10:1 
Lanes 8 9 10 11 12 13 14 
DNA:complex 
ratio 
8:1 6:1 5:1 4:1 3:1 2:1 DNA 
control 
 
Table 4.2 Ratios of plasmid DNA:complex used in gel electrophoresis experiments. 
 
The agarose gel (Fig. 4.22) for complex [Fe2L
OAcSug
3][BF4]4 shows that the circular and 
supercoiled forms of the pBR322 plasmid are not altered by addition of the complex, even 
at high concentrations. At a ratio of plasmid DNA:complex of 2:1 no bands can be seen 
corresponding to either forms of plasmid DNA, due to difficulties with ethidium bromide 
staining.  
 
Figure 4.22 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of circular (C) 
and supercoiled (SC) forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of 
complex [Fe2L
OAcSug
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of 
complex. 8% max. MeOH. 
 
 
The preliminary agarose gel (Fig. 4.23) for the hydroxyl-sugar cylinder, 
[Fe2L
OHSug
3][BF4]4, indicates that the complex is binding to the supercoiled form of DNA. 
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From a DNA:complex ratio of 30:1 the band corresponding to the supercoiled DNA can be 
seen to be migrating at a slower pace through the gel. As the complex concentration 
increases, the migration rate slows even more indicating unwinding of the supercoiled 
DNA. At a 6:1 DNA:complex ratio the supercoiled and circular band co-migrate, 
indicating that all of the supercoiled DNA has been unwound to the relaxed circular form. 
At higher complex loading, lanes 10-13, the absence of the supercoiled band indicates that 
the sugar cylinder does not positively supercoil the DNA, as has been observed for some of 
the cylinders developed, such as the triple bond complex. 
 
Figure 4.23 Agarose gel (1%) electrophoresis showing changes in electrophoretic mobility of C and SC 
forms of pBR322 plasmid DNA incubated at 20°C for 2 hours with different ratios of complex 
[Fe2L
OHSug
3][BF4]4 (lanes 2-13). Control lanes (1 and 14): pBR322 plasmid DNA in absence of complex.  
 
 
If the circular and supercoiled forms of the pBR322 plasmid co-migrate in the gel, 
unwinding angles can be calculated. The unwinding angle, Φ, is a measure of the number 
of degrees by which the DNA is unwound about its helical axis per molecule bound. 
Comparison of the unwinding angles of the parent, [Fe2L
TB
3][BF4]4 and [Fe2L
PA
3][BF4]4  
cylinders with the preliminary unwinding angle of the hydroxyl-sugar cylinder (Table 4.3), 
shows that [Fe2L
OHSug
3][BF4]4 is less able to unwind the supercoiled plasmid DNA than the 
parent cylinder. However, it has the same or similar activity as the [Fe2L
TB
3][BF4]4 and 
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[Fe2L
PA
3][BF4]4  functionalised cylinders. The unwinding angle is similar to that of 
cisplatin, which is 13°,
18
 therefore this complex does show some promising DNA 
unwinding activity.  
Complexes [Fe2L
P
3][Cl]4 [Fe2L
TB
3][BF4]4 [Fe2L
PA
3][BF4]4 [Fe2L
OHSug
3][BF4]4 
Φ values 27° ±3 5° ±1 6° ±1 6° ±1 
 
Table 4.3 Unwinding angles (Φ) of complexes calculated from gel electrophoresis experiments. 
 
 
4.5.4 PAGE studies 
Three-way junction polyacrylamide gel electrophoresis studies analogous to those 
performed with the alkyne cylinders (Section 2.6.4, Chapter 2) were carried out for 
[Fe2L
OAcSug
3][BF4]4, by co-worker N. Calle Alonso from the University of Birmingham, 
and are briefly described herein for completeness. Due to the insolubility of the complex in 
water, a small percentage of methanol was used to dissolve the compound. 
[Fe2L
OAcSug
3][BF4]4 was mixed with the three non-palindromic oligonucleotide strands to 
give a ratio of three-way-junction:cylinder of 1:1, incubated for one hour and run on a 15% 
polyacrylamide gel.  
 
The autoradiogram of the polyacrylamide gel (Fig. 4.24, cropped image; for whole gel see 
Appendix) indicates that the acetyl-sugar cylinder, [Fe2L
OAcSug
3][BF4]4, can promote the 
formation of a DNA three-way junction. Some precipitation of DNA can be seen in the 
loading wells, indicating binding of the complex to the single strands of DNA. 
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Figure 4.24 Autoradiogram of polyacrylamide gel run at 25 °C. Lanes 1-3: S3*, S3*+S2, S3*+S2+S1 
respectively; Lane 4: S3*+S2+S1+MgCl2; Lane 5: S3*+S2+S1 with [Fe2L
OAcSug
3][BF4]4. Ratio of three-way 
junction(S1+S2+S3*):complex of 1:1. Asterisk indicates 32P labelled strand.  
 
 
As the PAGE experiments were carried out in duplicate, only a preliminary comparison of 
the three-way junction promotion and stabilisation ability of the cylinders can be noted 
(Fig. 4.25). It is apparent that the [Fe2L
OAcSug
3][BF4]4 cylinder is less effective at stabilising 
the junction structure than the parent complexes, which may be due to the increased size of 
the functionalised cylinder. 
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Figure 4.25 Bar graph showing percentage of three-way junction formed by complexes. Data based on two 
repeats; error bars shown demonstrate the two data points (not standard deviation), and the bar their average. 
 
 
4.6 Conclusions 
In this chapter, the synthesis of an acetyl-sugar functionalised cylinder, 
[Fe2L
OAcSug
3][BF4]4, and the attempted synthesis of an hydroxyl-sugar functionalised 
cylinder, [Fe2L
OHSug
3][BF4]4, have been reported. These functionalised cylinders were 
designed in order to improve the targeting of these types of complexes to tumour cells with 
highly or overexpressed carbohydrate receptors. These two complexes were synthesised 
via the novel functionalisation route detailed in chapter 2, over three or four reaction steps, 
with a poor yield of 4% for [Fe2L
OAcSug
3][BF4]4.  
 
The acetyl-sugar was unfortunately not water soluble, however it was soluble in water-
miscible solvent and so could be further investigated. Excitingly, the hydroxyl-sugar 
cylinder was found to be water soluble, an important and desirable property for therapeutic 
agents. Unfortunately, it was very unstable in aqueous solution and so was very difficult to 
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work with and characterise. Although full characterisation could not be achieved, 
preliminary characterisation and DNA binding studies were performed to assess whether 
further work in this area would be beneficial.  
 
By attaching chiral sugar moieties to the edges of the cylinder it was thought that induction 
of chirality may be achieved and this was investigated by 
1H NMR ∆-TRISPHAT and 
circular dichroism studies. These studies revealed that the acetyl-sugar cylinder was in fact 
diastereoisomerically pure and was of the M helical configuration. Chiral induction was 
previously observed in the development of peptide conjugated cylinders, where 
conjugation of L- or D-arginine induced the formation of pure diastereoisomers of the M 
and P helical configuration respectively.
14,17
 Induction of chirality is usually achieved by 
attaching chiral substituents to the spacer groups of helicates,
19,20
 whereas induction by 
substituents placed further from the helicate core is less common and quite exciting.
14
 The 
chirality of the hydroxyl-sugar cylinder was also investigated. 
1H NMR ∆-TRISPHAT 
studies were inconclusive, with the spectra too weak and broad to allow proper analysis. 
However, the circular dichroism spectrum confirmed that the complex was chiral and a 
strong signal characteristic of the M helical isomer was observed.  
 
DNA binding studies were carried out for the [Fe2L
OAcSug
3][BF4]4 and [Fe2L
OHSug
3][BF4]4 
cylinders. Circular dichroism titrations with ct-DNA revealed that the complexes were able 
to bind to DNA. In the LD experiments, an induced LD signal was observed for the 
hydroxyl-sugar helicate indicating oriented binding to the DNA. Both complexes were 
found to coil/bend ct-DNA, even at low complex loading. At high complex concentration 
the sugar functionalised cylinders showed DNA bending/coiling comparable to 
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[Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4 and greater than that of the steroid 
functionalised cylinders. The hydroxyl-sugar cylinder also showed promising DNA 
unwinding activity in a preliminary gel electrophoresis study, with an unwinding angle of 
6°. The acetyl-sugar cylinder showed no DNA unwinding ability. These results may be due 
to the relative size of the two complexes, with the hydroxyl-sugar cylinder having a 
slightly reduced size. This may be due to the smaller cylinder being able to fit better into 
its DNA binding site, giving a closer proximity to the DNA and therefore allowing 
stronger contacts between the cylinder and the DNA. However, the acetyl-sugar was able 
to promote and stabilise the formation of a DNA three-way junction, as investigated by 
polyacrylamide gel electrophoresis. 
 
Unfortunately, as with the alkyne and steroid helicates presented in chapters 2 and 3, in 
vitro studies could not be undertaken with these sugar functionalised cylinders due to their 
insolubility or instability in the solvent systems required. Cytotoxicity assays, such as the 
MTT assay, are necessary to investigate the anti-tumour effect of the developed anti-cancer 
agent. The tumour targeting ability of the functionalised drug can also be assessed by 
comparing the cellular uptake and cytotoxicity in cells that display the targeted receptor 
and those that do not.   
 
In summary, iron(II) cylinders functionalised with sugars have been developed that retain 
some of the inherent DNA binding activity of the parent cylinder. It has been shown that 
by conjugating water solubilising groups, these alkyne functionalised cylinders can be 
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water soluble, however further investigation as to the effects on the stability of these 
complexes is needed.  
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4.7 Experimental: synthesis 
4.7.1 Materials and methods 
All reagents and solvents were purchased from Aldrich, Fisher, Apollo Scientific and 
Fluorochem and used without further purification. Deuterated NMR solvents were 
purchased from Goss Scientific. NMR spectra were recorded on Brüker AVIII300 and 
AVIII400 spectrometers and processed using standard Brüker software. Electrospray 
Ionisation (ESI) spectra were recorded on a Micromass LCT Time of flight mass 
spectrometer in positive ionisation mode. IR spectra were recorded on a PerkinElmer 
Spectrum 100 FT-IR spectrometer. UV-Vis spectra were performed using a Varian Cary 
5000 UV-Vis spectrometer. CD and LD spectra were recorded on a Jasco J-810 
spectropolarimeter. 
 
4.7.2 Synthesis of Acetyl Sugar, [Fe2L
OAcSug
3][BF4]4  
4.7.2.1 Synthesis of 2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-glucosaminide 
(8)
9 
 
 
 
C17H23NO9 
FW: 385.37 
 
A solution of 2-acetimido-2-deoxy-α-D-glucopyranosyl chloride 3,4,6 triacetate (0.400 g, 
1.09 mmol) and propargyl alcohol (0.12 ml, 2.06 mmol) in anhydrous DCM (8 ml) was 
stirred at -10°C for 15 minutes. Silver trifluoromethanesulfonate (0.312 g, 1.21 mmol) was 
added and the reaction mixture was stirred overnight at room temperature. The mixture 
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was then neutralised with aqueous saturated NaHCO3, filtered and the filter cake washed 
with DCM. The solution was separated and the organic layer washed with brine and 
evaporated to dryness in vacuo. The crude material was purified by column 
chromatography on a silica column (EtOAc:hexane 3:1) yielding a white solid (0.134 g, 
32% yield). 
1
H NMR (300 MHz, CDCl3): δ 6.04 (d, J = 9.0 Hz, 1H, HNH’), 5.27 (t, J = 10.0 Hz, 1H, 
H3’), 5.04 (t, J = 12.9 Hz, 1H, H4’), 4.84 (d, J = 8.3 Hz, 1H, H1’), 4.34 – 4.33 (m, 2H, H6’), 
4.28 – 4.19 (m, 1H, HCH2OAc’), 4.12 - 4.08 (m, 1H, HCH2OAc’), 3.98 – 4.88 (m, 1H, H2’), 3.74 
– 3.70 (m, 1H, H5’), 2.47 (s, 1H, H7’), 2.05 (s, 3H, HNHAc’/CH2OAc’), 1.99 (d, J = 2.8 Hz, 6H, 
HOAc’), 1.92 (s, 3H, HNHAc’/CH2OAc’). 
13
C NMR (100 MHz, CDCl3): δ100.1 (C1’), 74.2 (C3’), 73.6 (C5’), 70.3 (C4’), 63.7 
(CCH2OAc’), 63.5 (CCH2OAc’), 57.6 (C6’), 57.1 (C6’), 55.9 (C2’), 25.0 (CNHAc’/CH2OAc’), 22.5 
(CNHAc’/CH2OAc’), 22.4 (COAc’), 22.3 (COAc’). 
HRMS (EI): m/z = calculated for C17H23NO9Na [M+Na]
+
 408.1271; Found 408.1278. 
IR (ν) = 3267 (m, C≡C-H), 3091 (w, C-H), 2116 (m, C≡C), 1739 (s, C=O), 1655 (s, C=O), 
1566 (m, C=C). 
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4.7.2.2 Synthesis of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9) 
Synthesis based on literature procedure.
10
 
 
 
C23H26N2O10 
FW: 490.47 
 
 
A schlenk flask was charged with 2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide (8) (0.392 g, 1.02 mmol), 5-bromo-2-pyridinecarboxaldehyde (0.227 g, 1.22 
mmol), bis(triphenylphosphine)dichloropalladium(II) (0.032 g, 0.05 mmol) and copper 
iodide (0.020 g, 0.11 mmol). Anhydrous THF (28 ml) and diisopropylamine (0.91 ml) 
were added, and the reaction mixture stirred under an argon atmosphere with light 
exclusion at room temperature for 72 hours. The resulting dark brown crude mixture was 
evaporated to dryness in vacuo and purified by column chromatography on a silica column 
(EtOAc). To remove the triphenylphosphine oxide impurity diethyl ether and 2 M HCl 
were added to the pale yellow solid obtained, the layers were separated and the aqueous 
layer washed again with diethyl ether. The aqueous layer was neutralised with aqueous 
saturated NaHCO3 and extracted with ethyl acetate. The ethyl acetate was dried over 
Na2SO4 and evaporated in vacuo yielding a white solid (0.197 g, 40% yield). 
1
H NMR (300 MHz, CDCl3): δ 10.03 (s, 1H, Hald), 8.78 (s, 1H, H6), 7.92 – 7.90 (m, 2H, 
H3, H4), 5.93 (s, 1H, HNH), 5.46 – 5.32 (m, 1H, H4’), 5.10 – 5.01 (m, 2H, H1’, H3’), 4.62 (d, 
J = 2.8 Hz, 2H, H6’), 4.30 - 4.24 (m, 1H, HCH2OAc’), 4.16 – 4.11 (m, 1H, HCH2OAc’), 3.87 – 
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3.72 (m, 2H, H2’, H5’), 2.05 (s, 3H, HNHAc’/CH2OAc’), 2.01 (d, J = 2.6 Hz, 6H, HOAc’), 1.92 (s, 
3H, HNHAc’/CH2OAc’). 
13
C NMR (100 MHz, CDCl3): δ 192.4 (Cald), 152.5 (C6), 139.6 (C3/4), 120.9 (C3/4), 98.4 
(C1’/3’), 74.1(C4’), 71.9 (C2’/5’), 68.5 (C1’/3’), 61.9 (CCH2OAc’), 56.3 (C6’), 54.7 (C2’/5’), 23.2 
(CNHAc’/CH2OAc’), 20.6 (CNHAc’/CH2OAc’), 20.5 (COAc’), 20.4 (COAc’). 
HRMS (EI): m/z = calculated for C23H26N2O10Na [M+Na]
+
 513.1485; Found 513.1487. 
IR (ν) = 3306 (m, N-H), 2867 (w, C-H), 2163 (m, C≡C), 1739 (s, C=O), 1714 (s, C=O), 
1666 (m, C=C), 1546 (m, C=C). 
Elemental analysis (%) calculated for : C: 56.3; H: 5.7; N: 5.3; Found: C: 56.6; H: 5.6; N: 
5.7. 
 
4.7.2.3 Synthesis of [Fe2L
OAcSug
3][BF4]4  
 
[Fe2(C59H62N6O18)3][BF4]4 
FW: 3888.41  
 
To a solution of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (9) (0.080 g, 0.16 mmol) in ethanol (3 ml) was added a solution of 
4,4’-methylenedianiline (0.016 g, 0.08 mmol) in ethanol (2 ml) dropwise. A solution of 
iron(II) tetrafluoroborate hexahydrate (0.018 g, 0.06 mmol) in ethanol (2 ml) was then 
immediately added dropwise and the reaction mixture stirred overnight at room 
temperature. The resulting purple precipitate was collected by vacuum filtration, washed 
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with ethanol (1 L), diethyl ether (200 ml) and dried for 12 hours over silica, yielding a dark 
purple solid (0.032 g, 31% yield).  
1
H NMR (300 MHz, CD3CN) δ 8.98 (s, 2H, Him), 8.64 (d, J = 8.1 Hz, 2H, HPy3), 8.41 (d, J 
= 8.1 Hz, 2H, HPy4), 7.69 (s, 2H, HPy6), 6.94 (br s, 4H, HPha/Phb), 6.69 (d, J = 8.1 Hz, 2H, 
HNH), 5.56 – 5.40 (br m, 6H, HPha/Phb, H3’), 5.08 (d, J = 8.1 Hz, 2H, H1’), 4.97 (t, J = 9.7 
Hz, 2H, H4’), 4.56 (d, J = 3.5 Hz, 4H, H6’), 4.32 – 4.26 (m, 2H, HCH2OAc’), 4.13 – 3.99 (m, 
4H, HCH2OAc’, Hsp), 3.70 – 3.64 (m, 2H, H5’), 3.49 – 3.41 (m, 2H, H2’), 2.06 – 1.92 (m, 24H, 
HCH2OAc’, HNHAc’, HOAc’ + 39H, solvent).  
Mass spectrum (ESI): m/z = 885.6 [Fe2(C59H62N6O18)3]
4+
. 
IR (ν) = 2942 (w, C-H), 2232 (m, C≡C), 1739 (s, C=O), 1668 (s, C=O), 1544 (m, C=C), 
1035 (s, br, BF4). 
UV-Vis (1% MeOH:H2O): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 231 (90,800), 266 (60,400), 308 
(7,500), 540 (7,300), 596 (10,400). 
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4.7.3 Attempted synthesis of [Fe2L
OHSug
3][BF4]4  
4.7.3.1 Synthesis of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10) 
Synthesis based on literature procedure.
11
  
 
 
 
To a solution of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (9) (0.591 g, 1.20 mmol) in anhydrous MeOH (10 ml) was added 
sodium methoxide (0.071 g, 1.31 mmol) and the reaction mixture was stirred at room 
temperature for 2 hours. Dowex (50W x8, H
+
 form) (1.6 g) was then added until pH 5 was 
reached. The reaction mixture was then filtered, the Dowex washed with MeOH (30 ml), 
and the filtrate evaporated to dryness in vacuo. The off-white crude solid was purified by 
column chromatography on a silica column (MeOH:DCM 15:85) yielding a white solid 
(0.263 g, 60% yield). 
1
H NMR (300 MHz, D2O) δ 9.97 (s, 1H, Hald), 8.80 (d, J = 1.2 Hz, 1H, H6), 8.61 (d, J = 
1.2 Hz, 1H, H6hyd), 8.14 (dd, J = 8.1, 1.7 Hz, 1H, H4), 8.02 – 7.93 (m, 2H, H3, H4hyd), 7.64 
(d, J = 8.2 Hz, 1H, H3hyd), 6.02 (s, 1H, Hhyd), 4.78 – 4.76 (m, 2H, H1’), 4.68 (d, J = 11.0 Hz, 
C17H20N2O7 
FW: 364.35 
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4H, H6’), 3.93 – 3.89 (m, 2H, HCH2OH’), 3.75 – 3.67 (m, 4H, HCH2OH’, H2’), 3.60 – 3.53 (m, 
2H, H3’), 3.50 – 3.40 (m, 4H, H4’, H5’), 2.00 (d, J = 3.7 Hz, 6H, HNHAc). 
13
C NMR (100 MHz, D2O): δ193.8 (Cald), 152.3 (C6hyd), 151.0 (C6), 141.1 (C4,4hyd), 123.8 
(C3), 120.0 (C3hyd), 99.9 (C1’), 89.7 (Chyd), 76.0 (C4’/5’), 73.6 (C3’), 69.8 (C4’/5’), 60.7 
(CCH2OH), 57.3 (C6’), 55.5 (C2’), 22.2 (CNHAc’). 
HRMS (EI): m/z = calculated for C17H20N2O7Na [M+Na]
+
 387.1168; Found 387.1173. 
IR (ν) = 3263 (m, N-H), 3100 (w, C-H), 2210 (m, C≡C), 1710 (s, C=O), 1646 (s, C=O), 
1563 (m, C=C). 
 
4.7.3.2 Attempted synthesis of [Fe2L
OHSug
3][BF4]4  
 
[Fe2(C47H50N6O12)3][BF4]4 
FW: 3131.74 
 
To a solution of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10) (0.066 g, 0.18 mmol) in methanol (3 ml) was added a 
solution of 4,4’-methylenedianiline (0.018 g, 0.09 mmol) in ethanol (2 ml) dropwise. A 
solution of iron(II) tetrafluoroborate hexahydrate (0.021 g, 0.06 mmol) in ethanol (2 ml) 
was then immediately added dropwise and the reaction mixture stirred overnight at room 
temperature. The resulting purple precipitate was collected by vacuum filtration, washed 
with methanol (1 L), diethyl ether (200 ml) and dried for 12 hours over silica, yielding a 
dark purple solid (0.033 g, 35% yield).  
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1
H NMR (300 MHz, D2O) δ 9.35 – 9.18 (br m, 2H, Him), 8.99 (br s, 2H, HPy3/4), 8.67 (br s, 
2H, HPy3/4), 7.53 (br s, 2H, HPy6), 6.73 (br s, 4H, HPha/Phb), 5.69 (br s, 4H, HPha/Phb), 3.96 – 
3.86 (br m, 2H, Hsp), 2.09 (br s, 6H, HNHAc’). 
Mass spectrum (ESI): m/z = 696.4 [Fe2(C47H50N6O12)3]
4+
, 956.2 
[Fe2(C47H50N6O12)3][BF4]
3+
. 
IR (ν) = 3270 (m, OH), 2926 (w, C-H), 2165 (m, C≡C), 1646 (s, C=O), 1545 (m, C=C), 
1028 (s, br, BF4). 
UV-Vis (H2O): λmax [nm] (εmax/dm
3
mol
-1
cm
-1
): 233 (36,600), 269 (55,800), 303 (45,900), 
539 sh (4,400), 594 (5,800). 
 
4.8 Experimental: DNA binding studies 
4.8.1 Materials and methods 
All DNA binding studies were carried out using Ultrapure water (18.2 MΩ) purchased 
from Fisher Scientific. Calf thymus (ct) DNA, highly polymerised, was purchased from 
Sigma Aldrich and pBR322 plasmid DNA was purchased from New England Biolabs. 
Both were used without further purification and kept frozen. Tris-acetate-EDTA buffer was 
purchased from Fisher and agrose from USB Corporation. 
 
4.8.2 Circular and Linear Dichroism Experiments 
CD and LD measurements were recorded using a Jasco J-810 spectropolarimeter. CD 
measurements were carried out in quartz cuvettes of 1 cm (750-200 nm) or 0.1 cm (450-
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200 nm) pathlength. LD experiments were recorded in a flow couette cell (Krometek) with 
a 0.1 cm pathlength. 
 
Stock solutions of ct-DNA (3000 μM) in water were prepared and kept frozen until the day 
of the experiment. Sodium chloride (1 M) and sodium cacodylate (Na(CH2)2AsO2.3H2O) 
(100 mM) buffer stock solutions were used to prepare final ct-DNA solutions of 300 μM 
with 20 mM NaCl and sodium cacodylate (1 mM) (pH 6.8). DNA concentrations were 
determined by UV-Vis measurements using the known molar extinction coefficient of ε258 
= 6600 mol
-1
dm
3
cm
-1
 per DNA base.  
 
CD and LD titrations were carried out using three solutions; solution A (a 300 μM ct-DNA 
solution, containing  NaCl (20 mM) and sodium cacodylate (1 mM)); solution B (a 500 μM 
complex solution) and solution C (a 600 μM ct-DNA solution, containing 40 mM NaCl 
and sodium cacodylate (2 mM)). Firstly solution A was recorded, then equal aliquots of 
solutions B and C were added, keeping the concentration of ct-DNA constant throughout 
the titration. The titration was carried out to obtain an initial ct-DNA:complex ratio of 60:1 
decreasing to 4:1. The stock solution of complex was stored in ice during the experiment.  
 
4.8.3 Agarose Gel Electrophoresis 
Agarose gels were prepared by warming agarose (2 g) in 1x Tris-acetate-EDTA buffer 
which was then poured into a gel tray (210 x 150 mm) fitted with a 15 toothed comb, to 
produce sample wells. The gel was left to set for 40 minutes. Sample solutions (16 μl) were 
prepared containing 96.3 µM pBR322 plasmid DNA and different concentrations of 
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complexes (from 60 µM stock solution in water and up to 7% MeOH) to obtain 
plasmid:complex ratios ranging from 100:1 to 2:1. Theses sample solutions were incubated 
for 2 hours at room temperature. Before loading , 4 μl loading buffer (30% glycerol, 0.25% 
bromophenol blue) was added, the samples were mixed and then 16 μl of the samples 
loaded into the gel wells. The gel was run for 2.5 hours in an Amersham Biosciences 
HE99X Maxi submarine kit with an electrophoresis Power Supply-EPS 301 system, at a 
constant voltage of 120 V and 400 mA, in 1x Tris-acetate-EDTA running buffer. The gel 
was then stained with an ethidium bromide solution (0.5 mg.ml
-1
) in 200 ml of water for 20 
minutes and visualised using a UVtec–uvipro platinum 2.0 system (UVidoc, Cambridge, 
UK) at 312 nm.  
 
4.8.4 Polyacrylamide Gel Electrophoresis (PAGE) 
Procedure provided by S. Phongtongpasuk 
21
 and carried out by N. Calle Alonso, both of 
the Hannon group, University of Birmingham. 
4.8.4.1 Radioactive labelling 
Oligonucleotides (sequences S1: CGGAACGGCACTCG, S2: CGAGTGCAGCGTGG, 
S3: CCACGCTCGTTCCG) were purchased from MWG Eurofin. One strand was labelled 
with P
32
 at the 5’ terminus using T4 polynucleotide kinase (New England Biolabs) and [γ-
32P] adenosine 5’-triphosphate (Perkin Elmer). First ultrapure water (4.8 µl), 10x 
bacteriophage T4 poynucleotide kinase buffer (1 µl), oligonucleotide S3 (1.2 µl of 100 
µM), bacteriophage T4 poynucleotide kinase (1 µl) (New England Biolabs) and γ-32P ATP 
(2 µl of  6000 Ci/mmol) (Perkin Elmer) were incubated in an eppendorf at 37°C for 40 
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minutes. To deactivate the polynucleotide kinase, the solution was then heated to 80°C for 
3 minutes.  
 
To purify the radioactive-labelled DNA fragments from any unreacted ATP a QIAquick 
nucleotide removal kit (QIAGEN) was employed. 10 volumes of PN buffer were added to 
1 volume of reaction sample and this solution was loaded onto a QIAquick spin column 
with a 2 ml collection tube, centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. A new collection tube was then fitted to the column, PE buffer (500 µl) was 
added and this solution was centrifuged for 1 minute at 6000 rpm and the flow through 
discarded. Again, PE buffer (500 µl) was added and the solution was centrifuged at 13000 
rpm for 1 minute to remove residual buffer. The column was then put into a fresh 
eppendorf, ultrapure water (30 µl) was added to the column and this was left for 5 minutes. 
After centrifuging at 13000 rpm for 2 minutes a radiolabelled DNA stock solution (8 µM) 
was obtained. 
 
4.8.4.2 Polyacrylamide gel preparation 
A 15% native polyacrylamide gel was prepared by mixing 52.5 ml of ultra pure water, 10 
ml of 10x TB buffer (890 mM tris(hydroxymethy)amino methane and 890 mM boric acid) 
(pH 8.3), 37.5 ml of 40% acrylamide (29:1) (Geneflow), 500 µl of 10% (w/v) ammonium 
persulfate and 75 µl tetramethylenediamine (TEMED). This was then poured onto a set of 
glass plates and left to set for 40 minutes. The wells of the polymerised gel were washed 
with running buffer (TB buffer) and the gel was pre-run at 200 V for 5 minutes before 
sample loading.  
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4.8.4.3 PAGE electrophoresis experiment  
Sample solutions were prepared by mixing solutions of the complexes with stoichiometric 
amounts of oligonucleotides in TBN buffer (89 mM tris(hydroxymethy)amino methane, 89 
mM of boric acid and 100 µM NaCl) (pH 8.3) to give final concentrations of 0.4 µM for 
each single strand (1.2 µM total concentration of DNA) and 0.4 µM of complex. This gives 
a three-way junction:complex ratio of 1:1. The sample solutions were incubated for 1 hour 
at room temperature and then in ice for 15 minutes. To prepare the samples for loading, 5 
µl of 30% glycerol was added to each eppendorf. 13 µl of each sample was then loaded 
onto the 15% polyacrylamide gel. The gel was run for 4 hours at 120 V using Gel System 
equipment (Thermo Scientific UK). It was then exposed on a phosphor imaging plate for 
1-16 hours depending on how fresh the radioactive ATP used was. A radiogel image was 
obtained using a Molecular Imager FX (Bio-Rad) and the gel was quantified using 
Quantity One software.  
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Chapter 5: Conclusions and Future Work 
 
 
5.1 Conclusions 
Due to the successes of supramolecular metallo-cylinders developed in the Hannon group, 
the aim of the work described herein was to design and synthesise iron(II) cylinders 
functionalised with a range of chemical groups and biomolecules. It was hoped that these 
novel cylinders could be employed to further probe and advance the DNA and cellular 
recognition of metallo-cylinders. A novel functionalisation route was developed (Chapter 
2) to allow the easy and varied modification of these metallo-cylinders by attachment of a 
vast array of functional moieties.   
 
Several cylinders functionalised with simple chemical groups, such as hydroxyl and phenyl 
groups, were synthesised in few reaction steps with good yields, using this novel synthesis 
route. DNA binding studies carried out with these complexes demonstrated the importance 
of the size and shape of these cylinders to their DNA recognition. A better understanding 
has been gained of the type of functionalisation that can be tolerated by these complexes 
while still retaining their DNA binding activity.  
 
The triple bond, propargyl alcohol and hexyn-ol cylinders, [Fe2L
TB
3][BF4]4, 
[Fe2L
PA
3][BF4]4 and [Fe2L
Hex
3][BF4]4, were all found to be effective DNA binders when 
evaluated by CD and LD DNA binding studies. Gel electrophoresis studies found the triple 
bond and propargyl alcohol functionalised helicates to unwind supercoiled plasmid DNA 
Chapter 5: Conclusions and Future Work 
 
235 
 
with unwinding angles of 5° and 6° respectively. However the hexyn-ol functionalised 
cylinder showed no DNA unwinding in this experiment. PAGE studies revealed all three 
complexes were able to promote the formation of a DNA three-way junction.  
 
The phenylacteylene complex, [Fe2L
Phen
3][BF4]4, exhibited the lowest DNA binding 
activity of the four novel compounds, as investigated by linear dichroism and agarose and 
polyacrylamide gel electrophoresis studies, likely due to the bulky and hydrophobic nature 
of the phenylacetylene moiety that is attached at the ends of this cylinder. The main 
disadvantage of these novel iron(II) cylinders is their lack of solubility in water, preventing 
further investigation of their anti-cancer properties using in vitro studies.   
 
The aim of the work detailed in chapter 3 was to try to improve the targeting of these 
supramolecular helicates to cancerous tissue, by the conjugation of biomolecule vectors. 
Iron(II) cylinders conjugated to the steroid hormones testosterone and estrogen were 
synthesised in only two reaction steps, with moderate yields. Chirality studies revealed that 
these complexes were a mixture of M and P helical isomers, with a slightly higher 
proportion of the P configuration. DNA binding studies demonstrated that these 
compounds could bind to ct-DNA and induce intramolecular coiling of the DNA. These 
compounds showed no ability to unwind supercoiled plasmid DNA or induce the formation 
of a DNA three-way junction, which is likely due to their bulky size and shape.  As with 
the functionalised cylinders, detailed in Chapter 2, the main disadvantage of these novel 
steroid conjugated cylinders is their lack of solubility in water, preventing further in vitro 
studies and investigation of their possible targeting abilities.   
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In chapter 4, supramolecular cylinders were functionalised with sugars with the aim of 
targeting them to cancerous tissue expressing carbohydrate receptors and to increase their 
water solubility. Iron(II) complexes with acetyl and hydroxyl β-D-glucosaminide sugar 
moieties were designed and synthesised over three or four reaction steps. Unfortunately the 
yield of these syntheses was poor. The hydroxyl-sugar cylinder was found to be very 
unstable and therefore difficult to fully characterise. However, DNA binding studies were 
carried out to investigate the potential of the complex. The acetyl-sugar cylinder, 
[Fe2L
OAcSug
3][BF4]4, was found to be diastereoisomerically pure and of the M helical 
configuration. Chiral characterisation of the hydroxyl-sugar cylinder was ambiguous, 
however the complex is chiral and is predominantly of the M configuration.  
 
DNA binding studies were undertaken with the acetyl-sugar complex and revealed that the 
cylinder could bind to ct-DNA, induce intramolecular coiling and promote the formation of 
a DNA three-way junction. However the complex did not unwind supercoiled DNA. 
Preliminary DNA binding studies were also carried out with the hydroxyl-sugar cylinder 
and revealed a strong DNA binding ability. The helicate could bind to ct-DNA in an 
oriented manner, causing intramolecular coiling of the DNA helix. It was also able to 
unwind supercoiled plasmid DNA. Unfortunately further in vitro studies could not be 
undertaken due to the lack of solubility or stability of the sugar functionalised cylinders, 
and so the targeting ability of these sugar cylinders could not be investigated. 
 
The work detailed herein shows that cylinders with a range of functionalisation groups, 
including biomolecules, conjugated via alkyne linkers can be synthesised and that the 
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 inherent DNA binding activity of the parent cylinder is not lost due to this 
functionalisation.  
 
5.2 Future work 
Several supramolecular cylinders functionalised with biomolecules such as steroids and 
sugars have been described herein. However, there are many other biomolecules that could 
be explored to target the cylinder to specific tissues, organs or cancers; such as other 
sugars, folic acid or biotin. Another type of interesting functionalisation would be to 
conjugate a fluorescent probe to the cylinder, to allow cellular localisation studies to be 
performed.  
 
Another route to functionalised cylinders with enhanced properties would be to synthesise 
the ruthenium(II) analogues. The ruthenium(II) parent cylinder has enhanced stability 
compared to the analogous iron(II) complex, is luminescent and can bind and photocleave 
DNA in a sequence specific manner.
1,2
  
 
One of the main problems encountered during this work was the lack of water solubility of 
a number of the novel cylinders synthesised. This is a major disadvantage as in vitro 
studies, such as cellular uptake experiments and cytotoxicity assays, cannot be performed. 
One possible solution would be to attach the functional moiety to the ends of the cylinder 
via a linker that imparts water solubility, such as polyethylene glycol (PEG).
3
 If the 
aqueous solubility of the biomolecule-functionalised cylinders presented in this work could 
be improved, the possible targeting effect of these cylinders could be investigated using in 
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vitro studies. There are many known cancer cell lines that display estrogen or androgen 
(for testosterone conjugates) receptors and cellular studies with these would indicate 
whether some enhancement of cellular uptake has been imparted to the cylinder by the 
steroid functionalisation.  
 
Another interesting idea that could improve the functionalisation, solubility and DNA 
affinity of these compounds, would be to cap the ends of the cylinder (Fig. 5.1). This cap 
could be formed of three ‘arms’ that would be attached to the three ligands, with a 
chemical unit that would allow conjugation of a biomolecule. This would allow 
functionalisation of the cylinder without having to attach three bulky moieties to each end 
and may be more stable. The affinity for DNA may also be improved by this design as the 
cylinder would be more compact overall and so may fit better into the DNA major groove 
or Y-shaped junction. If relatively hydrophobic functional groups are to be attached, the 
difference in number may improve the solubility of the cylinder.  
 
Figure 5.1 Capped cylinder with functionalisation (blue spheres). [Adapted from Ref 4] 
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Appendix 
 
 
A.1 2D-NMR (COSY) of [Fe2L
P
3][BF4]4 
  
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.2 2D-NMR (COSY) of 5-ethynyl-2-pyridinecarboxaldehyde (2) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.3 2D-NMR (COSY) of [Fe2L
TB
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.4 2D-NMR (COSY) of 5-(3-hydroxyprop-1-ynyl)-2-pyridinecarboxaldehyde (3) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.5 2D-NMR (COSY) of [Fe2L
PA
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.6 2D-NMR (COSY) of 5-(hex-5-yn-1-ol)-2-pyridinecarboxaldehyde (4) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.7 2D-NMR (COSY) of [Fe2L
Hex
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.8 2D-NMR (COSY) of 5-(ethynylphenyl)-2-pyridinecarboxaldehyde (5) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.9 2D-NMR (COSY) of [Fe2L
Phen
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.10 2D-NMR (COSY) of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]ethisterone (6) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.11 2D-NMR (COSY) of [Fe2L
Test
3][BF4]4 
  
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.12 2D-NMR (COSY) of 17α-[(2-pyridinecarboxaldehyde)-5-ethynyl]estradiol (7) 
 
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
 
A.13 2D-NMR (COSY) of [Fe2L
Estro
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.14 2D-NMR (COSY) of 5-(2-N-acetyl-3,4,6-tri-O-acetyl-1-(2’-propargyl)-β-D-
glucosaminide)-2-pyridinecarboxaldehyde (9) 
  
1H-1H COSY NMR (400 MHz, CDCl3, 298 K) 
 
A.15 2D-NMR (COSY) of [Fe2L
OAcSug
3][BF4]4 
 
1H-1H COSY NMR (400 MHz, CD3CN, 298 K) 
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A.16 2D-NMR (COSY) of 5-(2-N-acetyl-1-O-(2’-propargyl)-β-D-glucosaminide)-2-
pyridinecarboxaldehyde (10) 
 
1H-1H COSY NMR (400 MHz, D2O, 298 K) 
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A.17 ESI mass spectrum of [Fe2L
P
3][BF4]4 
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A.18 ESI mass spectrum of [Fe2L
TB
3][BF4]4 
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A.19 ESI mass spectrum of [Fe2L
PA
3][BF4]4 
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A.20 ESI mass spectra of [Fe2L
Hex
3][BF4]4 
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A.21 ESI mass spectrum of [Fe2L
Phen
3][BF4]4 
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A.22 ESI mass spectrum of [Fe2L
Test
3][BF4]4 
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A.23 ESI mass spectrum of [Fe2L
Estro
3][BF4]4 
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A.24 ESI mass spectrum of [Fe2L
OAcSug
3][BF4]4 
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A.25 ESI mass spectra of [Fe2L
OHSug
3][BF4]4 
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A.26 Autoradiogram of polyacrylamide gel run at 25 °C.  
 
Lanes 1-3: S3*, S3*+S2, S3*+S2+S1 respectively; Lane 4: S3*+S2+S1+MgCl2; Lanes 5-10: S3*+S2+S1 
with [Fe2L
P
3][Cl]4, [Fe2L
P
3][BF4]4, [Fe2L
TB
3][BF4]4, [Fe2L
PA
3][BF4]4, [Fe2L
Hex
3][BF4]4, [Fe2L
Phen
3][BF4]4, 
[Fe2L
Test
3][BF4]4, [Fe2L
Estro
3][BF4]4 and  [Fe2L
OAcSug
3][BF4]4 respectively. Ratio of three-way junction 
(S1+S2+S3*):complex of 1:1. Asterisk indicates 32P labelled strand.  
